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Abstract 
 
Elf5 is a DNA transcription factor that has been identified as being involved in 
placentation of the early embryo. Elf5 is expressed in the extra embryonic 
ectoderm (ExE), a lineage that contributes to the placenta of the embryo. 
Pluripotent trophoblast stem (TS) cells can be derived from the ExE and can be 
cultured in vitro. Such cells can contribute to all the placental lineages when 
injected back into an embryo. Elf5 homozygous mutant embryos do not possess 
an ExE and trophoblast stem cells cannot be derived and the mutation is 
therefore embryonic lethal. When Elf5 is knocked out, the TS cells in the ExE are 
thought to differentiate into EPC/giant cells leading to the absence of the ExE. In 
previous experiments in this laboratory, potential Elf5 targets were identified by 
RNA interference in mouse trophoblast stem cells followed by global gene 
expression analysis using an Affymetrix array. In the present experiments these 
results have now been confirmed by siRNA induced knockdown of Elf5 in TS cells 
followed by quantitative real time PCR of potential target genes. Most of the 
target genes that were affected by Elf5 knockdown were changed in the same 
way by growth factor removal and therefore stem cell differentiation. This 
suggested that Elf5 usually acts to maintain the TS cells in a stem cell fate. As Elf5 
is expressed in the ExE, whole mount In situ hybridisation was used to determine 
if the genes showed the correct spatial and temporal patterning to be in vivo 
relevant Elf5 targets. The targets that were down regulated upon Elf5 
knockdown (and therefore positively regulated by Elf5) were expressed in the 
ExE as expected. Genes that were up-regulated upon Elf5 knockdown (and 
therefore usually repressed by Elf5) were expressed in the differentiated 
ectoplacental cone or giant cells. . Preliminary work was also carried out for the 
over-expression of Elf5 by a tamoxifen inducible Elf5. TS cells were stably 
transfected with a plasmid containing Elf5 fused to a tamoxifen inducible ERT2 
receptor and a VP16 transcriptional activation domain to turn Elf5 into a potent 
activator, and were analysed for target gene expression.  Preliminary data 
showed that Elf5 is involved in a complex transcriptional network of events as 
the genes did not behave as expected when Elf5 was turned into an activator. 
The effect of Elf5 knockdown on TS cells has been studied closely in terms of 
iii 
 
morphology, proliferation, changes in DNA content and apoptosis. The 
knockdown of Elf5 caused an increase in the number of differentiated cells (as 
shown by changes in morphology and DNA content). This further supported the 
knockdown and in situ data. There was no change in proliferation or apoptosis.  
These experiments which demonstrate which genes are regulated by Elf5 and 
the changes to TS cellular characteristics when Elf5 is knocked down, support the 
proposal that Elf5 acts as a trophoblast stem cell maintenance factor of the 
extraembryonic ectoderm of the mouse.   
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1 Chapter 1: Literature Review 
1.1 Overview 
The purpose of this research is to delineate the molecular cascade underlying 
placental development. The placenta is the first organ to develop (Simmons and 
Cross, 2005) and is vital for embryonic development as it mediates the 
interaction between the growing foetus and the maternal blood stream (Rossant 
and Cross, 2001). At the early blastocyst stage of embryo development, two cell 
lineages can be distinguished, the inner cell mass (ICM) and the trophectoderm 
(TE). The ICM gives rise to the embryo proper and the extra embryonic 
endoderm, the TE to the foetal part of the placenta. The polar trophectoderm 
which lies above the ICM receives signals from the ICM to form the extra 
embryonic ectoderm (ExE) and the ectoplacental cone (EPC) (Simmons and 
Cross, 2005). The EPC and ExE contribute to the placenta which is made up of a 
mixture of foetal and maternal compartments. Pluripotent trophoblast stem (TS) 
cells can be derived from the ExE and can be cultured in vitro in the presence of 
embryonic conditioned media, FGF4 and Heparin (Tanaka et al., 1998). A DNA 
transcription factor, Elf5 has been identified that is essential for placental 
development. Elf5 is expressed in the ExE lineage and hypothesised to be 
required for TS cell maintenance (Donnison et al., 2005). Elf5 homozygous 
mutants die around day 8.5-9.5 due to a failure to form an ExE. TS cells cannot be 
derived from these embryos suggesting Elf5 is essential for the preservation of TS 
cells in vivo (Donnison et al., 2005). To investigate why Elf5 is essential for the 
trophoblast lineage, Deane (2007) identified Elf5 target genes by RNA 
interference in TS cell lines, followed by global gene expression analysis using an 
microarray( affymetrix). This gave a group of genes that are up or down 
regulated upon loss of Elf5. The identification of genes that are regulated by Elf5 
provided insight to its role in the placenta.  
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1.2 Early Development 
Pre-implantation development begins with fertilisation and finishes with 
implantation which occurs at day 4.5 of development in the mouse. Following 
fertilisation the embryo undergoes a few rounds of cleavage with compactation 
occurring at the 8 cell stage, this is termed the morula. All the cells of the early 
morula are identical in terms of their morphology and development potential. 
During compactation the cells of the morula polarize and make epithelial like 
contacts. Calcium and the membrane binding protein E-cadherin is required 
during compactation and is involved in  cell polarisation and formation of cell to 
cell contacts (Kunath et al., 2004). Successive radial or tangential cell divisions 
occur to give outer polar cells (radial/symmetric division) or inner apolar cells 
(tangential/asymmetric division). If left undisturbed the outer polar cells go on to 
give rise to the trophectoderm (TE) while the inner cells give rise to the inner cell 
mass (ICM) (Johnson and Ziomek, 1983; Kunath et al., 2004), see Figure 1 and 
Figure 2.  Up to the 16 cell stage these lineage decisions are not irreversible as 
embryos assembled solely from inner or outer cells can develop into normally 
structured blastocysts (Suwinska et al., 2008). At the 32 cell stage only the inner 
cells have this same developmental potential. When 16 or 32 cell embryos are 
disaggregated the majority of the cells return to their original position within 24 
hours. This indicates positional factors are important during this stage of 
development (Suwinska et al., 2008). Once the late embryo reaches the 
blastocyst stage at day 3.5 the lineage decisions are made and this flexibility is no 
longer seen (Kunath et al., 2004).  
 
The trophoblast lineage provides the main components of the placenta whereas 
the ICM gives rise to the embryo proper as well as, the extra embryonic 
membranes such as the allantois and the amnion (Rossant, 2001). This lineage 
segregation is determined by the expression of key transcription factors, Oct4 
(octamer-binding transcription factor 4) and Cdx2 (caudal type homeobox 
protein 2) (Niwa et al., 2005).  
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Figure 1: Expression of the key genes in early development (Arnold and Robertson, 2009). 
 
Oct4 is initially expressed in all cells of the early embryo but then becomes 
restricted to the ICM of the blastocyst by Cdx2 (Figure 1) (Ralston and Rossant, 
2008). Oct4 is a pluripotency marker of the ICM. Oct4 homozygous mutant 
embryos can develop to the blastocyst stage but the ICM cells are not specified 
properly and the cells express trophectoderm markers (Nichols et al., 1998). 
Mouse embryonic stem (ES) cells can be derived from wild type ICM and epiblast. 
They can be maintained in vitro in the presence of leukaemia inhibitory factor 
(Williams et al., 1988). ES cells express Oct4, and when differentiation is induced 
Oct4 is down regulated (Rossant, 2001).  ES cells cannot be derived from Oct4 
mutant embryos and when Oct4 is repressed in ES cells they differentiate into 
trophoblast giant cells (Niwa et al., 2000). This data indicates Oct4 is essential for 
lineage allocation in the early mouse embryo and is required for the self renewal 
of ES cells. 
 
The HMG box transcription factor Sox2 plays a similar role to Oct4 as it preserves 
the ICM development potential, but unlike Oct4 it is also required in the 
proliferating trophoblast (Rossant, 2001). Sox2 is thought to play a role in 
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regulating Fgf4 expression. The down regulation of Sox2 in both ES and TS cells 
causes differentiation into other cell types (Avilion et al., 2003). 
 
The homeobox gene Nanog is expressed in the ICM and is also required for ES 
cell self renewal and maintenance of ICM cell fate. In Nanog mutants, ES cells 
and ICM cells differentiate into extraembryonic endoderm rather than 
extraembryonic ectoderm, which occurs when Oct4 is deleted (Strumpf et al., 
2005). This Suggests Oct4 and Nanog regulate different pathways in early 
development. The outer layer of the ICM forms the primitive endoderm (see 
Figure 1 and Figure 2); the primitive endoderm contributes to the yolk sac of the 
embryo. Expression studies and lineage tracing have shown that the random and 
mosaic ‘salt and pepper’ nature of expression of Nanog and Gata6 determine 
what cells form the epiblast and the primitive endoderm respectively (see Figure 
1). At E3.5 ICM cells exclusively express Nanog or Gata6 and this determines the 
fate of the cell  (Arnold and Robertson, 2009).  
 
The ICM also expresses two other signalling molecules Nodal and Bone 
morphogenic protein 4 (Bmp4). Nodal is expressed in the epiblast and visceral 
endoderm and is involved in anterior-posterior patterning of the embryo. Nodal 
induces Bmp4 in the ExE (Beck et al., 2002). The role of Bmp4 in the ICM is 
unclear as Bmp4 knockout embryos can develop normally up to gastrulation. 
Bmp4 is also necessary for the formation of germ layers and primordial germ 
cells in the ExE (Pfister et al., 2007).  
 
Cdx2 is initially expressed in all cells of the early morula but then becomes 
restricted to the outer cells of trophectoderm lineage at the 16 cell stage (E3.0) 
(see Figure 1) (Niwa et al., 2005). Cdx2 is a key transcription factor involved in 
the trophoblast lineage decision. Cdx2 mutants form normal blastocysts but they 
fail to maintain trophectoderm, instead forming a sphere of Oct4 positive cells 
(Kunath et al., 2004). Cdx2 is required for the repression of Oct4 and Nanog in 
the trophectoderm (Ralston and Rossant, 2008; Strumpf et al., 2005). The 
restriction of Oct4 by Cdx2 results in the first lineage specification of the 
blastocyst therefore trophectoderm is the first lineage to be specified (Rossant 
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and Tam, 2009). Cdx2 over-expression is also capable of inducing trophoblast 
differentiation in mouse embryonic stem (ES) cells (Niwa et al., 2005). As Cdx2 
mutants are capable of forming blastocysts another transcription factor may act 
up-steam of Cdx2 to initiate trophectoderm formation. The TEA-domain family 
member 4 (Tead4) has recently been identified and is required for 
trophectoderm lineage specification (Nishioka et al., 2008). Tead4 mutants have 
a more severe phenotype than Cdx2 mutants and Cdx2 expression cannot be 
maintained in these embryos indicating its expression is required before Cdx2 
(Yagi et al., 2007). 
 
 
Figure 2: Placental development in the mouse. The blastocyst forms at E3.5 from there the 
polar trophectoderm forms the ExE and the EPC while the ICM forms the epiblast and the extra 
embryonic membranes. Far right are the components of the placenta (Rossant and Cross, 
2001).  
Once the first lineage decision is made the trophectoderm cells overlying the 
inner cell mass, known as the polar trophectoderm continue to proliferate and 
differentiate before implantation from day 4.5 to form the extraembryonic 
ectoderm (ExE) and the ectoplacental cone (EPC) (see Figure 2) (Gardner et al., 
1973). The cells away from the ICM, the mural trophectoderm stop dividing but 
maintain DNA replication (endoreplication) to give rise to primary trophoblast 
giant cells which make contact with the maternal epithelium during implantation 
(Rossant, 2001; Rossant and Cross, 2001). The maintenance of the proliferation 
of the ExE is due to signalling from the ICM. In the absence of these signals the 
default pathway of giant cell differentiation occurs (Gardner et al., 1973). Fgf4 
signalling is a major pathway involved in the continued proliferation and the 
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prevention of differentiation of the trophoblast. The proliferative potential of the 
ExE is sustained by a population of trophoblast stem (TS) cells (Tanaka et al., 
1998).  
1.3 Placental Development and Gene Expression 
The extra-embryonic ectoderm is formed from the polar trophectoderm at day 
4.5-5.0, and gives rise to the chorion at day 7.5.  The ExE and the chorion express 
the marker genes Cdx2, Eomes and Errβ.  These genes are involved in the 
trophectoderm lineage decisions and trophoblast maintenance. 
 
The allantois which arises from the mesoderm at the posterior end of the 
embryo makes contact with the chorion. This event is termed chorioallantoic 
fusion. The allantois gives rise to the umbilical cord which is vital for nutrient and 
waste exchange of the embryo. During chorioallantoic fusion folds appear in the 
chorion which mark the sites where blood vessels will form (Rossant and Cross, 
2001). From here the labyrinth will form the inner part of the placenta at day 8.5 
(see Figure 2 and Figure 3). The labyrinth contains branched vili and a large 
surface area that is responsible for nutrient, gas and waste exchange between 
the developing foetus and the mother (Simmons and Cross, 2005). The placenta 
is a vital organ for the developing embryo as it also provides blood flow and 
produces growth factors and hormones (Cross et al., 2003).  
 
The labyrinth consists of different types of cells and is thought to arise from the 
chorion. The cell types include mononuclear trophoblast cells that express 
placental lactogen II, syncytiotrophoblast cells and foetal endothelial cells 
(Simmons and Cross, 2005). The syncytiotrophoblast cells of the labyrinth start to 
develop at E8.5 when the labyrinth is formed. Syncytiotrophoblast cells express 
the transcription factor GCM1; which is required for their differentiation. 
Syncytiotrophoblast cells arise via cell cycle exit following by the fusion of two 
cells to give a multinucleated cell containing two diploid nuclei (Cross et al., 
2003). Mouse TS cells can also give rise to syncytiotrophoblast cells when they 
are induced to differentiate in vitro. The lineage allocation of the placenta was 
7 
 
determined primarily by the expression of marker genes, see Figure 4(Cross et 
al., 2003). 
 
Figure 3: Diagram representing the trophectoderm lineages in the mouse which form the 
functioning placenta (Cross, 2005). 
 
The ectoplacental cone (EPC) is also derived from the polar trophectoderm at 
day 4.5-5.0 (see Figure 2). As gestation continues the outer part of the 
ectoplacental cone gives rise to secondary giant cells which are in direct contact 
with the maternal decidua. Trophoblast giant cells are in contact with the 
maternal tissue at every stage during development and they mediate the 
invasion of the placenta into the maternal decidua. Trophoblast giant cells 
produce factors that promote blood flow to the site of implantation and are 
associated with maternal arteries (Simmons and Cross, 2005). The rest of the 
ectoplacental cone forms the spongiotrophoblast which lies between the 
labyrinth and the giant cells (see Figure 2). The function of the 
spongiotrophoblast is not well understood but it is thought to act as a support 
tissue for the developing villous structures of the labyrinth (Simmons and Cross, 
2005). At around day 12.5 glycogen trophoblast cells form from the 
spongiotrophoblast and migrate towards the decidua and invade the uterus. See 
figure three for a diagram of the different lineages of the placenta.  
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The cell lineage decisions are controlled by the expression of different genes and 
transcription factors (see Figure 4). Genes involved in EPC and 
spongiotrophoblast allocation include Tpbp and Flt1. They are first detectable in 
the EPC and then later in the spongiotrophoblast. These genes are not expressed 
in trophoblast giant cells, the ExE or the labyrinth (Cross et al., 2003). The basic 
helix-loop-helix transcription factor Mash2 is expressed in the chorion, EPC and 
the spongiotrophoblast. Mash2 seems to prevent trophoblast differentiation into 
trophoblast giant cells and instead promotes EPC and spongiotrophoblast 
formation as loss of Mash2 results in the loss of the spongiotrophoblast and 
allows giant cell differentiation to occur (Cross, 2005). In contrast to Mash2, the 
bHLH transcription factor Hand1 promotes giant cell formation (Simmons and 
Cross, 2005); these two transcription factors have opposing functions.  
 
Isolated ExE or TS cells can give rise to giant cells in vitro in the absence of FgF4. 
They must go through a phase where they first express EPC and 
spongiotrophoblast markers Mash2 and Tpbpa (Simmons and Cross, 2005). Giant 
cells are characteristic of the mouse and rodent placenta and endoreplication of 
these cells can give a DNA content of up to 1024N (Zybina and Zybina, 1996). 
Giant cells first arise when the mural trophectoderm is formed. Secondary giant 
cells arise when the some of the EPC cells differentiate into giant cells (Cross et 
al., 2003). 
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Figure 4: Gene expression of key genes in different lineages of the mouse placenta (Simmons 
and Cross, 2005). 
 
1.4 Trophoblast Stem Cells as a Model for Placental 
Development 
The proliferative potential of the extra embryonic ectoderm is dependent on a 
population of trophoblast stem cells which reside there. Signals from the ICM are 
thought to maintain the pluripotency of the TS cells (Simmons and Cross, 2005). 
A major signalling molecule involved in the maintenance of TS cell pluripotency is 
FGF. Fgf4 is expressed in the early embryo, becoming restricted to the ICM of the 
blastocyst and later the epiblast (Niswander and Martin, 1992; Rappolee et al., 
1994). The FGF4 receptor Fgfr2 is expressed in the ExE, indicating FGF4 signalling 
from the epiblast to the ExE may be involved in trophoblast proliferation via this 
receptor (Simmons and Cross, 2005). Embryos with mutations of either Fgf4 or 
Fgfr2 are very similar and they fail to maintain trophoblast proliferation and 
identity (Arman et al., 1998; Feldman et al., 1995; Goldin and Papaioannou, 
2003). Embryonic stem cells can be derived from these embryos but TS cells 
cannot, indicating FGF signalling is required for TS cell maintenance (Wilder et 
al., 1997).  
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Trophoblast stem (TS) cells have been isolated from the blastocyst at D3.5, and 
the ExE at D6.5 (Tanaka et al., 1998) and the choronic ectoderm (Uy et al., 2002).  
Tanaka et al. (1998) isolated and cultured TS cells from the ExE of D6.5 embryos 
on a feeder layer of primary mouse embryonic fibroblast (EMFI) cells in the 
presence of FGF4 and heparin. The removal of FGF4, heparin or EMFI cells 
resulted in a rapid decline in proliferation and differentiation into giant cells. TS 
cells can be cultured in the absence of feeder cells by using 70 % embryonic 
conditioned media supplemented with Fgf4 and heparin (Tanaka et al., 1998). TS 
cells can be injected back into blastocysts to create chimeras and the TS cells  can 
only contribute to the trophoblast lineage of chimeras (Tanaka et al., 1998). 
Trophoblast stem cells can give rise to all of the differentiated trophoblast 
subtypes in vivo and in vitro. 
 
Embryonic fibroblast cells secrete additional factors that help to maintain TS cells 
in a proliferative, undifferentiated state. Transforming growth factor β (TGF- β) 
and/or activin are key components of the embryonic fibroblast conditioned 
media (Erlebacher et al., 2004; Guzman-Ayala et al., 2004). Members of the TGF-
β superfamily have been shown to be involved in the maintenance of TS cells. 
Members of this family include Nodal, BMPs and Activins. These molecules signal 
through type I and II transmembrane serine/threonine kinase receptors to their 
downstream Smad proteins. Activin and Nodal share the same receptors while 
TGF-β signals through Tgf receptors. Activin, Nodal and TGF-β activate the Smad 
pathway by causing the phosphorylation of smad2/3 which complexes with 
smad4 and translocates to the nucleus to activate transcription (Natale et al., 
2009). Although these proteins signal through the same pathway they have 
different roles in the cell.  
 
During gastrulation, Nodal is involved in antero-posterior patterning and is 
expressed in the epiblast and visceral endoderm. The proteases Furin and Pace4 
are expressed in the ExE and are required to activate the Nodal precursor (Beck 
et al., 2002). Furin, Pace4 and Nodal are required to maintain TS cells in the ExE 
during gastrulation. Nodal sustains FGF4 expression in the epiblast and acts 
directly on the ExE in conjunction with FGF4 to maintain the expression of TS cell 
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marker genes (Guzman-Ayala et al., 2004). Although Nodal has been shown to be 
important in vivo for TS cells it can be replaced by activin in vitro for TS cell 
maintenance (Natale et al., 2009). 
 
TS cells can be grown in the absence of embryonic fibroblast conditioned media 
by replacing it with Activin or TGFβ, while still supplementing with Fgf4 
(Erlebacher et al., 2004; Natale et al., 2009). Erlebacher et al. (2004) was able to 
maintain TS cells in an undifferentiated state in media supplemented with Activin 
for 1.5 months after which these cells could still contribute to all placental 
subtypes in chimeras. The combination of Fgf4 and Activin or TGFβ can act 
together to maintain the expression of TS cell marker genes and prevent their 
differentiation into giant cells (Simmons and Cross, 2005). Although both Activin 
and TGF-β can both act to maintain TS cells they have different effects on the TS 
cells upon the withdrawal of Fgf4. Activin promotes the differentiation of 
labyrinth trophoblast subtypes such as syncytiotrophoblast cells. Trophoblast 
giant cells produce Activin and may act in a negative feedback loop to promote 
the formation of other cell types in the absence of FgF4 (Natale et al., 2009). In 
contrast to Activin, TGF-β alone promotes the formation of trophoblast giant 
cells (Natale et al., 2009). 
1.5 Gene Expression in Mouse Trophoblast Stem Cells  
Over 100 genes are known to be required for placental development (Cross, 
2005) and are expressed at different stages in development. Markers of the extra 
embryonic ectoderm are also expressed in trophoblast stem (TS) cells. Markers 
include Errβ, Cdx2, Fgfr2 and Eomes. These genes are down-regulated when 
differentiation is induced (Tanaka et al., 1998). Cdx2 (caudal –type homeobox 2) 
and Eomes (eomesodermin homologue) belong to transcription factor gene 
families and are downstream targets of FGF signalling (Rossant and Cross, 2001). 
Both are expressed in the ExE and are required for early trophoblast 
development. Cdx2 is an early marker for the undifferentiated trophectoderm 
lineage and is involved in the trophectoderm or ICM choice at the morula stage 
(Niwa et al., 2005; Ralston and Rossant, 2008; Strumpf et al., 2005). Eomes is 
required later than Cdx2, at the polar trophectoderm/mural trophectoderm 
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choice at the blastocyst stage (Donnison et al., 2005; Russ et al., 2000). Eomes is 
required later than Cdx2 as Eomes mutants do not show reduced Cdx2 levels, 
while Cdx2 mutants do show reduced Eomes levels (Rossant and Tam, 2009). 
Eomes mutants arrest in development at the blastocyst stage as the 
trophectoderm cannot form trophoblast and TS cells are not maintained (Russ et 
al., 2000). Eomes mutants fail to implant. The orphan nuclear receptor Errβ is 
also expressed in the ExE and the chorionic ectoderm. Unlike Cdx2 and Eomes, 
Errβ is required for trophoblast maintenance and not the lineage decision. Errβ 
mutants die much later, around D10.5 due to an arrest in trophoblast 
development (Rielland et al., 2008). Another transcription factor that has been 
recently discovered that is involved in early lineage allocation is Tead4. Tead4 is 
expressed from the 2 cell stage with a maximum expression at the 8 cell stage. 
Tead4 mutants die before implantation, do not express Cdx2 and TS cells cannot 
be derived. Conversely ICM specific genes are still expressed and ES cells can be 
derived (Yagi et al., 2007). If Tead4 is knocked out after implantation embryos 
can complete development. This indicates Tead4 is now on top of the 
transcriptional hierarchy involved in the development of the trophectoderm.  
1.6 Elf5 in the Early Placenta 
Elf5, an epithelial specific transcription factor of the ETS super family is involved 
in maintaining the extra-embryonic ectoderm lineage of the placenta (Donnison 
et al., 2005). The ETS family of transcription factors share a highly conserved DNA 
binding domain and recognise and bind to a purine-rich GGA(A/T) core at 
promoters and enhancers of target genes (Zhou et al., 1998). Elf5 was initially 
found to be expressed in the mammary gland and other epithelial tissues and in 
the neonatal mouse and during embryogenesis (Zhou et al., 1998). Zhou et al., 
(1998) also revealed that Elf5 is expressed in the placenta in mice from day 9.5 
onwards. 
 
To study the function of Elf5 during early embryogenesis, two groups produced a 
mutated non-functional Elf5 allele using ES cells (Donnison et al., 2005; Zhou et 
al., 2005). Zhou achieved this by replacing exon 3 with a NLS-LacZ-neo construct 
and Donnison by inserting the puromycin gene into exon 2 of the Elf5 gene. 
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Heterozygote Elf5 +/- mice were viable and fertile. Elf5 +/- mice were crossed but 
no Elf5 homozygous mutants were obtained by either group indicating 
embryonic lethality (Donnison et al., 2005; Zhou et al., 2005). Normal Mendelain 
ratios were seen up to E6.5 indicating embryo lethality occurs sometime after 
gastrulation.  
 
Zhou et al., (2005) observed that Elf5 +/- females gave birth to viable offspring 
but their litters frequently died 24 to 48 hr after birth. This was found to be due 
to the inability of the female mice to lactate. Upon further investigation it was 
revealed that proliferation and differentiation in the mammary gland was 
defective and the secretory initiation phase was also inhibited (Zhou et al., 2005). 
Therefore Elf5 is essential for mammary gland development during pregnancy 
and one allele is not adequate for mammary gland function.  
 
Donnison et al,. (2005) studied the role of Elf5 in early embryogenesis. In situ 
hybridisation revealed Elf5 is expressed before gastrulation in the ExE lineage 
and is maintained during gastrulation. It was expressed at D5.5 to D8.5 with low 
levels detected by reverse transcriptase PCR (RT-PCR) at D3.5. Elf5 was not 
expressed in the EPC (Donnison et al., 2005).  
 
Interestingly Elf5 homozygous mutants do not form an ExE. Whole mount in situ 
hybridisation of Elf5 knockouts revealed the ExE molecular markers Cdx2, Eomes, 
Fgfr2, Furin and Spc4 were not expressed at E6.5-7.5 confirming the absence of 
the ExE. The Elf5 mutants could still form an EPC which suggests undifferentiated 
TS cells may not be maintained leading to an absence of the extra embryonic 
ectoderm. In confirmation of this, TS cells could not be isolated from Elf5 
homozygous mutant embryos. They were still able to be isolated from Elf5 
heterozygote embryos.  
 
Elf5 mutant embryos were smaller than their littermates and exhibited no signs 
of primitive streak formation. Elf5 null embryos also show patterning defects in 
the epiblast, this was shown to be due to defects in mesoderm formation 
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(Donnison et al., 2005). The mutant embryos did not express Nodal or any of its 
down-stream markers which are required for primitive streak formation.  
 
The authors suggested Elf5 is a marker for undifferentiated TS cells, as in Elf5 
homozygous mutant embryos TS cells differentiate into EPC progenitors causing 
an absence of the ExE and embryonic lethality (see Figure 5). The absence of the 
ExE may also cause the defects in the embryo patterning as Nodal activity is 
dependent on the ExE to provide the proteases Furin and Spc4 to cleave the 
precursor protein into its active form. From all this data it was proposed that Elf5 
acts downstream of Cdx2 and Eomes and is required for the decision between 
the ExE and the EPC which occurs after the blastocyst has implanted (see Figure 
5). As the EPC is present in homozygous mutants this means the polar 
trophectoderm has formed normally allowing the differentiation into the EPC. 
Eomes is required for the formation of the pTE and therefore is not affected at 
this stage by the removal of Elf5.  
 
 
Figure 5: The role of Elf5 in the formation of the mouse embryo. It is required after the 
formation of the polar trophectoderm, at the choice between ExE and EPC. In the absence of 
Elf5 TS cells differentiate into EPC. Figure provided by Peter Pfeffer, AgResearch, Ruakura.  
  
Recently Ng et al., (2008) showed that Elf5 expression was repressed in ES cells 
by methylation. In TS cells Elf5 was shown to be hypomethylated and therefore 
expressed. Elf5 can be expressed in ES cells via a mutation in the DNA 
methyltransferase Dnmt-1. They also find that Elf5 is expressed in the ExE and its 
expression is initiated later than Cdx2, which confirms the results by Donnison et 
al. The over expression of Elf5 in ES cells causes differentiation of the ES cells into 
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trophoblast cells and an up regulation of trophoblast cell markers like Cdx2 and 
Eomes. Interestingly they find that the over expression of Elf5 eventually causes 
the terminal differentiation into trophoblast giant cells.  
 
Another ETS family of transcription factor member, Ets2 is also expressed in the 
trophoblast from E5.0-6.75 and its phenotype is similar to Elf5. Ets2 mutants 
show a decrease in growth of the EPC, and some mutants lack ExE (Wen et al., 
2007) and its molecular markers (Georgiades and Rossant, 2006). The absence of 
Ets2 in the trophoblast (and therefore absence of the ExE) prevents primitive 
streak and mesoderm formation and improper localisation of the AVE. 
(Georgiades and Rossant, 2006). The inactivation of Ets2 also results in the 
prevention of TS cell self renewal. Ets2 inactivation causes the down regulation 
of Cdx2, Errβ and Pace4, but interestingly not Furin (Wen et al., 2007). The lack of 
signalling from the ExE probably causes the defects seen in embryo patterning 
(Georgiades and Rossant, 2006).  
 
Deane (2007) identified putative target genes of Elf5 by loss of Elf5 function via 
small interfering RNA (siRNA) expression in TS cells. This was followed by an 
Affymetrix array and quantitative real time PCR (qRT-PCR) to give a group of 
genes that are up or down regulated upon the loss of Elf5. These target genes 
are potentially involved in TS cell function and further studies can give insight to 
the pathways involved in trophoblast development. One such target is Sox2, Sox2 
knockouts die around implantation as it is essential for ICM development and 
later in the ExE and TS cells, it is thought to be a pluripotency marker (Avilion et 
al., 2003). 
1.7 Purpose of This Study 
The purpose of this study was to delineate Elf5 target genes and thus ascertain 
the role of Elf5 in placental development. Putative Elf5 target genes have been 
identified by Deane (2007), some of the most interesting targets were studied by 
repeat knockdown in mouse trophoblast stem cells. To further verify the genes 
that are regulated by Elf5, Elf5 was over-expressed by using a tamoxifen 
inducible Elf5. The expression of the proposed Elf5 targets was examined in vivo 
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to determine if they displayed the correct spatial and temporal pattering to be a 
target of Elf5. Once Elf5 was knocked down, the TS cells were characterised in 
terms of morphology, DNA content, proliferation and apoptosis to see if there 
was any change compared to untreated cells, to determine if cells with Elf5 
knocked down were still in fact TS cells. The identification of Elf5 targets and 
their function gave insight into TS cell maintenance and placental development.  
17 
 
2 Chapter Two: Methods 
All experimental work was carried out at AgResearch Ruakura, Hamilton. For the 
preparation of media, reagents and buffers, refer to the appendices. 
2.1 Cell Culture Protocols 
All general Trophoblast stem cell and mouse embryonic fibroblast cell culture 
protocols were obtained from the book ‘Placenta and Trophoblast, methods and 
protocols, volume 1, chapter 11 (Quinn et al., 2006). Cell culture was carried out 
in a laminar flow hood (Westinghouse Pty Ltd, NSW, Australia) which contains a 
0.2 µm HEPA filter and blows sterile air outwards to keep the contents of the 
hood sterile. The laminar flow hood was routinely wiped with 70 % ethanol 
before and after use and was kept going at all times, everything entering the 
hood was also thoroughly wiped with 70 % ethanol. Cells were grown and 
maintained in a 37 °C/ 5% CO2 water jacket incubator (Forma Scientific). 
2.1.1 Mouse Trophoblast Stem Cell Culture 
Mouse trophoblast stem m(TS) cells were maintained in media containing 70 % 
embryonic fibroblast conditioned media containing 25 ng/ml FGF4 (Sigma-
Aldrich) and 1 µg/ml Heparin (Sigma-Aldrich) (growth factors). Conditioned 
media provides additional growth factors that keep the mTS cells in a 
proliferative undifferentiated state with a tight epithelial morphology (Tanaka et 
al., 1998). The media was routinely changed every 48 hours. The pH of the media 
was monitored by the colour of the phenol red in the media. All media was pH 
adjusted to pH 7.2-7.4 with 1M HCl before filter sterilising through a 0.22 µM 
filter.  
 
2.1.1.1 Passaging of mTS Cells 
Cells were passaged every 48-72 hr using TrypLE™ Express (Gibco, Invitrogen). 
The frequency of passaging depended on the initial seeding density, which was 
usually 1:5 to 1:20 of the original culture. When the cells reached 80-90 % 
confluency they were passaged into a new well or plate to prevent 
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differentiation and to allow continued growth. For normal culture the cells were 
grown in 6-well dishes. For general passaging, the media was removed from cells 
and they were washed gently with PBS. 300 µl TrypLE Express was added to the 
cells to dissociate them and they were incubated for 4 min at 37 °C. After 4 min 
the cells started to form singular rounded cells as observed by using an inverted 
phase contrast Olympus CK2 microscope. When the cells were rounded and were 
beginning to detach 1 ml of mTS media was added to dilute the TrypLE Express. 
The media was pipetted up and down to remove the adherent cells and then 
centrifuged at 1000 rpm for 5 min in a Mistral 1000 bench top centrifuge 
(Labsupply, Auckland, New Zealand). The supernatant was aspirated and the cells 
were re-suspended in 1ml mTS media. For passaging every second day the cells 
were re-plated at a density of 1:10 of the original seeding density. 
 
2.1.1.2 Counting of Mammalian Cells 
To count TS or MEF cells, the cells were lifted from the culture plate by TrypLE 
Express as in section 2.1.1.1 centrifuged in a MSE Mistral 1000 centrifuge and re-
suspended in 1 ml of mTS media (TS cells) or DMEM (MEFs), refer to appendices 
for preparation of the media. 10 µl of the cell suspension was then counted on a 
Neubauer haemocytometer using a 20 x inverted phase contrast Olympus CK2 
microscope. The depth of the chamber was 0.1 mm and the central area 1 mm2; 
therefore the volume was 0.1 mm3 or 1 x 10-4 ml. The number of cells in each of 
the 4 of the 4 x 4 squares was counted and then divided by 4. To calculate the 
number of cells per ml the number of cells counted was multiplied by volume so 
n x 104 would give the number of cells per ml.  
 
2.1.1.3 Thawing of Cells 
Stocks of surplus cells were kept in liquid nitrogen (-196 °C). When the cells were 
removed from long term storage they were rapidly thawed by placing the 
cryovial in a 37 °C water bath until just thawed. Care was taken to prevent 
immersion in the water bath for too long as the cells become susceptible to the 
DMSO in the freezing media. Once thawed the vial was sprayed thoroughly with 
70 % ethanol and the cells were placed in 5 ml of fresh mTS media and 
centrifuged for 5 min at 200 x g. The supernatant was removed and the cells 
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were re-suspended in 2 ml of 70 % conditioned media containing growth factors. 
The cells were usually maintained in one well of a 6 well plate. The cells were 
passaged 2-3 times after thawing before use for experiments as the cells can 
take a while to recover from the freezing process.  
 
2.1.1.4 Freezing of mTS Cells 
When the cells were in excess they were frozen down to replenish the liquid 
nitrogen stocks. 1 x 106 cells were centrifuged for 5 min at 200 x g, the 
supernatant was aspirated and the cells were re-suspended in 1 ml of mTS 
media. 1 ml of freezing media was added to the cell suspension, which contained 
500 µl FCS, 300 µl mTS and 200 µl DMSO. The cells were divided into two 
cryovials and put into a “Mr Frosty” (Nalgene™ Cryo 1 °C Freezing container) 
containing isopropanol and frozen at -80 °C, this allowed slow freezing of the 
cells to prevent ice crystal formation which can cause damage to the cells. The 
following day the vials were transferred to liquid nitrogen for long term storage.                                                                                                
2.1.2 Mouse Embryonic Fibroblasts 
Mouse embryonic fibroblast (MEF) cells were used to produce the growth factors 
required for trophoblast stem cell maintenance. Without these growth factors 
trophoblast cells would differentiate into giant cells (Tanaka et al., 1998). The 
MEFs were kept at a low passage number (between passages 1-10) so they could 
continue to produce high levels of growth factors. MEFs were mitomycin C 
treated so the cells could produce growth factors without using them up 
themselves for growth and metabolism. Mitomycin C inhibits DNA synthesis by 
binding to DNA which induces DNA cross-linking 
 
2.1.2.1 Preparation of MEFs 
The MEFs were grown up in DMEM media (refer to appendices) before 
mitomycin C treatment. Upon thawing MEFs were seeded into a T25 flask 
(Nunc), and once confluent they were spilt 1:6 into 6 T75 flasks (Nunc). The cells 
were washed once with PBS, then 1 ml of TrypLE Express was added to the flask 
and the cells were left at 37 °C until the cells became rounded and began to 
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dislodge. The TrypLE was then neutralised with DMEM and the cells were 
centrifuged down for 5 min at 1000 rpm. The supernatant was removed and 6 ml 
of fresh DMEM was added to resuspend the cells. The cell suspension was spilt 
into 6 flasks containing 25-30 ml of DMEM. The cells were left for about one 
week until they became confluent. Once the cells were confluent, one flask was 
kept for re-seeding into 6 new flasks and the other 5 flasks were mitomycin C 
treated. 
 
2.1.2.2 Mitomycin C Treatment  
Mitomycin C prevents the replication of the MEFs so they produce growth 
factors but are not dividing so they don’t need to use the growth factors 
themselves. The majority of the media in the flasks to be mitomycin C treated 
was removed, leaving 5 ml in the bottom. 50 µl of a 1 mg/ml solution of 
mitomycin C (Sigma-Aldrich) was added to the flask to give a final concentration 
of 10 µg/ml of mitomycin C. The flasks were returned to the incubator and left 
for four hours at 37 °C. After this time the cells were washed three times with 
PBS and were then trypsinised. Once the cells were dislodged they were 
centrifuged and the supernatant was removed. The cells were resuspended in 5 
ml of mTS media and 10 µl was counted using a haemocytometer. The cells were 
then divided into flasks to give 2 x 105 cells per ml of mTS media. On average one 
confluent flask would provide 25-30 ml of conditioned media. The media in each 
flask was removed every 72 hours, three times. After the media was removed for 
the third time the cells were discarded. The conditioned media produced, 
contained the growth factors required for the maintenance of the trophoblast 
cells in a stem cell fate. The media was centrifuged, the supernatant was 
removed and filter sterilized through a 0.22 µm filter stericup (Nalgene Nunc 
International, USA) using a vacuum pump and then frozen at -20 °C until use. 
 
2.1.2.3 Culture of mTS Cells in Activin 
Activin can be used in place of conditioned medium (Erlebacher et al., 2004). Due 
to this we changed to using 10 ng/ml Activin plus 25 ng/ml of Fgf4 and 1 µg/ml 
Heparin in mTS media instead of using conditioned media. All other cell culture 
protocols were kept the same. The use of Activin was preferred as it is a more 
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controlled media, the amount of growth factors in the conditioned media can 
change with every batch.  
2.1.3 Transfection of cells with RNA -Transient Transfection 
2.1.3.1 Seeding of the Wells 
For a general transfection TS cells were grown up in one well of a 6 well plate. 
When the cells were about 80-90 % confluent the cells were passaged as in 
section 2.1.1.1 and resuspended in 1 ml of mTS medium. As a general rule about 
50-100 µl of this cell suspension was then added to each well of a 6 well plate for 
a 48 hr long transfection to prevent the overgrowth of the colonies. The cells 
were seeded at a slightly higher density for a 24 hr long transfection. The cells 
were grown in 70 % conditioned media with Fgf4 and heparin or activin until it 
was time to transfect the cells. The cells were about 30 % confluent at the time 
of transfection the following day. 
 
2.1.3.2 Transfection Procedure 
Transfections were carried out in 12 well or 6 well dishes. The Elf5 siRNA and 
negative control siRNA was obtained from invitrogen. All transfections contained 
a scrambled si negative control that was run alongside each transfection to 
account for any off target effects. The concentration used in 12 well plates was 
50 nM of siRNA (invitrogen) and 4 µl of lipofectamine 2000 (invitrogen). In 6 well 
plates it was 50 nM siRNA plus 10 µl of lipofectamine 2000.  
 
2.1.3.3 Transfection in a 6 Well Dish: 
100 pmol siRNA (5 µl of a 20 pmol solution) was added to 250 µl OptiMEM 
reduced serum medium (Gibco) at the same time 10 µl lipofectamine 2000 was 
added to 250 µl OptiMEM in a separate tube. These mixtures were incubated at 
room temperature (RT) for 5 min. After the 5 min incubation the two mixtures 
were combined and incubated at RT for 20 min. During this incubation time the 
media was replaced with 1.5 ml reduced serum (5 % FCS) mTS media as serum 
can reduce the transfection efficiency. After 20 min incubation the siRNA-
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lipofectamine mixture was added to the cells drop wise to create a final volume 
of 2 ml.  
 
2.1.3.4 Transfection in a 12 well dish: 
40 pmol siRNA (2 µl of a 20 pmol solution) was added to 98 µl of OptiMEM. At 
the same time 4 µl of lipofectamine was added to 96 µl of OptiMEM. These 
mixtures were incubated alone as above for 5 min and then combined and 
incubated for a further 20 min at room temperature. During this incubation time 
the media was replaced with 600 µl reduced serum (5 % FCS) mTS media. After 
20 min incubation the siRNA-lipofectamine mixture was added to the cells drop 
wise to create a final volume of 800 µl. 
 
The cells were incubated for 4-6 hours in the presence of the RNA. After this time 
the cells were rinsed with PBS and fresh complete media was added to all cells. 
The cells were then incubated for the required time period (24 or 48 hr). When 
the time period was reached the cells are washed with PBS and the cells were 
either fixed or if the RNA was to be isolated, the appropriate amount of Trizol 
Reagent (invitrogen) was added. For 6 well plates 500 µl of Trizol reagent was 
added to each well. For a 12 well plate 200 µl of Trizol was added.  
2.1.4 Stable Transfection of TS cells 
TS cells were stably transfected with the Elf5-mo-Vp16-ER-pyCAGizeo plasmid. 
This vector was for the over-expression of the Elf5 protein.  To further validate 
the Elf5 targets a tamoxifen inducible Elf5 was used. The opposite trends should 
be observed when Elf5 is over expressed. Tamoxifen binds to the estrogen 
receptor ligand binding domain of the Elf5-ER fusion protein causing 
translocation into the nucleus and the inducible activation of Elf5 targets. The 
VP16 transcriptional activation domain has been added to ensure robust 
transcription.  
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2.1.4.1 Preparation of Plasmid DNA 
Before transfection into the TS cells the plasmid must be linearised first. 4 µg of 
DNA was required for one transfection and the transfection was carried out in 
quintuplets so 20 µg of DNA was required. 30 µg of DNA was digested with a 
restriction enzyme which cut the vector in the ampicillin resistance gene and 
then it was purified using a Wizard column see section 2.3.2.4.1. 
 
2.1.4.2 Preparation of TS Cells  
This protocol was obtained and modified from Himeno et al.,(2008). 
To obtain an adequate number of cells for a stable transfection, the TS cells were 
grown up in 100 mm culture dishes. When the cells were about 80 % confluent 
the media was removed, they were washed with PBS and 1 ml of TrypLE Express 
was added. The cells were then put back in the incubator at 37°C for 4 min to lift 
the cells. 5 ml of mTS media was then added and gently pipetted up and down to 
break the cell aggregates. The cells were then washed and resuspended in 6 ml 
of mTS media. The cells were then counted and diluted in TS medium to give a 
cell number of 5 x 105 cells/ml. 
 
2.1.4.3 Preparation of the Lipofectamine Complex 
4 µg of the plasmid DNA was diluted in 250 µl of OptiMEM reduced serum media 
in a 1.5 ml eppendorf tube. In another tube 10 µl of lipofectamine 2000 was 
mixed with 240 µl of OptiMEM and incubated at room temperature for 5 min. 
After the 5 min incubation the DNA and lipofectamine mixtures were combined 
and incubated at room temperature for 20 – 40 min.  
 
2.1.4.4 Transfection of the TS Cells 
As the cells were not already plated at the time of transfection, this class of 
transfection is described as a reverse transfection. The DNA/lipofectamine 
complex was added to a 35 mm petri dish (non tissue culture, but sterile) and 
then 1 ml of the cell suspension was added and mixed by gentle pipetting. For a 
control cell line 1 ml of cells were mixed with 500 µl of 70 % conditioned media. 
The cell/lipofectamine complex was then returned to the incubator and left for 
4-5 hr.  
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After 4-5 hr the cells were transferred to a larger dish to allow growth of the cells 
during antibiotic selection without the need for passaging. The un-adherent cells 
were removed and placed in a 15 ml falcon tube. The adherent cells were 
washed with PBS and the PBS was transferred to a falcon tube (in case any cells 
come off during the wash) and then 300 µl of TrypLE Express was added to the 
cells and incubated for a few minutes until the remaining cells became loose. The 
cells were re-suspended in mTS media, centrifuged and then re-suspended in 10 
ml of 70 % conditioned media with Fgf4 and heparin. The cells were then plated 
in a 100 mm tissue culture dish. 
 
2.1.4.5 Antibiotic Selection for the Introduced Plasmid 
As the introduced Elf5-mo-VP16-ER-pyCAGizeo plasmid contained the gene for 
zeocin resistance the cells containing the plasmid integrated into their genome 
could be selected for with zeocin (invitrogen). 24 hours after the transfection the 
media was replaced with media containing 200 µg/ml zeocin. Zeocin causes cell 
death by intercalating into DNA and cleaving it. Zeocin resistance is obtained by 
the Sh ble gene product which inactivates zeocin by binding to it to prevent it 
binding to DNA (Invitrogen, 2009). The media was changed every second day 
until the cells without the plasmid began to die. As zeocin is quite a slow acting 
antibiotic this could take up to 2 weeks. The rate of cell death could be 
monitored by the control cell line. The control cell line was not transfected so 
when these cells died off the remaining cells could be considered as Zeocin 
resistant and therefore contained the plasmid DNA integrated into their genome.  
 
2.1.4.5.1 Modified Protocol- Selecting With Puromycin 
As zeocin is a slow acting antibiotic a rapidly acting antibiotic was used in 
following transfections. Puromycin is a fast acting antibiotic and cell death should 
occur within a couple of days. Puromycin resistance is conferred by expression of 
the Pac gene and must be introduced on a separate plasmid. A molar ratio of 
1/10 of the Elf5-mo-Vp16-ER-pyCAGizeo plasmid was required as it is not optimal 
to have lots of colonies that are resistant to puromycin but do not contain the 
plasmid of interest. Cells were transfected as per the protocol outlined above in 
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section 2.1.4.2 with both linearised plasmids. Selection with 1 µg/ml of 
puromycin (Sigma-Aldrich) began 24 hr after the beginning of the transfection.   
 
2.1.4.6 Picking Stably Transfected Lines 
Once the non transfected cells had died off Zeocin or puromycin resistant 
colonies began to appear. These colonies were picked to establish stably 
transformed clonal cell lines. Before the colonies were picked sufficient 24-well 
plates were prepared containing 10 µl of PBS (enough for the number of colonies 
to be picked). The media was removed from 100 mm dishes and replaced with 15 
ml of PBS. A TS cell colony was picked with 5-10 µl PBS using a 20 µl pipette 
under a microscope in the laminar flow hood. The colony was transferred to a 
well of the 24 well plate. After all the colonies were picked from one 100 mm 
dish 50 µl of TrypLE Express was added to each well containing a colony and 
incubated at 37 °C for 4 min. Each colony was pipetted gently to break up the 
colonies and 200 µl of 70 % conditioned media containing 1.5x the standard 
concentration of growth factors was added to each well. The same procedure 
was repeated for the other 100 mm dishes. The plates were incubated for 24 hr 
at 37 °C and then the media was replaced with 0.5 ml of 70 % CM with Fgf4 and 
heparin and 20 µg/ml zeocin or 1 µg/ml puromycin. 
 
2.1.4.7 Screening for Insertion into Genomic DNA 
To ensure the plasmid containing the Efl5-VP16-ER fusion was inserted into the 
genome, the genomic DNA was isolated from the clonal cell lines and a PCR was 
carried out to amplify a region of the plasmid. During passaging 100-200 µl of the 
cell suspension was put aside for genomic DNA isolation. The cells were 
centrifuged at 2,000 rpm for 10 min and the supernatant was removed. The cell 
pellet was re-suspended in 5-10 µl of lysis buffer containing 1mg/ml of 
proteinase K (Roche, Germany) and incubated at 55 °C for 1 hr. 45-90 µl of MQ 
water was added to the samples, mixed and then incubated at 100 °C for 5 min. 
The genomic DNA samples were stored in the fridge until required for the PCR. 
0.5-0.05 µl of purified genomic DNA was used in the PCR reaction to amplify a 
region on the plasmid, see section 2.3.1.8 for the PCR protocol.  
 
26 
 
2.1.4.8 Over Expression of Elf5 
The over expression of Elf5 was induced upon the addition of 4-
hydroxytamoxifen (OHT) where the fusion protein can translocate into the 
nucleus and fulfil its transcriptional functions. The cell lines for analysis were 
plated out the day before in 12 or 6-well plates to give an optimal density of 30-
50 % confluence the day of induction. The following day the cells were treated 
with 0, 0.5 µg/ml and 1 µg/ml 4-hydroxytamoxifen (Sigma), returned to the 
incubator and left for 24 hr in the dark (OHT is light sensitive). After this time the 
RNA was isolated for analysis by real time PCR (see section 2.3.1.1 to section 
2.3.1.7).  
 
2.1.4.9 Immunocytochemistry 
Immunocytochemistry was carried out on fixed cells to ensure the cells were 
expressing the Elf5-VP16-ER protein and that it translocated into the nucleus 
upon the addition of 4-hydroxytamoxifen (OHT).  
 
2.1.4.10 Fixation 
Cells were plated into 8-well chamber sides and left for 24 hr. After 24 hr 1 µg/ml 
of OHT was added to the induced well and left in the incubator in the dark for 
another 24 hr. Following the 24 hr incubation the slides were washed twice with 
PBS and then fixed with either 4 % paraformaldehyde (PFA) at room temperature 
for 5 min or with 100 % methanol at -20 °C for 10 min. The slides were then 
washed with PBS twice and covered with PBS and left at 4 °C until use.  
 
2.1.4.11 Permeabilisation 
If the cells were fixed with methanol permeabilisation was not required as 
methanol produces holes in the cell membrane. If they were fixed with PFA the 
cells were permeabilised with 0.1 % Tritron-X-100 for 5 min at room temperature 
and then washed twice with Tris-buffered saline (TBS). 
 
2.1.4.12 Staining 
Non specific binding was prevented by blocking with 1 % goat serum for 30 min 
at room temperature. The slides were then washed three times with TBS-tween. 
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The primary antibody was diluted in TBS-tween containing 0.1 % BSA and 
incubated for an hour at room temperature. The unbound antibody was washed 
off by washing with large volumes of TBS-tween three times for 10 minutes each 
while rocking. The secondary antibody was diluted in TBS-tween with 0.1 % BSA 
and was left on the cells in the dark for one hour at RT. Unbound secondary 
antibody was washed off with TBS-tween three times 10 min in the dark. The 
slides were then washed with 1:10,000 dilution of H33342 (invitrogen) for 10 
min, then washed twice with distilled water and left to drip dry. The chambers 
were removed and the slides were mounted with a cover slip containing 
fluorescent mounting media. The slides were left to dry in the dark at RT over 
night. The next day the slides were analysed for fluorescence in the blue 
(H33342) and green spectrum (alexa 488 secondary antibody). An Olympus BX50 
microscope was used to observe the fluorescent cells.  
2.2 Cell Analysis Protocols 
2.2.1 Morphology 
2.2.1.1 Preparation of the Cells 
The morphology of TS cells was analysed by staining with Phalloidin-TRITC 
(Sigma) and Hoechst 33342 (invitrogen). The protocol was obtained from the 
Sigma product information sheet. 
 
This procedure was carried out to determine the morphological changes of the 
TS cells when Elf5 is knocked down. Elf5 was knocked down as in 2.1.3.3. As no 
changes were observed at 2 days we decided to investigate changes in 
morphology 5-6 days after Elf5 knockdown. Due to this long period the cells were 
passaged 48 hr after transfection to prevent the cells becoming too confluent. 
The cells were trypsinised, 1 ml of mTS media was added to lift the cells then the 
cells were pipetted up and down. As giant cells tend to adhere to the culture 
dishes a lot stronger than TS cells the remaining cells were scraped off. The cells 
were spun down, re-suspended in 1 ml and then 100 µl of this suspension was 
added to each well of a 2-well chamber slide. The cells were then grown for a 
further 3-4 days, with the media being changed every two days. 
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2.2.1.2 Fixation and Permeabilisation of the Cells 
When the cells were ready for morphological analysis the media was removed 
and the cells were washed twice gently with PBS. The cells were then fixed with 
300 µl of 4 % paraformaldehyde for 5 min at RT. The PFA was then removed by 
aspiration and the cells were washed three times with PBS. The cells were then 
permeabilised with 300 µl 0.1% Triton x-100 for 5 min at room temperature. The 
Triton X-100 was removed by aspiration and the cells were washed again with 
PBS twice.  
 
2.2.1.3 Staining of the TS Cells 
The cells were stained with 5-20 µg/ml phalloidin for 30 min at room 
temperature in the dark. Once the actin was stained the unbound phalloidin was 
removed by washing three times with PBS. Following this 20 µg/ml H33342 was 
added to the chamber and left for 5min at RT. The cells were washed once again 
with PBS. The PBS was removed, the chambers removed and a few drops of 
fluorescent mounting medium was added to each slide. The slide was then 
covered with a cover slip and left over night in the dark at room temperature to 
dry. The following day the slides were put in the fridge until photos were taken. 
Photographs were taken using an Olympus BX50 fluorescent microscope.  
 
2.2.1.4 Flow Cytometry 
For flow-cytometric analysis, a FACScan™ (Beckton Dickinson, San Jose, CA, USA), 
with an Argon laser (488 nm) was used. The machine was calibrated every time 
before use with CaliBRITE™3 beads (BD Biosciences) to ensure there was 
sufficient separation for FSC, SSC, FL1-FL3 channels using the FACSComp 
software (BD). The beads were to adjust instrument settings, set fluorescent 
compensation and to check instrument sensitivity. The forward and side scatter 
settings were adjusted so the majority of the events fitted inside a line FSC/SSC 
dotplot. A total of 10,000 events were acquired for each measurement. The data 
was evaluated using Cell Quest Pro software (BD). Robin McDonald provided 
assistance every time optimisation was required for a new assay.  
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2.2.2 DNA Content 
To confirm the morphology results, the DNA content of the TS cells was 
determined upon Elf5 knockdown. Propidium iodide (PI) can be used to stain 
DNA; the amount of PI in the cell is proportional to the amount of DNA in a cell. 
Flow cytometry was used to determine the DNA content of the cells. PI can be 
used for cell cycle analysis and determination of the ploidy of a cell. PI was useful 
here because when the TS cells differentiate into giant cells their DNA content 
increases due to endoreplication (refer to section 1.3). So the proportion of giant 
cells in a cell population of a given treatment can be determined by measuring 
the DNA content. This protocol was provided by Robin McDonald. This is a 
standard PI staining procedure.  
 
Elf5 was knocked down as in 2.2.1.1 and the cells were passaged once as above. 
After 5-6 days the cells were trypsinised, PBS was added to neutralise the trypLE 
and then pipetted up and down and the remaining cells were scraped off. The TS 
cells that had been in media with no growth factors for 6 days had to be 
trypsinised for longer as giant cells are more resistant to TrypLE Express.  
 
2.2.2.1 Modification to Protocol 
The cells tended to be quite clumpy due to scraping the remaining giant cells. So 
instead of scraping the cells that had de-attached after 4-5 min of TrypLE Express 
treatment were removed and another 300 µl of TrypLE Express was added to 
each well. The cells were incubated at 37 °C until the remaining cells came off. It 
was very important that a single cell suspension was obtained as the cells can 
only pass one at a time through the sample injection port of the FACS to get an 
accurate reading. 
 
2.2.2.2 Fixation 
The cells were centrifuged, PBS removed and the cells were re-suspended in 100 
µl of PBS. 900 µl of ice cold 70 % ethanol was added to fix the cells. The cells 
were stored at -20°C for at least 24 hr. The following day the cells were counted 
and 1-2x106 cells were aliquoted into tubes. 
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2.2.2.3 Labelling of DNA 
The samples were centrifuged for 3 min at 300 x g to remove the ethanol. The 
cells were washed twice by centrifugation and were re-suspended in 500 µl PBS. 
To this 500 µl of DNA extraction buffer was added and the cells were vortexed 
gently to suspend the cells. They were then incubated at RT for 10 min. The DNA 
extraction buffer was removed by centrifugation and the cells were re-
suspended in 1 ml DNA staining buffer containing 50 µg/ml PI (invitrogen) and 50 
µg/ml RNase A (invitrogen). The cells were vortexed briefly and incubated in the 
dark for at least 30 min at room temperature. The cell suspension was passed 
through BD filter tops to remove any cell clumps before analysis by flow 
cytometry. DNA QC particles (BD) were used for verification of instrument 
performance and quality control of the FACS before DNA analysis. These particles 
ensured there was a good separation between the G1, S, and the G2/M phases 
of the cell cycle. DNA staining by PI was measured in channel 3 (FL3, bandpass > 
600 nm) with linear amplification.  
2.2.3 Proliferation 
Proliferation assays were used to determine if there was a change in 
proliferation when Elf5 was knocked down. The protocol was obtained from the 
cell signalling website  from invitrogen. This was a general protocol for antibody 
labelling of cells for flow cytometry. 
 
2.2.3.1 Controls 
Cell cycle-dependent H3 phosphorylation begins in late G2 and remains high 
through early anaphase (Hendzel et al., 1997). As a positive control, cells were 
treated with 15-100 ng/ml Nocodazole for 16 hr. Nocodazole halts cells in the G2 
phase and therefore can be used as a positive control for the phosphorylation of 
histone 3 at serine 10 as this marker is at a maximum at G2/M phase of the cell 
cycle. Mitomycin C treatment was used as a negative control. 
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2.2.3.2 Knockdown and Fixation  
Elf5 was knockdown as in section 2.2.1.1 and 2.2.2.1 and the cells were passaged 
once during treatment. The media was removed, and the supernatant was put 
into a 15 ml falcon tube. The cells were washed with PBS, and the supernatant 
was kept again as mitotic cells are loosely adhered to the plate. The cells were 
trypsinised as in 2.1.1.1, neutralised with PBS and all cells were removed all cells 
by pipetting up and down. The cells were centrifuged, the PBS aspirated and re-
suspended in 1 ml PBS. 1 ml of 4 % PFA was added to each tube to give a final 
concentration of 2 % PFA. The cells were fixed for 10 min at 37 °C and then 
chilled on ice for a minute. 
 
2.2.3.3 Permeabilisation 
The cells were pelleted by centrifugation and then re-suspended in 5 ml of 90 % 
methanol and incubated on ice for 30 min. The cells could be stored in 90 % 
methanol at this step if required.  
 
2.2.3.4 Staining Using Antibodies  
The cells were counted and 1 x 106 cells/ml were aliquoted into tubes. 2-3 ml of 
incubation buffer (see appendices) was added to each tube, rinsed by 
centrifugation and then repeated. The cells were re-suspended in 100 µl 
incubation buffer and the cells were blocked at room temperature for 10 min. 
Blocking prevents non specific binding of the primary antibody. The primary 
antibody was added at a dilution of 1:100 to 1:500 of a 5 mcg/ml solution (had to 
be optimised) and incubated for 60 min at room temperature. The primary 
antibody was Anti-phospho-Histone H3 (Mitosis Marker). The Peptide 
corresponding to residues 7-20 of histone H3; recognizes Histone H3 
phosphorylated on serine 10. This antibody reacts with all eukaryotes; the host 
was a rabbit (Upstate).  
 
Following this the cells were rinsed twice in incubation buffer by centrifugation 
and the cells were resuspended in a 1:1000 dilution of an Alexafluor 488 goat 
anti rabbit IgG antibody (invitrogen). Incubation at room temperature for a 
further 30 min was carried out. The cells were rinsed once again in incubation 
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buffer and resuspended in 0.5 ml PBS. The cells were filtered through a 35 µm BD 
filter top to remove any clumped cells. The proliferation was then analysed on 
the flow cytometer. The measured events were gated on the FCS/SSC plot to 
exclude any sub cellular fragments and clumped cells. Alexa 488 staining was 
measured in channel 1 (FL1, bandpass 515-545). 
2.2.4 Apoptosis 
An Apo-BrdU Tunel Assay kit was purchased from Invitrogen and the protocol 
was followed and apoptotic cells were detected by flow cytometry. This protocol 
is also described by Darzynkiewicz et al., (2008). Positive and negative control 
cells were provided by the kit. The positive control was a Human Lymphoma cell 
line treated with camptothecin. The negative control was the same cell line but 
untreated. In every assay a negative control without the TdT enzyme was also 
included. 
 
2.2.4.1 Cell Preparation and Fixation 
Elf5 was knocked down according to previous protocols and apoptosis was 
analysed 48 hr and 5 days after knockdown. The media was removed, and the 
supernatant was kept as cells floating in the media are likely to be dead or 
apoptotic. The cells were washed with PBS, the supernatant was kept again. The 
cells were trypsinised as in 2.1.1.1 and 2.2.2.1, neutralised with PBS and all cells 
were removed by pipetting up and down. The cells were centrifuged, the PBS 
aspirated and the cells were resuspended in 0.5 ml PBS. 5 ml of 1 % PFA was 
added to the cell suspension and they were incubated on ice for 15 min. The cells 
were centrifuged for 5 min at 300 x g to remove the PFA and washed twice with 
5 ml PBS. The cells were resuspended in 0.5 ml PBS and 5 ml of ice cold 70 % 
ethanol was added to the cell suspension. The cells were stored at -20 °C for at 
least 24 hr. 
 
2.2.4.2 Detection of Apoptotic Cells 
The cells were centrifuged for 5 min at 300 x g to remove the ethanol. The cells 
were washed twice with 1 ml of wash buffer. In the meantime 50 µl of the DNA 
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labelling solution was prepared for each treatment. The DNA labelling solution 
contained 10 µl of reaction buffer, 0.75 µl of TdT enzyme, 8 µl of BrdUTP and 
31.25 µl of MQ water. A negative control was included at this step which was the 
absence of the TdT enzyme. The DNA labelling solution was added to the cells 
and they were incubated in a 37 °C water bath for 1 hour. The tubes were shaken 
every 15 min to keep the cells in suspension. After the 1 hr incubation the cells 
were washed twice by centrifugation with 1 ml of rinse buffer. The antibody 
staining solution was added to each sample which contained 5 µl of the Alexa 
Fluor 488 dye-labelled anti BrdU antibody and 95 µl of rinse buffer. The cells 
were incubated in the antibody solution for 30 min in the dark. After the 30 min 
incubation time 0.5 ml of propidium iodide/ RNase A DNA staining solution was 
added to each sample and they were incubated for a further 30 min in the dark. 
Before analysis on the flow cytometer the cells were passed through a 35 µm BD 
filter top to remove any clumped cells. The Alexa 488 signal was collected in 
channel 1 (FL1, bandpass 515-545). And the PI signal was collected in channel 3 
(Fl3, bandpass > 600 nm). 
 
2.3 Molecular Biology Techniques 
2.3.1 Analysis of Gene Expression  
2.3.1.1 RNA Isolation 
RNA isolation was carried out in order to isolate the messenger RNA (mRNA) in 
the cell. mRNA is a RNA copy of the genes that have been transcribed and that 
will be then translated into protein. Therefore mRNA analysis is a suitable tool 
for gene expression analysis. The reactions were scaled up according to the 
amount of Trizol containing sample that was present to begin with. To 200 µl 
Trizol containing sample 1 µl pEnSpike and 1 µl MS2 RNA (800 µg/µl) was added. 
A spike was added to give an estimation of the yield of the RNA extraction at the 
end of the cDNA synthesis. MS2 RNA was used as a carrier. 40 µl chloroform was 
added and the samples were vortexed briefly, or shaken vigorously for 15 sec. 
The RNA containing samples were then centrifuged at 14,000 rpm for 15 min. 
The sample separated into three layers; the top aqueous phase contained the 
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RNA. The top aqueous phase was transferred into a new tube. An equal volume 
of isopropanol and 2 µl of linear acrylamide (5 µg/µl) were added to each 
sample. Linear acrylamide was added before precipitation to permit the 
visualisation of the RNA pellet. The samples were centrifuged again at 14,000 
rpm at 4 °C for 30 min. The supernatant was removed and the pellet was washed 
with cold 70 % ethanol and centrifuged again for 10 min. The supernatant was 
removed and the RNA pellet was air dried, care was taken to not over dry the 
pellet. The RNA pellet was resuspended in 8 µl DEPC treated water.  
 
2.3.1.2 DNase I Treatment 
DNase I treatment was carried out on the isolated RNA to remove any genomic 
or contaminating DNA. It digests single and double stranded DNA to oligodeoxy-
ribonucleotides containing a 5’ phosphate. 1 µl of 10 x DNase I reaction buffer 
(Invitrogen) plus 1 µl DNase I (Invitrogen) was added to the RNA, and they were 
incubated at 37 °C for an hour. After this time 1 µl of 25 mM EDTA (Invitrogen) 
was added to each sample and was incubated at 75 °C for 10 min to inactivate 
the DNase. Following this 1.5 µl sodium acetate and 45 µl 100 % ethanol was 
added, this was left at -20 °C over night to precipitate the RNA. The following day 
the RNA was centrifuged at 14,000 rpm for 30 min, the RNA pellet was washed 
with cold 70 % ethanol and the pellet was air dried. The pellet was resuspended 
in 12 µl DEPC treated water.  
 
2.3.1.3 cDNA Synthesis 
cDNA synthesis involves making a single stranded copy of DNA from mRNA. The 
enzyme reverse transcriptase is an RNA dependent DNA polymerase that is 
isolated from a retrovirus. The reverse transcriptase enzyme needs a 3’ primer as 
a start point; this is provided by the oligodT primer which hybridises with the 
polyA tail on the 3’ tail of the mRNA. The enzyme can then synthesise a 
complementary DNA copy of the mRNA by incorporating dNTPs that are added in 
the reaction mixture. To 12 µl RNA sample, 1 µl of 10 mM dNTP mix (Roche, 
Germany) and 1 µl of an oligodT14VN mix (invitrogen) was added to each sample. 
The sample was mixed and incubated at 65 °C for 5 min, then put on ice for a 
minute. 4 µl of a 5x first strand buffer (contains Mg2+ for the reverse 
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transcriptase, invitrogen) plus 1 µl of RNAse Out (an RNase inhibitor, invitrogen) 
and 1 µl of Superscript III reverse transcriptase (invitrogen) were added to each 
tube. The samples were mixed and incubated at 50 °C for 60 min to allow the 
enzyme to make a complimentary copy of the mRNA. After the 50 °C incubation, 
the temperature was raised to 70 °C for 15 minutes to inactivate the reaction 
and then put on ice to cool. 0.5 µl of RNase H (invitrogen) was added and the 
samples were placed at 37 °C for 30 min to remove the RNA of the RNA: DNA 
hybrid to leave a single stranded DNA copy of the mRNA message. After the 
RNase treatment 2 µl of sodium acetate and 60 µl of 100 % ethanol were added 
and the DNA samples were left at -20 °C overnight to precipitate. The following 
day the samples were centrifuged at 14,000 rpm for 30 min, washed with 70 % 
ethanol, air dried and the pellet was re-suspended in 100 µl T.1E. The DNA could 
then be amplified by real time PCR to see what genes were expressed and at 
what level.  
 
2.3.1.4 Primer Design for Real Time PCR 
The real time PCR primers were designed to amplify preferably the 3’ region of 
the gene of interest. The cDNA sequence of the gene of interest was found by 
using the reference gene accession number or the name of the gene. The 
sequence was imported into vector NTi which has primer designing software. 
The primers were designed for real time PCR with specific requirements. The 
amplicon should be designed over an intron to ensure contaminating genomic 
DNA was not present. The product length was a minimum of 150 bp maximum 
350 bp, Ta optimum of 56-60 °C, no complementary binding to avoid primer 
dimers. 18-22 nucleotides in length, avoid poly-base stretches to prevent 
inappropriate hybridisation, primers should have compatible melting 
temperatures (within 5 °C), 40-50 % GC, even spread of G and Cs and AA on the 
3’ end of both primers. With all these specifications the prefect primer pair was 
hard to come by therefore a few attempts may be required to get a good pair of 
primers to amplify the gene of interest. The primers were tested via reverse 
transcriptase PCR first to make sure one product was obtained. This was tested 
by running the product on an agarose gel and obtaining a single band. Also melt 
curve analysis was used make sure there was only one peak which will verify a 
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specific product. The PCR primers were resuspended in TE and then diluted to a 
10 µM working stock in either DEPC treated water or T.1E.  
 
2.3.1.5 Real Time PCR 
Real time polymerase chain reaction (qRT-PCR) was used to amplify a gene of 
interest while simultaneously monitoring the amplification of the product in real 
time. Real time PCR was carried out in triplicate, where 2 µl of the cDNA was 
used in duplicates along with a 1:2 dilution in MQ water. A 1:2 dilution was used 
to ensure the amplification was in the linear phase of the reaction. The 1:2 
dilution should be 1 cycle behind the neat sample. To 2 µl cDNA 5 µl of SYBR 
green master mix (Takara), 0.1 µl forward primer, 0.1 µl reverse primer and 2.8 
µl of water was added to give a final volume of 10 µl. The product was then 
amplified in real time in the Corbett Research real time PCR machine. The cycling 
conditions that were used were as follows; hold at 95 °C for 3 minutes to 
denature the DNA, and then 40 cycles of 95 °C for 10 seconds, 60 °C for 15 
seconds and then 60 °C for 20 seconds. After 40 cycles a melting step was 
performed from 72 °C to 99°C increasing by 1 °C in each step. If good results 
were not obtained with these conditions the annealing temperature was usually 
changed. If that was not successful GC rich solution was added to the master 
mix. And if that was unsuccessful the primers were redesigned.  
 
2.3.1.6 Analysis of Results 
The melt curve was analysed to ensure only one peak was present for each PCR 
primer pair. If there was more than one peak it was due to primer dimers or 
contaminating genomic DNA. When primers produce more than one peak the 
primers were usually redesigned. Once the melt curve had been analysed to 
ensure there was a clean melt curve, the comparative quantitation function was 
used to give the Ct value and the amplification efficiencies. The Ct values were 
analysed to ensure the duplicates were within ± 0.03 of each other and the 1:2 
dilution was one cycle later ± 0.03. The Ct values and amplification efficiencies 
were then copied into an excel file with specific formulas to calculate copy 
number for each sample. The initial copy number was calculated by the 
equation:  No = 1/Ef
Ct   (Wilkening and Bader, 2004). 
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Where No is copy number, Ef is efficiency and Ct is the crossing point or the Ct. 
The copy number was compared to the geometric mean of three housekeepers 
(Gapdh, β-actin and β-tubulin) to give relative expression levels. The change in 
gene expression was compared to an untreated sample as a control or a si 
negative control for the knockdown data.  
 
2.3.1.7 Spike 
Primers for the spike were used to amplify the spike RNA added to the RNA 
sample at the start of the RNA isolation. A good extraction usually yields a spike 
Ct value of about 20.0. If the Ct values were much later than this then it could be 
assumed that some RNA had been lost during the extraction. A spike was added 
to every sample during a RNA isolation.  
 
2.3.1.8 Reverse Transcriptase PCR 
Reverse transcriptase PCR was carried out to amplify a gene or DNA of interest. It 
was then followed by gel electrophoresis to examine expression of certain genes 
or to use the DNA for cloning. For a standard 25 µl reaction the following 
reagents were added to 1 µl cDNA synthesised in step 2.3.1.3. 19.8 µl MQ water, 
2.5 µl 10x PCR reaction buffer (Roche), 0.5 ml 10 mM dNTP mix (Roche), 0.5 µl of 
each of the forward and reverse primers and 0.2 µl of the fast start Taq 
polymerase (Roche). A standard PCR would have the following cycling conditions; 
95 °C for 5 min to denature the DNA, then 35-40 cycles of 95 °C for 30 sec to 
denature the DNA, 56-60 °C for annealing and 72 °C for 30 sec for elongation. 
Then a final elongation step at the end at 72 °C for 5-7 min. A PTC-200 Peltier 
Thermal Cycler was used for reverse transcriptase PCR. The amplified DNA was 
then stored at 4 to -20 °C until use. 
 
2.3.1.9 Agarose Gel Electrophoresis  
An agarose gel was used to view DNA fragments and to determine their 
molecular weight. DNA fragments can be separated according to size as smaller 
fragments run through the agarose gel faster than larger fragments. Depending 
on the size of the DNA fragment to be separated a 0.6-2 % gel was made. To 
separate small pieces of DNA a higher percentage gel was used as small 
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fragments travel through the gel matrix much easier than large fragments. To 
separate large fragments a low percentage agarose gel was used. Agarose 
powder was suspended in 0.1 % TAE buffer, heated in a microwave to dissolve 
the agarose and then poured in a gel cast with a comb and left to set. Ethidium 
bromide (Sigma) or SYBR safe (Molecular probes, invitrogen) was added to the 
gel before it was poured to allow visualisation of the DNA bands under UV light. 
A loading buffer was added to the DNA samples and then they were loaded into 
the wells of the gel. A molecular weight DNA ladder of 100 bp, 1 KB or an ultra 
ranger DNA ladder was added in an adjacent well at the same time so the size of 
the DNA bands could be determined. As DNA is negatively charged it would run 
towards the positive electrode when current was applied. The DNA separated 
according to size and then the samples with the correct size fragments were 
used for cloning or any other application. 
2.3.2 Sub Cloning 
Subcloning is the transfer of a gene of interest from one plasmid to another. Sub 
cloning was used to create the Elf5-mo-VP16-ER-pyCAGizeo plasmid. The Elf5-
mo-ER-pyCAGizeo plasmid was provided by Craig Smith (a Scientist at 
AgResearch, Ruakura). The VP16 cassette was added as it is a transcriptional 
activation domain which may improve the transcription of the Elf5 gene. The 
VP16 cassette was isolated from the pTet-Advanced plasmid (Clontech). 
 
2.3.2.1 Restriction of the Vector 
The vector into which the VP16 fragment was to be inserted into had to be 
restriction digested to open the vector at the site that the VP16 fragment was 
inserted into. In a 20 µl reaction 2-3 µg of the Elf5-mo-ER-pyCAGizeo plasmid 
DNA was cut to open with NheI for insertion of the VP16 product. 
 
2.3.2.2 Dephosphorylation of the Vector 
Dephosphorylation of the vector fragment ends was essential when the ends 
were compatible to each other. This prevented the re-ligation of the vector to 
itself. To 20 µl of the restricted plasmid DNA 24 µl of MQ water plus 5 µl of 10 X 
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CIP buffer (Roche) and 1 µl of CIP (Roche at 1 U/µl) was added. The mixture was 
incubated at 37 °C for 30 min then another 1 µl of the CIP was added and 
incubated for a further 30 min. The vector was then run on an agarose gel and 
gel purified (refer to gel purification 2.3.2.4). 
 
2.3.2.3 Cloning using PCR 
PCR was used to amplify the gene of interest for cloning. The Gene of interest 
was amplified for cloning by using primers containing a 5’ restriction sequence of 
choice and a 3-4 bp clamp as enzymes do not cut very well at the end of 
fragments. Two primers with the restriction sites SpeI and NheI were used to 
amplify the VP16 cassette. 1 ng of plasmid DNA was amplified in a 50 µl PCR 
reaction. The cycling conditions used were 95 °C for 5 min then 30 cycles of 95 °C 
for 30 sec, 60 °C annealing for 30 sec and then 72 °C for 30 sec for extension. This 
was followed by 72 °C final extension for 10 min at the end. The PCR was carried 
out as a traditional PCR (see section 2.3.1.8) and then the fragment was 
restriction digested with SpeI and NheI to remove the clamp, gel purified and 
ligated into the vector 
 
2.3.2.4 Gel Purification 
DNA fragments were purified from an agarose gel when the fragments were 
needed for cloning. There are three methods that have been used here, the 
Wizard® (promega), GENECLEAN® (Obiogene), MERmaid®(BIO 101). These 
products can also be used to purify PCR products directly without running a gel. 
 
2.3.2.4.1 Wizard 
The Wizard system can be used to extract and purify DNA fragments of 100 bp to 
10 Kb. The standard protocol is as follows. If purifying from an agarose gel, the 
gel slice containing the DNA of interest was weighed and 10 µl of membrane 
binding solution was added per 10 mg of gel slice. The mixture was vortexed and 
incubated at 50-65 °C until the gel slice dissolved. If beginning with a PCR 
product an equal volume of membrane binding solution was added to the PCR 
reaction. The dissolved mixture was added to the SV minicolumn which was 
placed in a collection tube. It was incubated at room temperature for one minute 
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and then centrifuged at 16,000 x g for one minute. The flow through was 
discarded and reinserted into the collection tube. The column was then washed 
twice with the membrane wash solution, the column was air dried and then the 
DNA eluted with 30- 50 µl of DEPC water or TE.  
 
2.3.2.4.2 GENECLEAN 
GENECLEAN can also be used to purify DNA from agarose gels or PCR reactions. 
The DNA bands were cut out of the gel, placed in pre weighed tubes and the gel 
slices were weighed. 4 volumes of Iodide mixture was added to each tube (kept 
at 4°C) and incubated at 55 °C for 5 min or until the gel was completely dissolved. 
The glass beads were vortexed vigoursly and then 5 µl of the glass beads were 
added to the mixture. The mixture was then centrifuged at full speed for one 
second. The supernatant was aspirated and 700 µl of cold ethanol wash was 
applied and the beads were resuspended. The sample was spun and washed 
again and the supernatant was aspirated. Then 5 µl of water was added to the 
purified DNA and incubated at 55 °C for 5 min, after this time the tube was spun 
again and the 5 µl of supernatant containing the purified DNA was retrieved. 
 
2.3.2.4.3 MERmaid 
This kit can also purify DNA from agarose gels or PCRs; only the gel purification 
method was used here. The MERmaid system can be used to successfully purify 
small fragments of DNA of 10-200 bp. 
The glassfog was re-suspended and 400 µl was added to the spin filter. Up to 300 
mg of gel slice was added to the matrix and it was heated in a 55 °C water bath 
to dissolve to gel. The sample was then incubated at room temperature for 5 min 
with agitation to mix and then centrifuged for 1 min at full speed to transfer the 
liquid to the catch tube. The matrix was then washed with 500 µl of the high salt 
wash and then washed twice with a cold ethanol wash. 10 – 25 µl of the elution 
solution was added to the filter and the glass fog was re-suspended by flicking 
the tube. The DNA was eluted by centrifugation. 
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2.3.2.5 Ligation  
For cloning the VP16 DNA was either ligated into P-GEM Teasy for TA cloning or 
the Elf5 tamoxifen inducible plasmid. Ligation was carried out using a Takara 
DNA ligation kit. To 2 µl DNA 1 µl of pGEM-T Easy plasmid and 3 µl of the Takara 
mighty mix was combined. For the VP16 cassette and the Elf5-mo-ER-pyCAGizeo 
plasmid, equivalent molar ratios were used. This was then incubated 30 min to 
over night at 16 °C. The mighty mix contains a T4 DNA ligase which joins the ends 
of the plasmid with that of the PCR product. 
 
2.3.2.6 Transformation 
The plasmid containing the PCR product was transformed into Invitrogen Max 
Efficiency® DH5α™ Competent Cells to amplify the plasmid containing the DNA of 
interest. Max Efficiency® DH5α™ Competent Cells were thawed on ice. The 1-2 µl 
of the ligation mix was added to the cells, and was mixed by stirring gently with a 
pipette tip. The cells were incubated on ice for 30 min. The cells were then heat 
shocked for 45 sec at 42 °C and then plunged into ice for 2 min. 200 µl SOC 
medium was then added and left shaking horizontally at 37 °C for an hour. 
During this time LB-Antibiotic plates were prepared containing 2.5 % LB broth, 
1.2 % agar and 100 µg/ml Ampicillin. The vector contained ampicillin resistance 
so only colonies containing the vector would be able to grow (with or with-out an 
insert). After an hour the transformed bacteria were spread onto the plates and 
left agar-up at 37 °C over night. The following morning white colonies of E.coli 
could be seen growing on the plates. They were left in the fridge until ready for 
picking for the minipreps.  
 
2.3.2.7 Minipreps 
Minipreps were carried out to isolate the amplified plasmid from the bacterial 
culture. In the late afternoon white colonies were picked using sterile toothpicks 
and were put into 3 ml LB/Amp broth and incubated O/N shaking at 300 rpm at 
37 °C. Up to 48 miniprep’s were carried out at one time to try and isolate 
colonies with the correct insert. The following morning, 1.5 ml was poured into a 
1.5 ml eppendorf tube for the miniprep and the other 1.5 ml was kept at 4 °C for 
a glycerol stock. The tubes were spun at 1100 rpm for 1 min, and the miniprep 
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procedure was followed. 100 µl solution 1 was added and the pellet was 
vortexed until it was fully re-suspended. Then 200 µl solution 2 (lysis buffer- 0.2 
N NaOH, 1 % SDS) was added to each tube and mixed well by inversion. 150 µl of 
cold solution 3 was then applied and the tubes were again mixed well by 
inversion. The samples were centrifuged at 13,000 rpm for 5 min at 4 °C, the SDS 
precipitates and the supernatant containing the DNA was then transferred to a 
fresh tube. An equal volume of isopropanol was added and centrifuged again at 4 
°C to precipitate the DNA. The supernatant was aspirated and washed with an 
equal volume of 70 % cold ethanol, centrifuged again and the DNA pellet was air 
dried briefly. The pellet was re-suspended in 30 µl TE containing 1:200 dilution of 
10 mg/ml DF-RNAase A and incubated at 37 °C for 30 min.  The purified DNA was 
stored at 4 °C until ready for restriction digestion. 
  
2.3.2.8 Restriction Digest of DNA 
To ensure the clones contained the correct insert the plasmid was restriction 
digested and then the products were run on an agarose gel to make sure they 
were the correct size. In a standard 20 µl reaction x mg DNA, 2 µl of restriction 
buffer and 1-2 µl of restriction enzyme was used. The volume was made up to 20 
µl with MQ water. As a general rule no more than 1/10 of the volume should be 
enzyme as restriction enzymes are stored in a 50 % glycerol solution, high 
concentrations of glycerol can inhibit the restriction enzyme or cause non 
specific (Star) activity.  
 
2.3.2.9 Maxi Preparation of DNA 
A maxi prep was carried out to get enough DNA for sequencing and to transfect 
the cells with. 200 ml of LB broth was inoculated with 1 µl of an overnight culture 
kept in the fridge that was used for the minipreps. Only 1 µl was used to try and 
get a single colony with the fragment of interest in the plasmid. The Roche maxi 
prep procedure was followed. The culture was incubated overnight shaking at 
300 rpm at 37 °C. The following morning the bacteria were centrifuged for 10 
min at 5,000 x g at 4 °C. The supernatant discarded and the pellet was re-
suspended in 12 ml of suspension buffer which contains RNase. The pellet was 
vortexed until the pellet was suspended in the buffer. 12 ml lysis buffer was 
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added to the suspension and mixed gently by inversion and then incubated on 
ice for 5 min. An SDS precipitate forms. The solution was separated from the 
precipitate by filtration. The column was then equilibrated and lysate was loaded 
on to the column and allowed to flow through (flow through discarded), the 
plasmid binds to the column. The column was washed two times with wash 
buffer. The column was put into a collection tube and the plasmid was eluted 
with 15 ml pre warmed elution buffer (50 °C). The DNA was then precipitated 
with 11 ml of isopropanol, mixed by inversion and centrifuged for 30 min at > 15, 
000 x g at 4 °C. The supernatant was discarded and the pellet was washed with 5 
ml chilled 70 % ethanol and centrifuged again. The ethanol was removed by the 
use of a vacuum pump. The pellet was re-suspended in 50 µl T.1E and left at 4 °C 
over night to dissolve. The next morning the DNA concentration was measured 
on the nanodrop. Other kits were also used (Invitrogen and Qiagen) but the 
general procedure was similar. 
 
2.3.2.10 Sequencing 
The maxiprep DNA was sent to the Waikato University DNA Sequencing facility to 
check the sequence of the ligation sites and the sequence of the insert. 
 
2.3.2.11 Glycerol Stocks 
Once a clone was obtained that had the VP16 inserted correctly a glycerol stock 
was made. 850 µl of the bacterial suspension saved from the miniprep was 
added to 150 µl of pure glycerol in a cryovial. The stocks were flask frozen by 
immersion in liquid nitrogen for a few seconds, and then stored at -80°C until 
required.  
 
2.3.2.12 The Nanodrop 
The nanodrop was used to estimate DNA or RNA concentration of a given 
sample. The machine was calibrated with water and then ‘blanked’ with 
whatever the DNA or RNA was re-suspended in (e.g. MQ or TE or T.1E). Then the 
concentration 1 µl of the sample was measured to give a concentration in ng/µl. 
The 260/280 and 230/280 absorbance ratios were also given which are an 
indication of solvent contamination and nucleic acid purity respectively. A 
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260/280 ratio of 1.8 or greater is considered pure for DNA; a lower ratio could be 
due to phenol, protein or other contaminants that absorb strongly at 280 nm. A 
260/230 ratio measures nucleic acid purity, a pure sample has a ratio of 2.0-2.2. 
2.3.3 Whole Mount in situ Hybridisation 
2.3.3.1 Probe Preparation 
Whole mount in situ hybridisation was used to examine the expression of the 
genes of interest in day 6.5-7.5 mouse embryos. 
 
2.3.3.2 Primer Design 
Primers were designed to amplify the 3’ end of the gene of interest. The optimal 
length of the PCR product was 700-1000 base pairs. Highly conserved regions of 
the gene should be avoided so the probes do not hybridise with mRNA of other 
genes. The prevention of cross hybridisation can be ensured by using the 
Ensembl web site: http://www.ensembl.org/Mus_musculus/index.html and 
determining how many members are present in the superfamily. If there were 
many members in the superfamily a blast search was carried out 
http://blast.ncbi.nlm.nih.gov against the mouse genome. If the overall identity of 
the two genes was over 85 % that area that showed possible cross hybridisation 
was excluded and also short stretches with over 95 % identity were also to be 
excluded. If the region could not be excluded a note was taken in case of cross 
hybridisation later on. Primers were designed by using vector NTi software or by 
eye. The sequence of each gene was also checked for abnormally high or low GC 
content. As cloning was carried out by TA cloning, primers were designed with an 
A or a G at the 5’ end as Taq polymerase is more likely to put an A on the 3’ end 
of the product. Adding an A at the 5’ end of the primer increases cloning 
efficiency (Peng et al., 2007). 
 
Primers were ordered from Sigma and they were re-suspended in Tris-EDTA to 
give a 1 mM stock solution and were stored at -80 °C. Primers were then diluted 
1:100 in DEPC treated water to give a 10 µM working solution, they are stored at 
-20 °C.  
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2.3.3.3 Cloning using PCR 
The genes of interest were amplified using PCR. The PCR was carried out in a 
PTC-200 Peltier Thermal Cycler containing the following reaction mix;  
MQ water 40.5 µl  
10 x PCR buffer 5 µl 
dNTP mix (10 mM) 1 µl 
DNA template 1 µl 
Forward primer (10 µM) 1 µl 
Reverse primer 10 µM 1 µl 
FastStart Taq Polymerase 0.5 µl 
 
The 10x PCR buffer provides a stable chemical environment for the Taq 
polymerase including Mg2+. The dNTP mix is deoxynucleotide triphosphates 
which were used as the building blocks for the new DNA. The samples were 
mixed and run at the following temperatures; 95 °C for 5 min (hot start), then 35 
cycles of 94 °C 30 sec (denaturation), 60 °C 45 sec (annealing- primer 
dependant), 72 °C for 1 min (elongation). Then 72 °C for 10 min and then held at 
4°C. Then 5 µl of the product was run on a 1 % agarose gel containing ethidium 
bromide with 1 µl gel loading buffer with a 100 bp ladder at 95 V until a good 
separation of the DNA bands was obtained. 
 
2.3.3.4 Purification of the PCR Product 
The PCR product had to be purified as Taq is difficult to inactivate and would fill 
in restricted ends, as primer dimers will compete for restriction enzymes and as 
nucleotides will interfere. Product purification was carried out using a Wizard® SV 
Gel and PCR Clean-Up System. The manufacturer’s instructions were followed 
see 2.3.2.4.1 above. The eluted DNA was stored at -20 °C until further use.  
 
2.3.3.5 Ligation of DNA into the Vector 
As Taq DNA polymerase adds a 3’ A to the end of the DNA strand (Zhou and 
Gomez-Sanchez, 2000) this single nucleotide overhang can be used in TA cloning 
46 
 
where the vector contains a single T over-hang which allows hybridisation of the 
product into the vector. 
 
Ligation was carried out using a Takara DNA ligation kit. To 2 µl DNA 1 µl of 
pGEM-T Easy plasmid and 3 µl of the Takara mighty mix were added on ice. This 
was then incubated over night at 16 °C. The mighty mix contains a T4 DNA ligase 
which joins the ends of the plasmid with that of the PCR product. 
 
2.3.3.6 Transformation 
The plasmid containing the PCR product is transformed into Invitrogen Max 
Efficiency® DH5α™ Competent Cells to amplify the plasmid containing the DNA of 
interest. Blue/white selection was used to identify cells that contain the plasmid 
with an inserted DNA fragment. The β galactosidase enzyme normally converts 
its substrate X-gal to a blue precipitate in the presence of an inducer IPTG which 
results in the formation of blue colonies. When a DNA fragment is inserted into 
the MCS, the β galactosidase gene is disrupted. When this gene is disrupted the 
enzyme cannot convert its substrate X-gal into a blue precipitate, instead white 
colonies are formed. 
 
The same transformation protocol was followed as in sub cloning, section 2.3.2.6 
above, except blue/white selection could be used with the PGem-Teasy plasmid. 
When the LB/Amp plates were set 40 µl of 20 mg/ml IPTG and 20 µl of 20 mg/ml 
X-gal was spread onto each plate as they are the substrates for blue/white 
selection. After an hour the transformed bacteria were spread onto the plates 
and left agar-up at 37 °C over night. The following morning blue and white 
colonies of E. coli could be seen growing on the plates. They were left in the 
fridge until ready for picking for the minipreps.  
 
2.3.3.7 Minipreps 
Minipreps are carried out to isolate the amplified plasmid from the bacterial 
culture. Usually only 6 minipreps were needed as TA cloning usually has a high 
efficiency and blue/ white selection was used. 6 white colonies were picked and 
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the same protocol was followed as in section 2.3.2.7 to give purified plasmid 
DNA containing the insert of the gene of interest. 
 
2.3.3.8 Restriction Analysis for Insert 
To see if the miniprep clones contained the gene of interest 3 µl of the purified 
DNA was analysed by restriction digest with EcoR1 and the DNA was digested 
over night at 37 °C. There are Eco R1 sites on either side of the MCS of P-Gem, so 
the product obtained should be the same size as the product produced from the 
primers for the gene of interest.  
 
2.3.3.9 Restriction Analysis for Orientation 
Restriction digest was then carried out with the clones that had the correct sized 
insert to determine the orientation of the PCR product. As TA cloning was used 
the PCR fragment could be inserted in the forward or reverse orientation. The 
genes of interest were analysed on Vector NTI to determine what restriction 
enzymes can be used to produce two fragments of different size to determine 
what orientation the genes are in. The restriction site should be present in the 
PCR fragment and in the MCS to get appropriate sized products.  
 
2.3.3.10 Glycerol Stocks 
One clone showing the correct restriction analysis for each gene was used to 
make a glycerol stock. 850 µl of the bacterial suspension saved from the 
miniprep was added to 150 µl of pure glycerol in a cryovial. The stocks were flask 
frozen by immersion in liquid nitrogen for a few seconds, and then stored at -
80°C until required.  
 
2.3.3.11 Maxi Preparation of DNA 
A maxi prep was carried out to get enough DNA for sequencing and for probe 
template preparation. The same procedure was followed as described in 2.3.2.9. 
The DNA was pellet was dissolved in T.1E or DEPC water, concentration 
determined on the Nanodrop and sent for sequencing. 
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2.3.3.12 Sequencing 
An aliquot of maxiprep DNA was sent to the Waikato University DNA sequencing 
facility for sequencing. This is to ensure the insert is in fact the correct one and 
that the ligation sites are correct. Primers were supplied by the sequencing 
facility and used either SP6 (reverse orientation) or T7 (forward orientation) 
polymerases. The sequence of the insert can then be compared to that of the 
original by using vector NTi software. Any mismatches can be checked if they are 
real by looking at the chromatogram to see if an incorrect call has been made by 
the software.  
 
2.3.3.13 Probe Template Preparation 
To prepare a RNA probe the template must be linearised first by restriction 
enzymes. Restriction enzymes to use were determined by finding an enzyme cuts 
uniquely on the 5’ end and that creates a 5’ overhang. If the insert was in the 
forward orientation in the plasmid then the SP6 RNA polymerase was used to 
create an antisense RNA copy of the DNA. And if in the opposite orientation the 
T7 RNA polymerase was used.  
 
10 µg of the gene of interest DNA was digested at 37 °C for 2 hrs. After 2 hr 1.25 
µl of 2 mg/ml Proteinase K was added and incubated at 37 °C for a further 30 
min. RNase free solutions were used from here on. After 30 min, 50 µl of TE was 
added and a phenol chloroform extraction was performed with through 
vortexing and centrifugation for 2 min at 13 K. The top aqueous layer was 
transferred into a new tube. Chloroform extraction was performed by adding 
100 µl of pure chloroform to the supernatant tube followed by vortexing and 
centrifuged again. The top aqueous layer was transferred to a new tube and 10 
µl of 3 M sodium acetate (pH 5) and 250 µl of 100 % ethanol was added. The 
solution was mixed and left at -20 °C for at least 3 hr. After this time the samples 
were centrifuged at 4 °C for 15 min and the pellet was washed with 70 % 
ethanol, centrifuged again, the ethanol was aspirated and the pellet was air 
dried. The pellet was dissolved in 15 µl RNase free 10 mM tris, 0.1 mM EDTA. The 
concentration was estimated by running a 1:10 dilution of the DNA on a 1 % gel 
against 2 and 5 µl of a lambda standard. 
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2.3.3.14 Preparation of Riboprobes 
Dig probes were prepared from the following mixture: 
10 x transcription buffer      2 µl 
10 x Dig labelling mix (Boehringer)     2 µl 
RNase Out (invitrogen)      1 µl 
RNA polymerase (T7 or SP6) (Boehringer)    2 µl 
Linearised DNA template      1 µg 
DEPC to 20 µl 
 
The reaction mix was left a 37 °C for 2-3 hrs to allow the RNA polymerase 
produce an RNA copy of the DNA. After 2-3 hrs the RNA was run on a 1.4 % gel 
with a Lambda DNA ladder. A thin sharp slow migrating DNA band was expected 
to be seen along with two intense RNA bands that were smaller in molecular 
weight. If bands were what was expected they were run through a Roche quick 
spin column for RNA. This column works by size exclusion, where the larger 
molecules will be eluted at an earlier time than the smaller molecules as they get 
absorbed into the matrix. This allows the separation of nucleic acids from other 
molecules like the labelling mix. The probe was then ethanol precipitated by 
adding 2 µl of 4 M lithium chloride and 3 volumes of ethanol and incubated 
overnight at -20 °C. After this time the RNA was centrifuged at 13,000 rpm for 15 
min, washed with 75 % ethanol and air dried. The pellet was resuspended in 20 
µl of DEPC water.  The RNA concentration of the probe was estimated by using 
the nanodrop and then run on a 1.4 % agarose gel. 
2.3.4 Whole mount in situ hybridisation 
2.3.4.1 Embryo Retrieval and Dissections 
Wild type or +/- Elf5 female mice were mated and checked for plugs daily (a sign 
of mating). The mice were then left for the embryos to develop for the required 
time period (6.5 or 7.5 days). Upon this time the pregnant female mice were 
culled by cervical dislocation or gassed with CO2 and the uterine horns were 
removed and put into PBT (phosphate buffered saline with Tween). My animal 
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ethics application was approved on the 18/07/08 by the University of Waikato 
animal ethics committee, protocol number 731.  The multiple decidua that 
contained the embryos were carefully removed from the uterine lining. The 
embryos were found inside the top half of the pear shaped decidua. Up to 12 
embryos could be extracted from one pregnant female. The embryos were then 
fixed in 4 % paraformaldehyde in PBT for 2 hr at room temperature for E7.5 or 
one hour for E6.5. After this time the embryos were dehydrated in methanol by 
washing with PBT two times and then 20 %, 40 %, 60 %, 80 % and 100 % 
methanol. The embryos were then washed 3 x in methanol and stored at -20 °C 
until further use.  
 
2.3.4.2 Hybridisation of embryo’s 
The method was received by personal communication from Ye at al., (1995). 
 
2.3.4.3 Pre-treatment and Hybridisation 
The embryos were rehydrated through 75 %, 50 % and 25 % methanol in PBT and 
then washed 2 x in PBT. The embryos were then treated with 10 µg/ml 
proteinase K in PBT for 5 min. Proteinase K was used to permeabilise the 
embryos to allow the RNA probe to enter the tissue easily to enhance the signal. 
Permeabilisation was not allowed to continue longer than 5 min as it can damage 
the embryos. They were then rinsed carefully with PBT to remove the proteinase 
and post fixed for 20 min in 4 % PFA containing 0.1 % glutaraldehyde in PBT. The 
embryos were then rinsed and washed once in PBT. They were then rinsed once 
in 1:1 PBT and hybridisation mix when embryos had settled (and therefore 
equilibrated), then once with 1 ml hybridisation mix and allowed to settle again. 
The hybridisation mix was then replaced with fresh mix and the embryos were 
incubated horizontally for 1 hr at 65 °C. The embryos were then divided into 6 
tubes (for 6 different probes) and after one hour 1 ml pre warmed hybridisation 
mix with 1 µg/ml (~2 µl) of the digoxygenin(DIG)-labelled RNA probe was added 
and immediately placed at 65 °C. It was very important at this step to keep 
everything at 65 °C to prevent background forming. The embryos were then 
incubated horizontally at 65 °C over night, rocking gently.  
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2.3.4.4 Post Hybridisation Washes 
After the overnight incubation the embryos were rinsed twice with 65 °C pre-
warmed hybridisation mix. Then washed twice at 65 °C for 30 min with 1.5 ml 
hybridisation mix, again rocking gently. Then another wash was carried out 
horizontally for 10 min at 65 °C with 1.5 ml of pre-warmed 1:1 hybridisation: 
MABT mix. The following rinses were then carried out: 2 x with 1.5 ml MABT, 2 x 
with 1.5 ml MABT500 at room temperature. The Embryos were incubated in 
MABT500 containing 100 µg/ml RNase A at room temperature for 30-60 min. 
The embryos were then rinsed 2x with MABT500 and 2x with MABT. The embryos 
were then incubated for one hour in MABT containing 2 % Boehringer blocking 
reagent at room temperature. This was followed by an incubation at room 
temperature for 1 hour in MABT containing 2 % Boehringer blocking reagent and 
20 % heat treated lamb serum. After an hour the embryos were incubated over 
night at 4 °C in fresh MABT containing 2 % Boehringer blocking reagent and 20 % 
heat treated lamb serum plus a 1:2000 dilution of Alkaline phosphatase-anti-DIG 
antibody. Alkaline phosphatase converts its substrate NBT and BCIP to a blue 
coloured product. 
 
2.3.4.5 Post Antibody Washes and Histochemistry 
After the overnight incubation the embryos were rinsed three times with 1.5 ml 
MABT and transferred to glass scintillation vials. They were then washed 3x for 
an hour with 10 ml MABT by rolling. And then washed two times, for 10 min with 
10 ml NTMT. For colour development of the probe the embryos were incubated 
at room temperature with 1.5 ml NTMT + 4.5 µl/ml NBT (75 mg/ml in 70 % 
Dimethyl Formamide) + 3.5 µl/ml BCIP (X-phosphate; 50 mg/ml in 70 % DMF). 
The embryos were left in the dark for the colour to develop. Colour development 
took up to three days. When the colour had developed to the desired extent the 
embryos were rinsed 2x in PBT and transferred to an 80 % glycerol solution and 
kept at 4 °C in the dark. 
 
Photographs of the embryos were taken using the Leica DMI6000B microscope 
and camera. 
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2.4 Statistics 
Whole mount in situ hybridisation falls outside statistics as it is a picture of fixed 
embryos, it cannot be quantified. Gene expression by quantitative real time PCR 
(qRT-PCR) was normalised against three house-keeping genes (GAPDH, β-tubulin 
or β-actin). The geometric mean of the three housekeeping (HK) genes was taken 
to average out the effect of the house keeper (n√ (multiplication of nHK)). All 
samples had biological repeats in either duplicates or triplicates and triple qRT-
PCR measurements were taken to calculate the standard error of the mean 
(SEM). Significance was calculated by Students t-tests. 
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3 Chapter Three: Elf5 target genes in mouse Trophoblast 
Stem Cells 
3.1 Introduction 
Elf5 is a transcription factor that is essential for the maintenance of the extra-
embryonic ectoderm and the trophoblast stem cells that reside within. The role 
of Elf5 can be delineated by understanding the genes that it controls during early 
development. A common method used to delineate targets of genes is to knock 
the gene down in vitro by RNA interference (RNAi). Once the gene is knocked 
down potential down-stream targets can be identified by virtue of their change 
in expression.  
 
Such a global analysis of gene expression was carried out for Elf5 by Deane 
(2007) using an microarray (affymetrix). The expression of 22 genes were 
changed in common by two independent short interfering RNA molecules 
(siRNA) targeting Elf5 mRNA. I have analysed these candidate target genes 
further, by repeating the knockdown and analysing expression at two time points 
(24 and 48 hr post siRNA treatment) using quantitative real time RT-PCR to 
measure expression levels.  
3.2 Background to technology used 
3.2.1 RNA Interference 
RNA interference is a highly specific and powerful gene silencing event that is 
carried out by double stranded RNA. RNA interference was discovered when 
researchers Andrew Fire and Craig Mello who were studying larval development 
in the nematode worm Caenorhabditis elegans, discovered a gene lin-4 encoding 
short RNA transcripts, inhibited the translation of another gene, lin-14 (Lee et al., 
1993). RNA interference is wide spread and is seen in plants, fungi and animals. 
Small RNAs like micro RNAs (miRNA) and small interfering RNAs (siRNAs) have 
important and wide spread functions including development, disease, apoptosis 
and cancer (Rana, 2007). Small interfering RNAs (siRNA) and miRNAs are 19-25 
base pairs long and use the same machinery to elicit a gene silencing response. 
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SiRNAs have not been found to be produced endogenously in cells but they can 
be introduced into cells and use miRNA machinery. Both RNAs induce post 
transcriptional gene silencing of their targets by complementary binding to 
target mRNA sequences and causing either cleavage or translational inhibition. 
 
Small interfering RNAs can be introduced exogenously to cells to provoke RNAi. 
SiRNAs induce gene silencing by causing specific degradation of the target 
sequence upon recognition. The target sequence is only degraded if prefect 
binding is achieved. Micro RNAs do not cause degradation of their targets as 
perfect complementarity is not achieved, instead translation is suppressed (Rana, 
2007). Small interfering RNA is double stranded, one strand is the sense strand 
and the other is the antisense or guide strand. The guide strand is incorporated 
into the RNAi machinery, the RNA induced silencing complex (RISC) to silence the 
target mRNA. The sense strand of the siRNA is degraded. The RISC complex 
containing the guide strand binds to the target mRNA and prevents the 
expression of that gene by cleavage of the target mRNA (Rana, 2007).  
 
The function of genes can be elucidated by targeted silencing in vitro or in vivo. 
This can be achieved by the addition of exogenous siRNAs to knock down the 
gene of interest. After the gene of interest is knocked down the down-stream 
effects can be analysed. There are many problems associated with RNAi, 
including achieving a high transfection efficiency, specificity and activity (Hough 
et al., 2006). The ‘seed region’ which is base 2-8 from the 5’ end of the guide 
strand of the RNA is very important for target site recognition (Rana, 2007). 
There are two major factors that must be taken into account with regard to 
siRNA specificity; off target effects due to mRNAs with similar sequence as the 
target mRNA and immune stimulation (Bumcrot et al., 2006). RNAi silencing of 
target genes can be very specific, but off target effects can occur due to 
sequence similarity of mRNAs particularly at the 3’ end that binds to the seed 
region of the siRNA (de Fougerolles et al., 2007). Chemical modification of the 
riboses of the guide strand can reduce off target effects. In particular 2’-O-
methyl modification at nucleotide 2 suppresses most off target effects without 
affecting the suppression of the desired target (Bumcrot et al., 2006; de 
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Fougerolles et al., 2007; Jackson et al., 2006). Off target effects can also occur 
due to the sense strand being incorporated into the RISC machinery instead of 
the anti sense strand. It has been revealed that designing siRNAs with weaker 
binding at the 5’ end of the desired guide strand increases specificity as the RISC 
machinery will preferentially incorporate that strand. This can be accomplished 
by making a nucleotide substitution at the 5’ end (Bumcrot et al., 2006; de 
Fougerolles et al., 2007).   
 
Immune stimulation can be caused by interaction with toll like receptors 
resulting in the production of interferon. Sequences that have similarity to toll 
like receptors should be avoided, 2’-O-methyl modifications within the siRNA 
also prevent most immune responses (de Fougerolles et al., 2007). Most 
companies that offer siRNAs have algorithms that can design siRNA duplexes 
with these specifications. 
 
An optimal transfection efficiency depends on many things including cell density, 
RNA concentration, lipofectamine concentration and media components (Dalby 
et al., 2004). As nucleic acids and cell membranes are negatively charged 
something is needed to mediate transfection to overcome the electrostatic 
repulsion. Lipofectamine is a positively charged liposome that can complex with 
RNA to facilitate up take into cells (Dalby et al., 2004).  The lipofectamine 
complexes with the RNA and upon addition to cells, fuses with the cell 
membrane to release the RNA into the cell. Serum and antibiotics in the media 
can also reduce the transfection efficiency (Dalby et al., 2004).  
 
3.2.2 Quantitative Real time PCR 
Quantitative real time reverse transcribed  polymerase chain reaction (qRT-PCR) 
is used to detect and quantify messenger RNA (mRNA) in samples. Real time PCR 
permits the detection of the PCR product during the exponential phase of 
amplification allowing the simultaneous detection and amplification in one 
(Giulietti et al., 2001). The fluorescent signal increases as the DNA is being 
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amplified in each PCR cycle. qRT-PCR can be used to compare the expression of 
mRNA in different tissues, different sample treatments and can detect RNA from 
as little as one cell or embryo and is therefore a very sensitive technique (Bustin, 
2000). As well as its sensitivity, no post PCR processing is needed unlike 
conventional reverse transcriptase PCR (Giulietti et al., 2001). 
 
Before DNA can be amplified with a real time PCR machine, mRNA must be first 
isolated and converted into cDNA via reverse transcription. RNA isolation is 
carried out using TRizol reagent (invitrogen) and then copy DNA is made using 
superscript III reverse transcriptase (invitrogen). Reverse transcriptase is an 
enzyme purified from E. coli which synthesises a single strand of DNA that is 
complementary to the RNA. Oligo dt primers are used to amplify mRNA as mRNA 
contains a poly A tail at the 3’ end. Oligo dt primers contain a string of T’s on the 
end to prime to the complementary mRNA. This allows the amplification of 
mRNA only; this is useful as mRNA contains the sequence of a gene that will then 
be expressed in the form of a protein or enzyme. Once the cDNA is made specific 
DNA can be amplified using real time PCR.  
 
There are numerous chemistries available for the detection of the target DNA 
product that is formed. The one used in our lab is SYBR green. SYBR green is a 
double stranded DNA binding dye that exhibits little fluorescence when in the 
presence of single stranded RNA or DNA, but when incorporated into double 
stranded DNA during the elongation step emits fluorescence. The fluorescence is 
measured in real time after the elongation step of every cycle to give the amount 
of DNA that is present (Bustin, 2000). The intensity of the fluorescence is 
proportional to the amount of DNA produced. The amount of starting material 
can be determined by the threshold cycle (Ct). The Ct value is determined by the 
cycle that the fluorescence of the individual sample passes a defined threshold or 
background fluorescence value (Nolan et al., 2006). The higher the amount of 
starting DNA the lower the Ct value obtained. The Ct value is the cycle number 
that the fluorescence level crosses the threshold (Giulietti et al., 2001). SYBR 
green is the most commonly used material as it can be used with any primer pair. 
A disadvantage of SYBR green is that SYBR green will also bind to non specific 
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products and primer dimers. To ensure products are specific a melt curve 
analysis is performed. This is achieved by plotting fluorescence against melting 
temperature of the amplified product. A single peak should be obtained that is 
characteristic of the product (Bustin, 2000). Primer dimers can be excluded as 
they have a lower melting temperature.  
 
To quantify the results obtained the comparative threshold method is used. This 
is when formulas are used to calculate relative expression levels compared to 
some sort of calibrator like an untreated sample or control (Giulietti et al., 2001). 
The gene expression of the treated sample is compared to the untreated control 
to give a fold change in gene expression. Normalisation must be carried out to 
account for differences in starting material between samples, variation in 
amplification efficiencies and differences between samples (Bustin et al., 2005). 
This is achieved by normalisation to a house keeping gene. A house keeping gene 
should be expressed constitutively in a cell and should not be affected by 
different treatments. Common house-keeping genes include glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH), β-actin and ribosomal RNA. GAPDH is an 
ubiquitous glycolytic enzyme present in most cell types and β-actin encodes a 
cytoskeleton protein (Giulietti et al., 2001). There is no single RNA that is an ideal 
house-keeping gene so for greater accuracy the geometric mean of three 
housekeeping genes is commonly used (the geomean) (Bustin, 2000). 
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3.3 Elf5 Knockdown in mouse trophoblast stem cells 
3.3.1 Overview 
Extra cDNA samples as used for the affymetrix array were analysed for changes 
in gene expression of some of the Elf5 targets. For further verification the 
knockdown in mouse trophoblast stem cells was repeated and the target genes 
were analysed by real time PCR. Before a successful knockdown could be 
obtained, the transfection had to be optimised. A successful Elf5 knockdown of 
greater than 80 % was achieved with optimisation, allowing analysis of the Elf5 
targets by real time PCR. This provided further verification of those genes as Elf5 
targets in mouse trophoblast stem cells.  
3.3.2 Verification of microarray samples (Pilot experiments) 
Two Elf5 mRNA targeted siRNAs were shown previously (Deane, 2007) to give 
greater than 80% knockdown of Elf5 in mouse trophoblast stem cells following 
24 hr of transfection. The two siRNAs that were used were 337 and 733 (refer to 
Table 1). The name of the siRNA corresponds to the base pair position of the 
start of the siRNA on the Elf5 mRNA. The sequences of the siRNAs are given 
below. 
 
Table 1: Sequence of siRNA molecules used to knockdown Elf5 in mouse trophoblast stem cells. 
Start  Position Sense RNA Sequence 5'-3' GC% 
337 CCAACUGCAUCUCCUUCUGUCACUU 48 
733 GGAAGAAGAAUGACAGGAUGACGUA 44 
 
Real time PCR was carried out on some of the remaining cDNA from the 
affymetrix array. These samples were extra cDNA samples that were produced in 
the same knockdown experiment as the samples that were used for the 
affymetrix array. To confirm the affymetrix array a quantitative technique was 
also used to study the genes not already examined by Deane (2007).  
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The two samples that were used to knockdown Elf5 were 337 Elf5 KD and 733 
Elf5 KD. The controls were an untreated sample (no treatment) and a scrambled 
siRNA with no targets in mammalian cells (si negative control). The effect of 
differentiation/removal of growth factors was also included. When growth 
factors were removed Elf5 expression decreased, see Figure 6.  
 
 
Figure 6: The level of Elf5 Knockdown obtained by the 337 and 733 siRNAs and with no growth 
factors. N= 3. A scrambled oligonucleotide was included as a negative control (si negative). 
Expression is shown relative to the geometric mean of Gapdh, β-actin and β-tubulin. 
 
The changes in expression of those target genes not analysed by Deane (2007) 
were examined by real time PCR. This was to verify the original microarray 
samples by the use of a different technique and for more of the identified genes. 
Results are shown in Table 2 below as a fold change in expression compared to 
the untreated control. The average of three individual biological replicates was 
taken. For comparison to the microarray refer to Table 3.  These genes were 
affected only by the 733 siRNA. The results are shown as the fold change 
compared to the untreated control (N), see Table 2. 
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Table 2: Verification of the original microarray samples on genes not already examined in 
Deane (2007), results shown as fold change compared to the untreated control (N). n=3. 
  
Up or 
Down 
No GF vs. 
N 337 vs. N 733 vs. N N vs. Si- 
Elf5 - 2.0 1.8 2.6 1.3 (+) 
Mme - 3.3 1.4 (+) 2.4 1.8 (+) 
Ly6a + 9.1 (-) 1.1 2.9 1.3 
Elavl2 - 3.8 1.3 (+) 1.2 1.2 (+) 
Zic3 - 5.4 1.3 (+) 1.4 1.4 (+) 
Keratin7 + 1.2 1.1 1.9 1.1 
Bex1 - 1.1 1.9 1.4 1.1 
HOPX + 3.9 (-) 1.3 (-) 2.1 1.1 (-) 
1700112C13RIK - 6.7 1.3 (+) 1.9 1.5 (+) 
GM784 - 4.3 1.2 2.2 1.1 (+) 
 
3.3.3 Knockdown of Elf5 in TS cells 
To further this investigation we wanted new samples that were independent to 
the affymetrix array data. Furthermore two different time points were to be 
investigated, 24 and 48 hr following the initial transfection. This will provide 
independent verification of the affymetrix array data and provide more 
information about the target genes and the time response to the knockdown of 
Elf5.  
 
3.3.3.1 Replacement of Embryonic Fibroblast Conditioned Media with Activin 
TGFβ and activin are key components of embryonic fibroblast conditioned 
media. Erlebacher et al,. (2004) demonstrated that EFCM can be replaced by 
TGFβ or activin (while still supplementing with Fgf4 and heparin). The TS cells 
could be cultured in this media without any apparent changes in their stem cell 
characteristics. As this is a more controlled way of maintaining TS cells (the 
components of each batch of conditioned media (CM) can be quite variable) we 
were quite interested in using activin in our media instead of CM (refer to 2.1.2.3 
in methods). The production of conditioned media is also a lengthy process (refer 
to section 2.1.2 of methods) so the use of a commercial product was desirable. 
To ensure the gene expression of the TS cells didn’t change in any way upon 
switching to activin the expression of TS cell marker genes were analysed in four 
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lines grown in CM and compared to four lines grown in activin. The genes were 
analysed by real time PCR and these were Elf5, Eomes, Cdx2, Fgfr2 and Bmp4.  
 
 
Figure 7: Gene expression profile of trophoblast stem cells grown in activin vs. conditioned 
media, N=4. There was no significant difference in gene expression of any gene grown in 
conditioned media compared to activin. Expression was normalised to the geomean and then 
compared to the conditioned media sample (100 %).  
 
There was no obvious change in gene expression apart from the up-regulation of 
Cdx2 in the activin treatments (see Figure 7above). Two samples in the activin 
treatments had high Cdx2 levels while two other samples had similar levels to 
conditioned media samples. This change was not significant due to the high 
variation of expression in each sample. These samples were cultured at different 
time points and were in different RNA isolation and cDNA synthesis runs so that 
may have accounted for some of the variability between the samples in the same 
treatment. The experiments from here on were grown in activin instead of 
conditioned media.  
 
3.3.3.2 Initial Knockdown of Elf5 
To confirm the Elf5 target genes, Elf5 was knocked down in trophoblast stem 
cells for 24 and 48 hr. This was followed by real time PCR to analyse gene 
expression of Elf5, and the effects of Elf5 knockdown on the genes that were 
identified as target genes by the microarray.  
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The knockdown of Elf5 was initially carried out in 12 well (4 cm2) plates. For a 12 
well plate 40 pmol of siRNA is used per well plus 2 µl of lipofectamine 2000 as in 
2.1.3.4. The siRNA treated cells were harvested in 200 µl Trizol after 24 or 48 hr. 
The greatest knockdown of Elf5 achieved using this protocol was only about 50-
60 %. As we wanted knockdown of Elf5 of at least 70-80 %, optimisation was 
clearly needed. Two different siRNAs were used to knockdown Elf5- 337 and 733. 
The controls were the si negative control which was a scrambled siRNA with no 
mammalian targets, and an untreated control. A sample was also added with the 
removal of growth factors to see what effect differentiation has on gene 
expression.  
 
 
Figure 8: The best knockdown of Elf5 achieved before optimisation in mouse 
trophoblast stem cells. At 24 hr only 40 % knockdown of Elf5 was achieved, after 48 hr 
60-65 % knockdown was obtained by both siRNAs compared to the no treatment 
control. Expression was normalised to the house keeping gene Gapdh.  
 
3.3.3.3 Transfection efficiency and optimisation of seeding density with 
RNAiMAX 
The optimisation of seeding density was considered first, this is because seeding 
density can severely affect the transfection efficiency. According to the 
invitrogen lipofectamine 2000 transfection protocol (2002) a seeding density of 
30 to 50 % confluency was optimal for a transient transfection. An optimal 
seeding density in 12 well plates was difficult to obtain due to the small surface 
area. The cells tended to clump in the middle making it hard to achieve 30- 50 % 
confluency at the time of transfection. For a 48 hr long transfection the cells 
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were passaged at a lower density than those that were left for 24 hrs, as the cells 
were far to over grown if seeded at the same density as a 24 hr long transfection. 
In 12 well plates only an Elf5 knockdown of 60 % or less was ever obtained, see 
Figure 8. During this time a seeding density of 2x104 cells/cm2 for a 24 hr 
transfection and 1.5x104 cells/ cm2 for a 48 hr transfection seemed optimal.  
 
The transfection efficiency of the RNA was investigated by transfecting the TS 
cells with a Block-iT Alexa Fluor Red Fluorescent oligonucleotide (Invitrogen) 
which is essentially an oligonucleotide (oligo) coupled to a fluorescent 
compound. At the same time a novel type of lipofectamine, RNAiMax 
(invitrogen) was also tested. Both forward and reverse transfections were carried 
out. For a reverse transfection the cells were plated at the time of transfection 
(not the day before as in a forward transfection). Two different seeding densities 
were also investigated. 
 
For the reverse transfection 12 pmol of the fluorescent oligo was combined with 
200 µl of optiMEM. 2 µl of RNAiMAX was added to the optiMEM/oligo mixture 
and was incubated for 20 min. A confluency of 30-50 % of cells was desired after 
plating so 40,000-100,000 cells per well were needed. 1 ml of cells was combined 
with 200 µl of the Lipofectamine/RNAi mixture and the cells were plated down. 
For a forward transfection 12 pmol of RNAi was added to 100 µl optiMEM, and 2 
µl of lipofectamine or RNAiMAX was added to 100 µl optiMEM. After 5 min the 
two were combined and incubated for 20 min (refer to 2.1.3.2 of materials and 
methods). Then the mixture was added drop wise to the cells. The cells were left 
to incubate with the siRNA for 4 hr and then the media was replaced. After 24 hr 
the cells were washed with PBS and then fixed with paraformaldehyde. The 
transfection efficiency was then observed with a LEITZ DM IRB microscope 
(Leica). The reverse transfection did not work, as no fluorescence was observed. 
No fluorescence was observed using the RNAiMAX lipofectamine either. Due to 
the failure of the reverse transfection and the new lipofectamine, the results 
were only comparing two different seeding densities of a forward transfection. A 
lower seeding density appeared to result in a higher transfection efficiency, see 
Figure 9.    
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Figure 9: TS cells transfected to optimise the seeding density with an Alexafluor 
oligonucleotide, Transfection at a higher seeding density A), and transfection at a lower 
seeding density B). A 10x magnification was used. The fluorescence was artificially coloured red 
and the cells green. Photographs were taken using a LEITZ DM IRB microscope (Leica). 
 
3.3.3.4 Optimisation of siRNA and Lipofectamine Concentration 
The forward transfection above was repeated while optimising for lipofectamine 
2000 concentration, seeding density and siRNA concentration. The results were 
quite subjective as they were analysed by light microscopy, possibly a better 
transfection efficiency was achieved using twice the amount of lipofectamine, 
see Figure 10. The results depended on what colony was photographed and 
exposure times. Photographs were taken using a LEITZ DM IRB microscope 
(Leica). 
 
 
Figure 10: Transfection with 12 pmol of an alexa- fluor fluorescent oligonucleotide with a 
double lipofectamine concentration to determine the transfection efficiency. Photographs 
were taken at a 10x magnification. The fluorescence was artificially coloured red and the cells 
green. Photographs were taken using a LEITZ DM IRB microscope (Leica). 
B A 
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3.3.3.5 Flow Cytometry to Determine Transfection Efficiency 
As the microscopy results were quite subjective, flow cytometry (FACS) was used 
to determine the transfection efficiency of the mTS cells with the fluorescent 
oligo. For FACS analysis 2x105 to 1x107 cells were required. Due to this the 
transfection was shifted to a 6 well dish to obtain an adequate number of cells to 
analyse. Firstly unlabelled cells were used to give an idea of the cell population 
that was being studied. One 50 % confluent well of a 6 well plate was washed 2 x 
with PBS, trypsinised, and re-suspended in PBS containing 1 % FCS to prevent cell 
clumping. The cells were passed through a 35 µm filter (BD) to remove any cell 
clumps as only one cell at a time can pass through the sample injection port 
(SIP). Forward scatter and side scatter settings were optimised for the cells on 
the Becton Dickinson FACScan™.  
 
Once the machine was optimised for the cell type, the cells were transfected as 
per usual (section 2.1.3.4) but the reaction was scaled up to account for larger 
volumes. Only one concentration was used to optimise the machine and then the 
transfection conditions were to be optimised at a later time. 50 nM siRNA plus 
10 µl lipofectamine 2000 was used. Cells were washed and trypsinised after 24 hr 
as above. The fluorescence was captured on FL2 channel. Of the gated cells 91.83 
% of the population (cells of interest) were fluorescing, see Figure 11. This meant 
that the transfection efficiency was already very high and there was no need to 
optimise the transfection conditions. Region 1 (M1)/purple histogram contained 
the unlabelled cells, there was no fluorescence. When the cells were transfected 
with the fluorescent oligo the majority shifted to region 2 (M2), which 
demonstrated that there was a high transfection efficiency. 91.83 % of cells were 
in the M2 region which means these cells had been transfected with the 
fluorescent oligo. The peak was quite broad which implicates that different cells 
were transfected with varying amounts of the fluorescent oligo. When the TS 
cells were transfected under these conditions a knockdown of greater than 80 % 
was obtained (see Figure 12). This was presumably due to doubling the 
lipofectamine 2000 concentration and having the cells evenly spread out in the 
dish which makes them more accessible to the siRNA. 
66 
 
 
 
Figure 11: Transfection efficiency determined by flow cytometry. Region M1 contains the 
untransfected cells; there was no fluorescence as the cells were in the 10
0
-10
1
 region on the 
histogram (purple shading). When the cells were transfected with the Alexa-fluor 
oligonucleotide 91 % of the cells shifted to region 2 (green line). This indicated a high 
transfection efficiency was achieved. 
 
3.3.3.6 Transfection of mTS cells with Elf5 siRNA 
As a 92 % transfection efficiency was obtained in 6 well plates all transfections 
were carried out in 6 well plates hereafter. The TS cells were grown in activin for 
these experiments. The reactions were scaled up accordingly. 50 nM of siRNA 
was combined with 250 µl optiMEM and 10 µl of lipofectamine 2000 with 250 µl 
optiMEM. The mixtures were combined after 5 min and then incubated for 20 
min at room temperature. During this time the media in the plates were replaced 
with 1.5 ml 5 % FCS media (no antibiotics). After 20 min 500 µl of the 
siRNA/lipofectamine mixture was added drop wise to the cells. 
 
 The Elf5 oligos 337 and 733 were added in triplicates and the siRNA negative 
oligo and no treatment cells were prepared as duplicates as they act as 
duplicates for each other. The removal of growth factors was included to 
determine the effect of differentiation on Elf5 and its target genes. A 24 hr or 48 
M1 
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hr after the beginning of the transfection 500 µl Trizol reagent was added to each 
well. The RNA was extracted (see 2.3.1.1 and cDNA synthesised (see 2.3.1.3).  
 
Real time PCR was carried out on the 24 hr and 48 hr samples separately 
according to the protocol outlined in 2.3.1.5. Gene expression was normalised to 
the geometric mean of three house-keeping genes, GAPDH, β-actin and β-
tubulin. A greater than 80 % knockdown of Elf5 was achieved 24 and 48 hr 
following the siRNA transfection. Expression of Elf5 is shown relative to one of 
the no treatment samples, see Figure 12 below.  
 
 
Figure 12: A >80 % knockdown of Elf5 was achieved after 24 and 48 hr transfection, if averaged 
both 337 and 733 are significantly different to the si negative control p<0.005 for 24 hr and 
p<0.0002 for 48 hr. The expression was normalised to the geometric mean of the three 
housekeeping genes, Gapdh, β-actin and β-tubulin. Expression is then shown relative to one of 
the no treatment samples.  
3.3.4 Genes of Interest Identified by the Affymetrix Array 
The genes of interest identified by the affymetrix array were summarised in a 
table showing the fold change of every probe set compared to the control upon 
the knockdown of Elf5. Table 3, shows several of the genes of interest identified 
by the affymetrix array. The text in red shows the genes that are affected by both 
siRNAs and growth factor removal, the text in blue is affected by both siRNAs but 
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not growth factor removal and the purple text is affected by only 733 and by 
growth factor removal. 
 
Table 3: List of genes identified by the affymetrix array as possible Elf5 target genes. Data 
provided by Deane (2007). The results are shown as a fold change compared to the no 
treatment sample (N). Red= affected by both siRNAs and growth factor removal, blue = both 
siRNAs but not growth factors and purple is affected by only 733 and growth factor removal.  
Genes of 
Interest   
Up or 
Down 
No GF 
vs. N 
337 vs. 
N 
733 vs. 
N 
N vs. 
Si- 
Cyr61 IGFBP,cysteine rich protein 61 - 2.0 1.3 2.0 1.2 
Sox2 high mobility group box protein SOX2 - 8.6 1.4 1.9 1.0 
WDR40B WD repeat domain 40B - 3.3 1.9 2.1 1.3 
Synpo2l Synaptopodin 2-like protein - 4.2 2.1 2.4 1.1 
Mme 
Neprilysin (EC 3.4.24.11) (Neutral 
endopeptidase) (NEP) (Enkephalinase) (Neutral 
endopeptidase 24.11) (Atriopeptidase) (CD10 
antigen). - 2.4 1.3 2.3 1.1 
CALCB (incl 
EG:797) 
Alpha 
Cgrp,CA,Cal1,CAL6,Calc,Calc1,CALC2,Calca,CALC
B,Calcitonin,CGRP,Cgrp alpha,CGRP-1,CGRP-
II,CGRP2,Ct,Ctn,FLJ30166,MGC130530,RATCAL6 - 2.0 1.5 1.7 1.0 
Ly6a lymphocyte antigen 6 complex, (Sca1) + 5.3 1.2 2.2 1.1 
Sct secretin + 2.2 1.5 2.2 1.2 
Elavl2 
ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 2 (Hu antigen B) - 2.1 1.0 1.8 1.1 
Spi8 serine protease inhibitor 8 - 2.1 1.2 1.7 1.1 
Hmga2 high mobility group AT-hook 2 - 1.6 1.1 2.0 1.1 
Zic3 
Zic family member 3 heterotaxy 1 (odd-paired 
homolog, Drosophila)zinc finger protein of the 
cerebellum 3 - 7.5 1.0 2.1 1.1 
KRT7 keratin 7 + 1.8 1.2 2.1 1.1 
Rex3 Bex1 - 1.3 1.4 2.1 1.1 
HOPX HOP homeobox + 2.2 1.0 1.6 1.1 
1700112C1
3RIK RIKEN cDNA 1700112C13 gene - 3.0 1.2 2.1 1.1 
GM784 gene model 784, (NCBI) - 3.3 1.6 2.5 1.2 
 
The genes in the table above were identified by the affymetrix array as possible 
Elf5 target genes. Real time PCR was carried out only on these genes upon Elf5 
knockdown as these were the main genes of interest. Other possible targets 
were identified but they were eliminated due to low expression levels, or a high 
si negative effect. 
 
Primers were designed according to the outline on 2.3.1.4, the primer sequences 
used are given in Table 4 and Table 5 below. The primers were tested via reverse 
transcriptase PCR and the product was run on an agarose gel to ensure a product 
of the correct size is obtained (refer to sections 2.3.1.8 and 2.3.1.9 of methods). 
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All primers gave one PCR product of the correct size so they were able to be used 
in real time PCR.  
 
Table 4: Sequences of the primers used to amplify the housekeeping genes  
House 
Keeping 
genes Forward, reverse 5'-3' 
Amplicon 
Size 
No. of introns 
spanned 
GC 
rich 
Gapdh  
TGCACCACCAACTGCTTAG, 
GATGCAGGGATGATGTTC 175   1 No 
βactin  
CAGAAGGACTCCTATGTGGG, 
TTGGCCTTAGGGTTCAGGG 200  1 No 
βtubulin  
TGTAGAACCCAGCCCAATTC, 
CCTGAGGCTGAGAGATGAGG 200   1 No 
 
 
Table 5: Sequences of primers used to amplify the genes of interest by real time PCR. The GC 
rich genes have to have 1x GC rich solution included in the PCR mix.  
Gene Forward, Reverse 5'-3' 
Amplicon 
Size 
No. of 
introns 
spanned 
GC 
rich 
Cyr61  
AAAGAGACCCGGATCTGTGAA, 
TCCATCTTCGCATCGGAA 237 1 No 
Sox2  
GAGCTAGACTCCGGGCGATGAA, 
CACGAAAACGGTCTTGCCAGTA 279 1 No 
Calca  
AGCAGATCAGGAGGTGTGGTGAA, 
AGCCAGAACCATGCTGTCATGT  335 1 No 
Wdr40B  
TGAGCCTATCCAGCTCACTG, 
CACGGCATCCCATTATCTCT 253 2 No 
Hmga2  
AGCCGAGGTGCATTATCTTG, 
GGTTTGGTTTGGTTTTGGTG 201 1 No 
Spi8  
TATCTGGCACCACAAAACCA, 
AGGCAGAGTCCCCTGTATCA 249 0 No 
Secretin  
CGATGCTACTGCTGTTGCTG, 
CCAGGCTGTTCTCTGGGATA 201 1 Yes 
Bex1  
GAAGAGCGGAGCAGGTCTGAGAA, 
ACCCTCTGCATCAGGTCCCA  314 2 No 
Elavl2  
AAGCGGATTGAGGCAGAA, 
GTTGTACACAAATATGCACC 325 2 No 
Mme  
ACGCAGCAGTCGGCAAATAA, 
GCAAAGTCCCAATGATCCTGA 349 4 No 
Gm784  
CCCTTGCTTGCGCTATGAA, 
CCAGTGATAGGAGAGCCATGA 246 1 No 
Ly6a  
CCA TTT GAG ACT TCT TGC CCA TC,  
GGTCCAGGTGCTGCCTCCATTG 243 1 No 
Zic3  
CGAGTGCACACTGGCGAGAA, 
CATGTGTTTGCGCAGGGA 264 2 No 
Kert7  
AGACGGAATGGGACCTGTGAA, 
CAGGGACATGAGATGGACAAA 244 1 No 
1700112c13  
TTGGCTGTCAGGATTGTGAA, 
AGTCAAAGTTCCAGCTCACCA 211 1 No 
Hopx  
GGTGGAGATCCTGGAGTACAA, 
GAGATGGAGTTCCAAGAGCAA 223 1 Yes 
Synpo2L  
TCACTACCACCTACACCCAGAA, 
CCGCCGCTTCTTAAACAT 170 1 No 
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3.3.5 Analysis of Target Genes 
As a good knockdown of Elf5 was achieved (see Figure 12) the expression of the 
Elf5 targets were analysed by real time PCR following Elf5 knockdown. 
Expression was normalised to the geomean and the results were averaged and 
the error bars show the standard error of the mean (SEM). The expression levels 
are shown relative to the no treatment control, see Figure 13. For raw real time 
data refer to tables 16-18 in the appendices. 
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Figure 13: Changes in gene expression of the target genes in mouse trophoblast stem cells after 
24 and 48 hr knockdown of Elf5 n=3. Expression was normalised to the geometric mean of 
Gapdh, β-actin and β- tubulin and then to the no treatment. Significance compared to the si 
negative control * p=<0.05, **p=< 0.01. 
 
Of the 16 genes analysed 11/16 were confirmed as Elf5 target genes. These 
results corroborate the results from the affymetrix array carried out by Deane 
(2007). Suitable primers for Synpo21 could not be found. The change in 
expression after 24 hr was not as great as the change noted by the affymetrix 
array. The affymetrix results seem to lie between the 24 hr and 48 hr knockdown 
results. See Table 6 for a comparison of gene expression between the affymetrix 
array and the knockdown data obtained here. Activin was used in the TS cell 
culture and may have caused the subtle difference in the time it took to have an 
effect.  
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Cyr61 was rapidly down-regulated 24 and 48 hr following Elf5 knockdown, this 
gene is a very promising target as the effects are rapid. It was also affected by 
the removal of growth factors. Sox2 was down regulated by 20 to 40 % after 24 
hr and by 70 to 80 % after 48 hr. It was dramatically affected by growth factor 
removal. Another promising target is Wdr40B. It was significantly down 
regulated at both time points studied and was affected just as much by growth 
factor removal. Mme was down regulated by 50 % at both time points and was 
affected by growth factor removal only after 48 hr. Mme may be an indirect 
target of Elf5.  
 
Calca is another promising gene; it was significantly down regulated at both time 
points following the knockdown of Elf5. It was also severely affected by growth 
factor removal. There was a si negative effect in the 24 hr samples but the 
change in expression was still significant. Ly6a was difficult to interpret as the 
results changed. At 24 hr the gene was up regulated upon Elf5 knockdown (as 
was the si negative control), the change was still significant. After 48 hr the gene 
seemed to be down regulated. The removal of growth factors caused the down 
regulation of this gene. Secretin was up regulated upon Elf5 knockdown and with 
the removal of growth factors. Spi8 appeared to be a reproducible target, more 
so 48 hr after Elf5 knockdown. It was also affected by growth factor removal. 
Hmga2 was only affected by the 733 siRNA at 24 hr and then by both after 48 hr. 
Zic3 follows the same trend, it was affected by only the 733 siRNA at 24 hr and 
then both at 48 hr. This also occurred in the microarray. Keratin 7 was up 
regulated by the knockdown of Elf5 at both time points and by the removal of 
growth factors. 1700112c13RIK appeared to be a good target, it was down 
regulated by Elf5 knockdown at both time points studied and was extremely 
affected by growth factor removal. The final gene investigated was GM784; it 
was down regulated at both time points, more so after 48 hr and was also 
affected in the same way by growth factor removal.  
 
Elavl2 is not a target gene of Elf5 as it was affected by Elf5 knockdown in exactly 
the same way as the si negative control. Bex1 is not a target of Elf5, there was no 
change in gene expression upon Elf5 knockdown. There also was no change 
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when real time PCR was carried out on the extra microarray cDNA (the results 
were variable). Hopx is also not a target gene of Elf5 according to these results. 
 
  
7
8
 
Table 6: Summary of Elf5 knockdown and comparison to the Affymetrix array. Results are presented as a fold change compared to the no treatment control (N). Fold changes 
of the Elf5 targets were also compared to the no treatment control.  
 
Microarray Results 
 
24 hr Elf5 Knockdown 
 
48 hr Elf5 Knockdown 
 
Up or 
Down 
No GF vs. 
N 
337 vs. 
N 
733 vs. 
N 
N vs. 
Si- 
 
Up or 
Down 
No GF vs. 
N 
337 
vs. N 
733 
vs. N 
N vs. 
Si- 
 
Up or 
Down 
No GF 
vs. N 
337 
vs. N 
733 
vs. N 
N vs. 
Si- 
Elf5 - 3.4 2.4 3.1 1.0 
 
- 2.6 4.8 6.0 1.0 
 
- 5.1 5.5 9.3 1.0 
Cyr61 - 2.0 1.3 2.0 1.2 
 
- 1.5 2.9 2.3 1.2 
 
- 5.9 4.9 3.5 1.4 
Sox2 - 8.6 1.4 1.9 1.0 
 
- 14.8 1.4 1.6 1.0 
 
- 53.7 2.3 4.1 1.0 
WDR40B - 3.3 1.9 2.1 1.3 (+) 
 
- 4.7 1.3 1.8 1.1 (+) 
 
- 3.1 1.9 3.5 1.2 (+) 
Synpo2l - 4.2 2.1 2.4 1.1 
 
-         
 
-         
Mme - 2.4 1.3 2.3 1.1 
 
- 1.0 2.1 1.4 1.2 
 
- 8.2 1.6 1.8 1.0 
CALCB - 2.0 1.5 1.7 1.0 
 
- 26.3 2.0 2.4 1.4 
 
- 95.5 2.9 6.2 1.2 (+) 
Ly6a + 5.3 (-) 1.2 2.2 1.1 
 
+ 4.8 (-) 1.9 1.8 1.4 
 
+ 51.2 (-) 1.2 1.8 (-) 1.1 
Sct + 2.2 1.5 2.2 1.2 (-) 
 
+ 1.4 1.7 1.3 1.0 
 
+ 5.6 2.3 1.6 1.4 
Elavl2 - 2.1 1.0 1.8 1.1 
 
- 4.2 1.1 1.4 1.3 
 
- 10.5 2.2 3.3 2.3 
Spi8 - 2.1 1.2 1.7 1.1 
 
- 2.1 1.6 1.3 1.1 
 
- 5.3 2.1 4.7 1.2 (+) 
Hmga2 - 1.6 1.1 2.0 1.1 
 
- 2.9 1.1 1.7 1.2 (+) 
 
- 2.2 1.7 1.6 1.2 
Zic3 - 7.5 1.0 2.1 1.1 
 
- 24.8 1.2 (+) 1.4 1.1 
 
- 3.4 1.4 2.8 1.1 
KRT7 + 1.8 1.2 2.1 1.1 (-) 
 
+ 1.8 1.3 1.7 1.0 
 
+ 3.4 1.7 1.8 1.3 
Rex3 - 1.3 1.4 2.1 1.1 
 
- 1.1 1.0 1.1 1.1 
 
- 1.1 1.3 1.2 1.2 
HOPX + 2.2 (-) 1.0 1.6 1.1 
 
+ 1.4 (-) 1.1 (-) 1.2 1.1 
 
- 6.5 1.1 1.5 1.0 
1700112C13RI
K - 3.0 1.2 2.1 1.1 
 
- 69.3 1.2 1.3 1.0 
 
- 199.7 3.3 12.5 1.0 
GM784 - 3.3 1.6 2.5 1.2 
 
- 4.1 1.1 1.4 1.0 
 
- 16.5 2.3 3.7 1.2 (+) 
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3.3.6 Summary 
Affymetrix array experiment carried out by Jessica Deane as a part of her 
Master’s thesis, identified genes that were differentially expressed upon the 
knockdown of Elf5 in mouse trophoblast stem cells. In total the gene expression 
of 22 genes was changed by both siRNAs. Of these, 9 were also changed by the 
removal of growth factors. To confirm these results the Elf5 targets of interest 
were analysed by repeat knockdown of Elf5 for 24 and 48 hours and their gene 
expression measured by quantitative real time PCR. The expression of 16 genes 
were analysed in this study. These genes were from different groups identified 
by the affymetrix array. Those changed by both siRNAs and growth factor 
removal, those changed only by the knockdown of Elf5 and those changed only 
by one siRNA and by growth factor removal. Interestingly, those genes that were 
identified as transformed by only one siRNA (733) were usually changed by both 
siRNAs after 48 hr of knockdown, suggesting that these genes are probably 
indirect targets of Elf5.  
During this time the conditioned media that the TS cells were cultured in 
routinely was replaced by activin. Activin is thought to be one of the main 
components of embryonic fibroblast conditioned media and was shown by 
Erlebacher et al., (2004) to be able to replace conditioned media for the culture 
of TS cells. I found that the TS cells could be cultured in media containing activin 
in place of conditioned media as there was no change in gene expression apart 
from the up-regulation of Cdx2 which is a TS cell marker. However, after one to 
two months of continuous culture in activin replacement media the morphology 
of the cells began to change (refer to 6.2.1.2 in chapter 6). The cells no longer 
grew in colonies and they had a spiked appearance, thus losing their TS cell 
characteristics. The gene expression at this point was not analysed. Due to this 
change in morphology the rest of the thesis was carried out with TS cells grown 
in conditioned media. The use of activin was fine for gene expression 
experiments or for short periods of culture but not for morphology.  
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4 Chapter Four: Whole mount In situ hybridisation of Elf5 
targets 
4.1 Overview 
Whole mount in situ hybridization was carried out to ensure the genes of interest 
identified in chapter three were expressed at the right time and in the right place 
in the embryo (in vivo) to be Elf5 targets. Whole mount in situ hybridisation is an 
excellent method to get a three dimensional idea of gene expression patterns. 
Elf5 is expressed in the extra embryonic ectoderm (ExE) from day 5.5 and is then 
later expressed in the chorion the derivative of the ExE at day 8.5, see Figure 14 
below. For the genes to be targets of Elf5 signalling they must be expressed in 
the ExE in order to be activated or repressed by Elf5. If not, they are likely to be 
indirect targets.  In situ hybridization allows the detection of messenger RNA in 
whole embryos. The ability to visualise the expression of genes in embryos is a 
effective device to allow the understanding of spatial and temporal relationships 
among different molecules during development (Irving, 2008). Non-radioactively 
labelled nucleic acid probes are used to visualise mRNA sequences in whole 
embryos. The probes are labelled with dioxygenin which are then detected with 
an antibody conjugated to alkaline phosphatase which converts the substrates 
nitro blue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate 
(BCIP) to a blue precipitate.  
 
 
Figure 14: Elf5 expression in the extra embryonic ectoderm (ExE) from day 5.5 to 7.5 in mouse 
embryos. It is expressed in the chorion at E8.5 which is the derivative of the ExE (Donnison et 
al., 2005). Elf5 is not expressed in the ectoplacental cone (EPC). 
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In chapter three the Elf5 target genes were verified by repeating the knockdown 
of Elf5 in mouse trophoblast stem cells. Subsequently whole mount in situ 
hybridisation was used to verify that the targets were expressed in the right 
place to be activated or repressed by Elf5. 
 
4.2 Results 
4.2.1 Cloning of gene fragments to be used for Preparation of the 
Riboprobes 
4.2.1.1 Available genes and required gene probes 
Probes for Whole mount in situ hybridisation were required for the following 
genes; Ly6a, 1700112c13RIK, Hopx, Keratin7, Elavl2 and Zic3. After looking at Elf5 
target results from the knockdown data, probes were also made for Calca and 
Cyr61.  
 
4.2.1.2 Primer design 
Primers were designed according to the specifications in section 2.3.3.2. The 
following table contains a list of the primers used to amplify DNA for cloning. 
 
Table 7: Primer sequences used to amplify genes of interest for probes. 
Primer Name Sequence Length Tm Product length 
Ly6amo-fwd2 AGTTTTATCTGTGCAGCCCTTC 21 55 612bp 
ly6amo-rev2 CCTAGAGAGGATTAGAGCACC 21 55 612bp 
1700112c13mo-fwd2 TGCAAGGTGGTTAAATGGGAA 21 62 875bp 
1700112c13mo-rev2 AGCAGAGAGGAGGGAAAGTAG 21 62 875bp 
Zic3mo-fwd2 CGAGTGCACACTGGCGAGAA 19 65 781bp 
Zic3mo-rev2 AACATCACCACCACCAAGCCAT 22 65 781bp 
Hopxmo-fwd2 AAGGGGACAGGGCTGAGTGAA 21 65 938bp 
Hopxmo-rev2 GTGTTTAGTGAAGCAGAAGGAA 22 65 938bp 
Kert7mo-fwd2 CATGCAGGATGTGGTGGAA 19 65 955bp 
Kert7mo-rev2 CAGGGACATGAGATGGAACAAA 22 65 955bp 
Elavl2mo-fwd2 GTACCAGTCTCCAAACAGAA 20 56 730bp 
Elavl2mo-rev2 ATGTCTTCCCTTAGCTGAA 19 56 730bp 
Cyr61mo-fwd2 GAAGAGTGGGTTTGTGATGAA 21 55 765bp 
Cyr61mo-rev2 AAGAATGAGCAAGGCACCAT 20 55 765bp 
Calcamo-fwd2 AAGAGTCACCGCTTCGCA 18 55 813bp 
Calcamo-rev2 AGAAGAGCAAGAGGCAGTGT 20 55 813bp 
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Cloning using PCR 
The genes of interest were cloned from cDNA from previous experiments. The 
cDNA used was from mTS cells grown in complete medium for samples that are 
down regulated upon the loss of Elf5 (1700112c13RIK, Elavl2, Zic3, Calca and 
Cyr61) and TS cells grown in mTS media with no growth factors for those genes 
that are up regulated upon the loss of Elf5 (Ly6a, Hopx, Keratin 7). A PCR was 
carried out to amplify the genes of interest, see 2.3.3.3 and then the resulting 
DNA was run on a 1 % agarose gel, see Figure 15 below. 
 
 
Figure 15: amplification of genes of interest by PCR. 1=1kb ladder, 2= 1700112c13 product, 3= 
Elavl2 product, 4=Zic3 product, 5= Ly6a product, 6= Hopx product, 7= Keratin7 product. No 
product was obtained for Elavl2, Ly6a or Hopx. 
 
4.2.1.2.1 Trouble shooting 1: 
No Products were obtained for Elavl2 and Hopx and only a faint band for Ly6a, 
see Figure 15. This was probably due to inappropriate annealing temperature for 
the specific primer. So a temperature gradient from 54 °C to 64 °C was carried 
out to find the optimum annealing temperature. Ly6a worked at all 
temperatures tested. Elavl2 only worked at 54 °C and Hopx didn’t work at all 
(Figure 16). 
 
1              2           3          4            5            6            7   
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Figure 16: PCR gradient results to check primers. 1= 100bp ladder, 2-5 Elavl2, 6-9 Hopx, 10-13 
Ly6a, 14= 100bp ladder. Ly6a worked at all temperatures, Elavl2 worked at 54 °C and Hopx did 
not work.  
 
4.2.1.2.2 Trouble shooting 2: 
As Hopx is a GC rich gene it was suggested to try a 5x GC-rich solution in the PCR 
reaction. When a gene is quite GC rich the polymerase tends to fall off the DNA. 
The temperature gradient was carried out again, and a product of the correct 
size was obtained for an annealing temperature of 54 °C, Figure 17.  
 
 
Figure 17: Optimised PCR conditions for Hopx, 1 = ladder, 2 is Hopx at 54 °C, 3 is Hopx at 56.8 
°C. 
Once the optimal PCR conditions were determined, all of the products were re-
amplified using the optimal conditions. 
 
4.2.1.3 Purification of the PCR product 
The PCR product was purified with a Wizard column as described in 2.3.2.4.1 
 
4.2.1.4 Ligation of PCR product into pGEM-Teasy 
The PCR product was ligated into the pGEM- T Easy plasmid (Promega) so it could 
then be transformed into E. coli to be amplified. The pGEM-T Easy vector 
contains a single T overhang at the insertion site to increase the efficiency of 
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ligation of the PCR product into the plasmid. This is by preventing re-
circularisation of the plasmid and providing T overhangs for the A overhangs of 
the insert produced by the Taq polymerase. pGEM-T Easy contains T7 and SP6 
RNA polymerase promoters flanking the multiple cloning site (MCS) in the coding 
region of the protein β galactosidase, see Figure 18. When the PCR product is 
inserted into the MCS this protein is no longer expressed and E. coli colonies 
containing the insert can be selected by the colour of the colony (Promega, 
2007).  
 
Figure 18: Diagram of pGEM-T-easy used to ligate the DNA of interest into and to transform 
into E. coli. There was an ampicillin resistance gene so only cells that had the transformed 
plasmid could grow on the LB/Amp plates. The DNA was ligated into the multiple cloning site 
(MCS). 
 
4.2.1.5 Transformation 
The plasmid containing the PCR product was transformed into Invitrogen Max 
Efficiency® DH5α™ Competent Cells to amplify the plasmid containing the DNA of 
interest. The method for the transformation of the plasmid into E. coli is 
described in 2.3.2.6. 
 
4.2.1.6 Minipreps 
Minipreps are carried out to isolate the amplified plasmid from the bacterial 
culture. The miniprep method is described in 2.3.2.7. Only 6 colonies of each 
gene were minipreped as TA cloning is efficient and blue/white selection was 
used. 
 
 
pGEM-T-easy
3015 bp
Amp-r
f1
MCS
M13-rev
pUC-M13-fwd
SP6-Prom
T7-Prom
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4.2.1.7 Restriction analysis 
3 µl was analysed by restriction digest with EcoR1 to make sure the clones 
contained the insert. The DNA as digested over night at 37 °C. There are EcoR1 
sites on either side of the MCS (see Figure 19); the product obtained should be 
the same size as the product produced from the primers for the gene of interest.  
 
 
Figure 19: Multiple cloning site (MCS) of the pGEM-T Easy plasmid showing EcoR1 restriction 
sites on either side of where the gene of interest DNA was inserted.  
 
The digest was then run on a 1 % agarose gel against a 1 Kb ladder to determine 
which clones contained the insert of interest. The Keratin 7 and Zic3 products 
had internal EcoR1 sites so two products would be produced instead of one. The 
expected product sizes were; 1700112c13- 875 bp, Elavl2- 730 bp, Ly6a- 612 bp, 
Keratin7- 189 bp and 745 bp, Zic3- 635 bp and 124 bp (see figures 20-22).  
 
 
Figure 20: Restriction digests of the miniprep DNA to ensure a product of the expected size was 
obtained. 1 = 100 Kb ladder, 2-7 = 1700112c13 clones, 8-14 = Elavl2 clones, 15= 1 kb ladder. 
Products of the expected size were obtained.  
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Figure 21: Restriction digest of the miniprep DNA to ensure a product of the expected size was 
obtained. 1= 100 kb ladder, 2-7 = Keratin7 clones, 8-14 = Zic3 clones, 15-19= Ly6a clones, 20 = 1 
kb ladder (can’t see smaller product of Keratin 7 and Zic3 as they are only about 100 bp).  
Products of the expected size were obtained.  
 
 
Figure 22: 1= 100 kb ladder, 2-7 = Hopx clones of the correct size.  
 
4.2.1.8 Determination of orientation of the product 
Restriction digest was then carried out with the clones that had the correct sized 
insert to determine the orientation of the PCR product. As TA cloning was used 
the PCR fragment could be inserted in the forward or reverse orientation. The 
genes of interest were analysed on Vector NTI to determine what restriction 
enzymes could be used to produce two fragments of different size to determine 
what orientation the genes were in. The restriction site should be present in the 
PCR fragment and in the MCS to get appropriate sized products. Table 8 shows 
what restriction enzymes were used to determine the orientation of the 
products.  
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Table 8: Restriction enzyme used to determine orientation of each insert in p-Gem-Teasy 
    Product size (bp) 
Gene RE Forward Reverse 
Ly6a Pst1 197 420 
1700112c13 Pst1 768 85 
Hopx Pst1 787 128 
Keratin 7 Sac1 389 677 
Elavl2 Sac1 340 483 
Zic3 Clal 1 and Pst1 23 757 
 
 
 
Figure 23: 1 = 100 kb ladder, 2-7 = Ly6a clones, 7- 12 = Hopx clones, 13- 16 = 1700112c13 clones, 
17 = 1 kb ladder.  All the Ly6a clones had their insert in the reverse orientation, Hopx clones 
were in the forward orientation. 1700112c13 clones were in the forward orientation. 
 
 
Figure 24: 1 = ladder, 2-4 = Keratin7 clones, 5- 10 = Elavl2 clones, 11 – 14 = Zic3 clones,15 = 1 kb 
ladder. Keratin7 was in the forward orientation, Elavl2 forward and Zic3 reverse. 
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4.2.1.9 Glycerol Stocks 
One clone showing the correct restriction analysis for each gene was used to 
make a glycerol stock see 2.3.3.10. The stocks were flash frozen by immersion in 
liquid nitrogen for a few seconds, and then stored at -80°C until required.  
 
4.2.1.10 Maxi Preparation of DNA 
A maxiprep was then carried out of one colony of each gene showing the correct 
sized fragment and orientation see 2.3.3.11. The DNA concentration from the 
maxi prep was measured on the nanodrop. 
 
Table 9: Nanodrop measurements of DNA concentration and purity 
Sample ng/ul 260/280 260/230 
Hopx 982.8 1.91 2.31 
Keratin 7 4966.6 1.17 1.41 
Zic3 4998.2 1.08 1.3 
Elavl2 5020 1.07 1.28 
1700112c13 1888.8 1.88 2.29 
ly6a 2951 1.84 2.25 
 
 
I was concerned as the 260/280 and 260/230 ratio for Keratin 7, Zic3 and Elavl2 
were low, see Table 9. A 260/280 ratio of 1.8 or greater is considered pure for 
DNA; a lower ratio could have been due to phenol, protein or other 
contaminants that absorb strongly at 280 nm. A 260/230 ratio measures nucleic 
acid purity, a pure sample has a ratio of 2.0-2.2. It was suggested that the values 
for the three samples were out of the linear range of the nanodrop as the DNA 
concentration was very high. So the DNA was diluted 1:10 in T.1E and the DNA 
concentration was measured again.  
 
 
 
 90 
 
Table 10: Nanodrop measurements after dilution of the DNA 
1:10 
Dilution ng/ul 260/280 260/230 
Keratin 7 929.6 1.91 2.31 
Zic3 1098.6 1.91 2.33 
Elavl2 954.6 1.92 2.33 
 
The ratios improved considerably and were now in the acceptable range, Table 
10. The DNA of these three samples was diluted 1:10 for further use.  
 
4.2.1.11 Sequencing 
Aliquots of maxiprep DNA were sequenced at the Waikato University DNA 
sequencing facility. This was to ensure the ligation sites were correct. Sequencing 
primers were either SP6 (reverse orientation) or T7 (forward orientation) 
polymerases. The sequence of the insert could then be compared to that of the 
original by using vector NTi software. Any mismatches were checked if they were 
real by inspecting at the chromatogram to see if an incorrect call had been made 
by the software.  
 
4.2.1.12 Probe Template Preparation 
To prepare a RNA probe, the template must be first linearised by restriction 
enzymes. Restriction enzymes to use were determined by finding an enzyme that 
cuts uniquely on the 5’ end and that creates a 5’ overhang. If the insert was in 
the forward orientation in the plasmid then the SP6 RNA polymerase was used to 
create an antisense RNA copy of the DNA. And if in the opposite orientation the 
T7 RNA polymerase was used. The Table 11 below shows what restriction 
enzymes were used and what polymerase to make an RNA copy of the DNA. 
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Table 11: Enzymes used to linearise the DNA for probe template preparation 
Sample RE Polymerase 
Elavl2 Asp718 Sp6 
Hopx NcoI Sp6 
Keratin 7 SphI Sp6 
Ly6a Sal1 T7 
Zic3 Sal1 T7 
1700112c13 NcoI Sp6 
 
 
The DNA was linearised by following the procedure in 2.3.3.13. The 
concentration of the DNA was estimated by running a 1:10 dilution of the DNA 
on a 1 % gel against 2 µl and 5 µl of a lambda standard, Figure 25.  
 
 
Figure 25: 1 = 2 µl of Lambda DNA 2 = Elavl2 DNA 3 = Hopx DNA 4 = Keratin 7 5 = 1700112c13 6 
= Ly6a 8 = 5 µl of Lambda DNA standard. The DNA concentration of each sample was estimated 
by the intensity of the DNA band in comparison to the lambda DNA ladder.  
 
1700112c13 had a low DNA concentration so the lineraisation and purification 
was repeated which resulted in a higher yield. The DNA was then used to 
prepare DIG probes. 
 
4.2.1.13 Preparation of Riboprobes 
The riboprobes were prepared by following the protocol in 2.3.3.14. After 2-3 
hours the RNA was run on a 1.4 % gel with a Lambda DNA ladder. A thin sharp 
slow migrating DNA band was expected along with two intense RNA bands that 
were smaller in molecular weight. If bands were what was expected they were 
run through a Roche quick spin column for RNA. This column works by size 
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exclusion, where the larger molecules will be eluted at an earlier time than the 
smaller molecules as they get absorbed into the matrix. This allows the 
separation of nucleic acids from other molecules like the labelling mix. The RNA 
probe was then ethanol precipitated, washed and the pellet was resuspended in 
DEPC water. The RNA concentration of the probe was estimated by using the 
nanodrop (see Table 12) and then run on a 1.4 % agarose gel (see Figure 26). 
 
Table 12: RNA concentration and quality of the riboprobes 
Sample ng/ul 260/280 260/230 
Hopx 534.9 1.85 1.93 
Keratin 7 543.9 1.82 1.8 
Zic3 507.7 1.87 1.92 
Elavl2 37.7 1.94 1.53 
1700112c13 522.6 1.82 1.92 
ly6a 516.6 1.9 1.97 
 
 
Figure 26: Gel of the riboprobes. 1 = 2 µl Lambda DNA ladder, 2 =Ly6a, 3 = Keratin 7, 4 = Zic3, 5 
= Elavl2, 7 = 1700112c13, 8 = 5 µl Lambda ladder. The Elavl2 probe was lost and the Keratin 7 
probe ran oddly.  
 
4.2.1.13.1 Trouble shooting (Figure 26) 
The Elavl2 pellet was lost presumably by the aspiration after the precipitation 
step and the Keratin 7 probe (lane 3) ran oddly on the gel (see above gel). This 
could have been due to degradation or due to incomplete digestion with the 
restriction enzyme. Preparation of the riboprobe was repeated for Elavl2 and 
Keratin 7. A probe of good concentration was obtained for Elavl2 with an RNA 
concentration of 478.4 ng/µl and a 260/280 ration of 2.08 and 260/230 ratio of 
2.04. After RNA was transcribed for Keratin 7, it was run on a 1.4 % gel. The same 
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thing occurred, the smear of RNA reaching to very high molecular weight 
suggested read through with random termination which would happen if the 
DNA had not been cut properly with the restriction enzymes. So the Keratin 7 
DNA was instead cut with the restriction enzyme Asp718 and the probe was re-
transcribed. A good RNA probe was obtained with a concentration of 439.8 
ng/µl.  
4.2.2 Whole mount in situ hybridisation 
Elf5 is expressed in the embryo between the developmental stages of E5.5 to 
E8.5 (see Figure 14). Whole mount in situ hybridisation was carried out to ensure 
the genes of interest were expressed in similar spatial and temporal patterns as 
Elf5. E5.5 embryos are extremely difficult to obtain due to their very small size 
and E8.5 embryos show more background staining (P. Pfeffer, personal 
communication). Due to this we decided to focus on E7.5 embryos and then once 
I was more experienced we also included the E6.5 embryos.  
 
The embryos were retrieved from pregnant mice after timed matings from the 
small animal colony at AgResearch, Ruakura. See section 2.3.4.1 of methods. The 
protocol was followed in 2.3.4.2-2.3.4.5 to give successful production of a blue 
precipitate where the mRNA of the gene of interest was expressed. 
 
4.2.2.1 Pilot experiment one: 
There was no colour development observed for Hopx and Elavl2 after three days 
in the BCIP/NBT colour development solution. Zic3 developed at the epiblast end 
of the embryo at days 6.5 and 7.5. Ly6a seemed like the best probe, developing 
in the ExE of day 7.5 and day 6.5 embryos. Keratin 7 looked like it was expressed 
in the EPC of the embryos, but needed further embryos for conformation. 
1700112c13 was expressed in the chorion of day 7.5 embryos and the tip of day 
6.5 embryos. There were problems with precipitate forming all over the 
embryos; this was thought to be due to old MgCl2 in the NTMT. This resulted in a 
lot of embryos that couldn’t be used as they had a black precipitate all over 
them, when a photograph was taken the black precipitate could not be 
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distinguished from the DIG probe. All components of the NTMT were made up 
fresh for the next time. 
 
4.2.2.2 Pilot experiment two: 
Only day 7.5 embryos were used. The probes were diluted 1:5 in hybridisation 
mix to allow longer storage at -80 °C. As we were getting a problem with 
precipitation of the NTMT the embryos were put in solutions made from 
NBT/BCIP tablets. No colour development was seen after 3 days incubation at 
room temperature. This could have been due to many reasons including, probe 
degradation, incorrect salt concentration in the hybridisation mix, the secondary 
antibody could have gone off, the Tris may have not been the correct pH and the 
tablets were expired. The pH of the Tris buffer was checked, it was the correct 
pH (pH 9.5) so that was not the reason and the salt concentration was correct in 
the hybridisation mix. Then 5 µl of the probes were run on a 1.4 % gel to ensure 
they had not been degraded by RNases. The RNA probes were not degraded. It 
was concluded that the problem was either the secondary antibody or the 
NBT/BCIP tablets. I decided to try adding the secondary antibody again to see if 
any colour develops, the embryos were washed 3 x in MABT and then the 
protocol was followed from the blocking step (refer to 2.3.4.4). Some colour 
developed after a few days in freshly made NTMT with BCIP/NBT but not with 
the tablets. These tablets were not used for subsequent experiments.  
 
4.2.2.3 In vivo expression 
Zic3 was expressed in the epiblast at E6.5 and then the embryonic mesoderm or 
ectoderm at E7.5. Keratin 7 was expressed at low levels in the visceral endoderm 
on the anterior side and in the giant cells/EPC at E7.5 and in the EPC at E6.5; the 
expression in the ExE was background. It was expressed in late embryos too. 
1700112c13 was expressed strongly in the chorion at late day 7.5 embryos. But 
there was no staining in earlier embryos. Ly6a was expressed in the ExE at day 
6.5 and the chorion at day 7.5. Elavl2 was expressed in the ExE in both E6.5 and 
E7.5 embryos. See Figure 27and Figure 28 for a schematic of the different tissues 
of the embryo at these early stages. Figure 27 shows a stage earlier than Figure 
28. 
 95 
 
 
After deciding what genes look interesting I also made probes for Calca and 
Cyr61, the same protocol was followed and successful results were obtained. 
Calca was expressed in the node of E7.5 embryos. Cyr61 was expressed in the 
ExE at E6.5 and later the chorion and allantois at E7.5.  
. 
 
Figure 27: Mouse embryos at the periimplantation (A, E4.5) and post-implantation (B, E 6.0; C, 
E 7.0) stages of development, showing the allocation of derivatives of the inner cell 
mass/epiblast, primitive endoderm and trophectoderm, to different tissue compartments of 
the embryo (Tam and Rossant, 2003). 
 
Figure 28: Figure of different cell types at gastrulation from Arnold & Robertson (2009). This is 
a later stage embryo, E7.5. This figure shows the Node of the embryo where Calca was 
expressed.  
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4.2.2.4 In vivo Expression of Elf5 targets in E6.5 embryos 
 
 
 
 
Figure 29: Expression of genes of interest at E6.5. A) Cyr61 expressed in the ExE B) Elavl2 
expressed in the ExE C) Hopx expressed in giant cells D) Ly6a expressed in the ExE E) Keratin7 
expressed in the EPC F) Zic3 expressed in the epiblast. Calca could not be detected at E6.5 and 
neither was 1700112C13. 
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4.2.2.5 In vivo expression of Elf5 targets in E7.5 embryos 
 
 
 
 
Figure 30: Expression of genes of interest at E7.5. G) Ly6a was expressed in the ExE H) Keratin 7 
expressed in the EPC I) Calca expressed in the node J) Elavl2 expressed in the ExE K) Cyr61 
expressed in the ExE L) Zic3 expressed in the embryonic mesoderm or ectoderm. Hopx has not 
been included as only stains giant cells surrounding the embryo. 1700112c13 was expressed at 
in late D7.5-8.0 embryos unfortunately no good photographs were able to be obtained.  
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4.2.2.6 Other target genes 
The expression of other possible Elf5 targets in vivo were examined by Martyn 
Donnison.  
 
 
 
Figure 31: In vivo expression of other targets examined by Martyn Donnison. M) Secretin was 
expressed in the EPC, N) Sox2 was expressed in the ExE, O) Wdr40B was expressed in the ExE, 
P) Bex1 was expressed in the ExE, Q) GM784 has mosaic expression in the ExE, and R) Mme was 
expressed in the ExE. M-O are E6.5, P-R are E7.5. 
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4.2.3 Summary 
4.2.3.1 Changes in gene expression upon Elf5 Knockdown 
Table 13: Summary of Elf5 targets. This table shows where the targets are expressed and 
whether they are up or down regulated upon the loss of Elf5. 
Down 
Regulated Cyr61 Sox2 Wdr40B Mme Calca Zic3 
Expressed ExE ExE ExE ExE Node Epiblast 
Down 
Regulated Elavl2  Spi8 Hmga2 GM784 Bex1 1700112c13 
Expressed ExE ExE ? ExE ExE Chorion? 
       Up Regulated Ly6a Secretin Keratin7 Hopx 
  
Expressed ExE EPC EPC 
Giant 
cells 
   
The majority of the genes that were down regulated upon Elf5 knockdown were 
expressed in the ExE, see Figure 29, Figure 30 and Figure 31. This suggested that 
Elf5 normally acts to maintain or up-regulate the expression of these genes. This 
provided evidence for the theory that Elf5 acts to maintain the ExE.  Most of 
these genes were also down regulated when differentiation of the TS cells was 
induced. This also provided support for the theory that Elf5 maintains TS cells in 
an undifferentiated /proliferative state and prevents differentiation into the EPC 
see Figure 5 (see also corroborative evidence in chapter 6). Calca was expressed 
in the node. Calca mRNA levels in TS cells (determined by real time PCR) were 
quite low, around 0.01-0.02 as compared to Elf5 expressed at 0.5 (relative to the 
geomean). This could mean that Calca levels were too low in the ExE to be picked 
up by whole mount in situ hybridisation. The development of colour could not be 
left for any longer as Calca was also expressed in the node and this staining 
would spread over the entire embryo. 
 
The genes that were up regulated upon the knockdown of Elf5 were expressed in 
the EPC or giant cells. The exception was Ly6a, but I am unsure whether this 
gene was a target of Elf5 as a large si negative effect was seen in the 24 hr 
knockdown and then at 48 hr one siRNA caused up-regulation of Ly6a and the 
other caused down regulation. Secretin, Keratin7 and Hopx were expressed in 
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the EPC or giant cells and were usually down regulated or their expression was 
restricted by Elf5. This also provided evidence for our initial theory that Elf5 acts 
to maintain the ExE by preventing differentiation into EPC or giant cells. Elf5 
prevents the up-regulation of these genes and therefore is helping prevent 
differentiation into this subtype. Keratin7 and Secretin were up-regulated when 
differentiation was induced. Hopx was not up-regulated when differentiation 
was induced according to the results attained here.  
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5 Chapter Five: Over-expression of Elf5 by the tamoxifen 
inducible system 
5.1 Overview 
Although the Elf5 knockdown and whole mount in situ hybridisation are all 
strong evidence for the target genes to be valid, it would be interesting to see if 
we could get the opposite effect upon gain of function. Therefore we wanted to 
overexpress Elf5 in mouse trophoblast stem cells. To see a change in gene 
regulation upon the over expression of Elf5, an inducible system can be used. 
The classical overexpression system is the Tet system. The tet system relies on 
two components, a tetracycline controlled transactivator and a Tet responsive 
promoter that controls the expression of downstream cDNA (the gene of 
interest). This system is tightly controlled by the presence or absence of 
tetracycline or a derivative like doxycycline (Jaisser, 2000). This system requires 
two stable transfections, the first with the regulator plasmid to generate stable 
cell lines. And then with the response plasmid containing gene of interest under 
control of the responsive promoter. This system has caused great difficulties in 
our lab (see Deane, (2007)) so other possible methods for over expression were 
explored. The tamoxifen system can be used to over express proteins of interest. 
The tamoxifen system contains a mutated estrogen ligand binding domain (ER-
T2) that binds synthetic antagonists such as tamoxifen but not circulating 
estrogens (Jaisser, 2000). In this system, 4-Hydroxytamoxifen (OHT) a metabolite 
of tamoxifen is used instead of tamoxifen as it has a higher affinity for estrogen 
receptors. This domain is fused to the protein of interest and is placed down-
stream of a strong cytomegalovirus IE promoter. For example, Niwa et al,. (2005) 
used a 4-hydroxytamoxifen-inducible Cdx2 which was fused to the ligand binding 
domain of the mutant mouse estrogen receptor. When expressed in ES cells they 
could be induced to differentiate into trophectoderm in the presence of Fgf4.  
 
To study the over expression of Elf5, TS cells can be transfected with a plasmid 
containing the Elf5 gene fused to an ERT2 receptor. Upon addition of 4-
hydroxytamoxifen (OHT), ERT2 binds to this ligand and undergoes a 
conformational change resulting in it no longer binding to a heat shock protein in 
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the cytoplasm. The heat shock protein would have kept the fusion protein in the 
cytoplasm and therefore prevented DNA binding (Danielian et al., 1993). Upon 
the addition of OHT Elf5-ERT2 thus is free to translocate to the nucleus and fulfil 
its transcriptional functions. The plasmid also contains the gene for zeocin 
resistance downstream of the fusion protein. Thus TS cells stably transfected 
with this vector, can be selected by zeocin resistance. These cells have the 
plasmid inserted in their genome. Zeocin is a member of the bleomycin family of 
antibiotics that were isolated from Streptomyces. Zeocin is active against 
bacteria, fungi, plants and mammalian cell lines. Zeocin causes cell death by 
binding to DNA and cleaving it. Zeocin resistance is encoded by the Sh ble gene, 
which encodes a protein which binds to Zeocin to prevents DNA cleavage activity 
(Invitrogen, 2002). Therefore transfected cells can be selected for with Zeocin by 
the expression of the Sh ble gene on the construct of interest.  
 
Once stable cell lines are generated, Elf5 can be activated by addition of 4-
hydroxytamoxifen (OHT). Cells can then be harvested for target gene analysis by 
real time PCR.  
 
5.2 Transfection of Mouse Trophoblast Stem Cells 
5.2.1 Strategy One: 
5.2.1.1 Initial transfection of mTS cells with Elf5 mo ER pyCAGizeo 
The initial construction of this plasmid and the stable transfection of the mouse 
trophoblast stem (TS) cells were carried out by Craig Smith. Craig encountered 
immense difficulties trying to get this plasmid constructed, as there are inherent 
problems with this plasmid. The plasmid used initially to transfect the TS cells for 
the over expression of Elf5 is shown below in Figure 32. 
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Figure 32: Elf5 mo ER PyCAGiZeo plasmid which was used as a start point for the 4-
hydroxytamoxifen inducible system, Elf5 is fused to the Esr-T2 receptor. 
 
Craig stably transfected TS cells with this plasmid to over express the Elf5 protein 
and adhered to the protocol described in 2.1.4. Craig performed the RNA 
isolations and cDNA synthesis and gave me the cDNA to perform real time PCR, 
method described in section 2.3.1.5. The expression of some of the Elf5 target 
genes were analysed to see if there was a specific up or down regulation of the 
target genes as expected. The expression of Elf5, Sox2, Ly6a, 1700112c13 and 
Keratin7 was investigated, Figure 33.  
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Figure 33: Expression levels of Elf5, Sox2, Keratin7, 1700112c13 and Ly6a shown in transfected 
mouse trophoblast stem cells. Expression is shown relative to the geometric mean of three 
house-keeping genes. N=1. Two concentrations of 4-hydroxytamoxifen were used, 0.5 µg/ml 
and 1 µg/ml. The red bars are the control and green bars are O OHT. 
 
No trend could be identified as an up or down regulation of the target genes. 
There were no cell lines that showed a higher level of Elf5 mRNA in comparison 
to the control. The addition of 4-hydroxytamoxifen (OHT) seemed to have an 
effect on the house keeping genes gapdh and βactin. The addition of OHT also 
seemed to up regulate Eomes in the control lines (graph not shown), which is a 
marker of TS cells. The addition of OHT alone also caused a change in target gene 
expression in the control cell lines. Careful consideration will need to be taken 
when repeating this transfection in terms of controls. This experiment did not 
seem to work as Sox2 was down regulated upon the addition of OHT in most cell 
lines. Sox2 was assumed to be up-regulated when Elf5 is over expressed as it is 
down regulated when Elf5 is knocked down. Different lines showed different 
trends in terms of the changes in gene regulation upon the addition of OHT. This 
experiment was abandoned.  
5.2.2 Strategy Two: Addition of VP16 
The lack of effect upon the over expression of this fusion protein (ERT2-Elf5) 
suggested a novel approach was required to make a stronger activator out of Elf5 
by fusing it with VP16. The VP16 domain is a potent transcriptional activation 
domain (Ghosh et al., 1996). This system has been used by others as a fusion 
protein with GAL4-ER to allow the activation of transcription from the GAL 
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promoter in the presence of estradiol (Quintero et al., 2007). In the Tet-
advanced system three minimal ‘F’ type transcriptional activation domains from 
the VP16 protein are used in place of the full domain. This provides the same 
activation as the full product but it reduces cross reactivity with other 
transcriptional machinery and cytotoxicity to the cells (Baron et al., 1997). The 
VP16 transactivation domain of the herpes simplex virus was added to our Elf5-
ER plasmid to ensure robust transcription (Nishioka et al., 2009). 
 
This plasmid was prepared by subcloning the VP16 fragment from the pTet-
advanced plasmid; refer to section 2.3.2 of methods. The new plasmid to be 
created is shown in Figure 34 below. The VP16 cassette was inserted in between 
the Elf5 and Esr-T2 proteins as described below.  
 
 
Figure 34: The Elf5 mo VP16 ER pyCAGiZeo plasmid. The VP16 cassette is to be inserted 
between the Elf5 and EsR-T2 gene in the plasmid.  
 
5.2.2.1 Restriction of Elf5 mo ER pyCAGiZeo 
The Elf5 mo ER pyCAGiZeo plasmid was cut at the Nhe I site which is between the 
Elf5 gene and the EsrT2 gene to allow the incorporation of the VP16 cassette into 
the Elf5 mo ER pyCAGiZeo the vector (refer to Figure 32). This was the site that 
the VP16 was inserted into. The plasmid was cut in a 20 µl reaction as in 2.3.2.1 
at 37 °C for 2 hr. The plasmid was then dephosphorylated (refer to 2.3.2.2) to 
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prevent the ends from re-joining during ligation and then run on a 1 % gel. For an 
unknown reason there was an unexpected faint 500 bp band in the digestion 
product.  Due to this the Elf5 mo ER pyCAGiZeo plasmid was digested with Cla I 
and Not I enzymes to ensure the plasmid was in fact the correct one. Products of 
the expected size were obtained. 
 
5.2.2.2 PCR amplification of the VP16 cassette 
The VP16 cassette was obtained from the pTet-Advanced plasmid by PCR 
amplification. Genes of interest can be amplified for cloning by using primers 
containing a 5’ restriction sequence of choice and a 3-4 bp clamp before the 
restriction site. The clamp is inserted as enzymes do not cut optimally at the end 
of fragments. The primers designed have restriction sites in them so that the 
restriction sites can be used for insertion into the Elf5 mo ER pyCAGiZeo plasmid. 
The sequence of the primers used to amplify the VP16 cassette were; VP16-Spe-s 
ctctACTAGTccggccgacgcccttgacgatt and VP16-Nhe-a ctctGCTAGC 
accggggagcatgtcaaggtcaa. The ctct at the beginning of each primer is a clamp. 
The VP16 cassette was PCR amplified by using the conditions stated in 2.3.2.3. 
The concentration of the pTet-Advanced plasmid was 2.4 µg/µl so the plasmid 
was diluted 1:3000 to obtain a suitable starting amount for PCR (to about 1 
ng/µl). 
 
5.2.2.3 Gel purification of the VP16 cassette 
The PCR amplified VP16 cassette was run on a 1.2 % gel and a strong band was 
obtained at the expected size of 130 bp. The VP16 band was cut out of the gel, 
weighed and purified from the gel using a wizard column as in 2.3.2.4.1. 
 
 
5.2.2.4 Restriction of the VP16 cassette 
To remove the clamp and to get the cassette ready for ligation into Elf5 mo ER 
pyCAGiZeo, the purified DNA was cut with Spe1 and Nhe1. 
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5.2.2.5 Gene Clean of the VP16 cassette 
The restricted VP16 cassette was run on a 1.5 % gel and then purified using 
GENECLEAN. The protocol outlined in 2.3.2.4.2 was followed. A few microliters of 
the product were run on a gel after purification with GENECLEAN. No product 
was visible at 130 bp. After reading through the gene clean product information 
it was discovered that it was not optimal for the purification of products less 
than 200 bp long. 
 
5.2.2.6 Repeat of VP16 amplification and purification 
The PCR amplification of the VP16 cassette was repeated, it was purified on a 
Wizard column and then restriction digested. The product was then run on a gel. 
No product at 130 bp was obtained. According to the product information 
provided with the Wizard columns, a yield of about 80 % is obtained when 
purifying DNA smaller than 200 bp. But there was obviously a large amount of 
DNA lost during gel purification so the mermaid kit was only used at both steps 
(see section 2.3.2.4.3). When the mermaid kit was used instead a faint band was 
seen at 130 bp. As the yield was low, seven 50 µl PCR reactions were carried out 
to amplify the VP16 cassette. It was purified using the mermaid kit, the product 
was restriction digested, and a few microlitres were run on a gel to determine if 
there was a product. There was a product so it was put through the mermaid 
column again and eluted in 20 µl and then the product was run on a gel. 1 µl of 
the VP16 cassette was run on a gel to estimate the concentration against a 
lambda standard. The concentration of the DNA was estimated to be 4.69 ng/µl, 
see Figure 35. 
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Figure 35: 1= strong VP16 band at 130 bp before gel purification, this was one 50 µl reaction. 2 
= 1 µl of VP16 DNA at 130 bp after pooling of 7 PCR reactions, purification, digestion and re-
purification. The DNA was run against a lambda standard (both ladders) to give the estimated 
DNA concentration of 4.69 ng/µl.  
 
5.2.2.7 Ligation of the VP16 cassette into Elf5 mo ER pyCAGiZeo 
When performing a ligation equivalent molar ratios of the insert to the plasmid 
are required. The VP16 concentration was 4.6 ng/µl and the vector concentration 
was 88.7 ng/µl. The VP16 was 130 bp long while the vector was 8017 bp long 
which is 1/61. So 2 µl of the plasmid and 1 µl of the VP16 DNA was combined 
with 3 µl of the Takara mighty mix (see protocol 2.3.2.5). As a negative control 
the plasmid alone was added to the Takara mighty mix to observe how often the 
plasmid re-ligates to itself.  
 
5.2.2.8 Transformation into DH5α max efficiency cells 
The ligation product was subsequently transformed into DH5α max efficiency 
competent cells, for a detailed protocol see section 2.3.2.6, and left overnight to 
grow on LB/Amp plates. No colonies were produced from either the negative 
control or the sample itself. As no colonies were obtained, the ligation and 
transformation were repeated again, this time the uncut plasmid was also 
included as a positive control. No colonies were produced from the positive 
control or the ligation.  
 
 
 
         1                    2 
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5.2.2.8.1 Repeat of transformation 
As no colonies were obtained a new batch of competent cells were thawed and 
aliquoted out. The cells had been frozen incorrectly by immersion in liquid 
nitrogen last time so the cells may have died causing this problem. The cells were 
defrosted on ice, aliquoted out into 25 µl aliquots on ice and then re-frozen in a 
slurry of dry ice and isopropanol. The transformation was then repeated with 
these fresh cells, no colonies grew again. Only 2 colonies were obtained from the 
positive control uncut plasmid. During the same transformation I also 
transformed 1 pg/µl of Puc19 DNA which is provided with the competent cells. 
Over 200 colonies were obtained from the Puc19 transformed colonies. This 
demonstrates that there was nothing wrong with the competent cells.  
 
5.2.2.9 Restriction digest of Elf5 mo ER pyCAGiZeo 
As the cells were not the problem, either the ampicillin resistance on the plasmid 
was not there or not being transcribed or there was something wrong with the 
origin of replication. So the Elf5 mo ER pyCAGiZeo plasmid was digested with 
restriction enzymes in varying places in the plasmid, including in the Amp 
resistance gene to see if products of the correct size were produced. The 
enzymes used were ApaI, BamHI, EcoRI, SacIII, Xhol to check the plasmid itself 
and then ScaI and BamHI in the same reaction to check the Amp resistance. All 
products were the correct size. 
  
5.2.2.10 Miniprep of Elf5moERpyCAGiZeo 
As the plasmid itself was fine in terms of sequence, there was something wrong 
with the growth of this plasmid. So a new preparation of the plasmid was sought 
out. Due to this some colonies from the glycerol stock of the plasmid were plated 
out and a miniprep (see protocol 2.3.2.7) of a few colonies was carried out. A 
miniprep of the few colonies that grew on the positive control plates from an 
earlier transformation was also prepared. This DNA was digested with Nco I and 
all minipreps gave fragments of the expected sizes. 
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5.2.2.11 Maxi prep of Elf5 mo ER pyCAGiZeo 
A maxi prep (see protocol 2.3.2.9) from one of these colonies was performed to 
give a DNA concentration of 2770 ng/µl in 100 µl T.1E. The 260/280 ratio was 
1.87 and the 230/280 ratio was 2.23 so the DNA was pure. This DNA was the new 
stock of the plasmid for further work. 
 
5.2.2.12 Re-digestion of Elf5 mo ER pyCAGiZeo 
This newly purified plasmid was digested again with Nhe I, to ensure the plasmid 
was cut with Nhe I, 1 µl was cut with Cla I and a fragment at 767 bp was 
produced as expected. The rest of the digested plasmid DNA was 
dephosphorylated. The ligation and transformation was repeated along with the 
controls. About 50 colonies grew on one plate and about 100 colonies on the 
other. 1pg of control uncut plasmid gave 100 colonies as well, as a positive 
control. 
 
5.2.2.13 Miniprep of Elf5 mo VP16 ER pyCAGiZeo colonies 
The miniprep was repeated with 24 colonies and the DNA was digested with Nhe 
I and Cla l. If the plasmid contained the insert of interest a DNA band at 896 bp 
would be expected. If there was not an insert or if it was in the reverse 
orientation a fragment at 774 bp would be expected. The digested DNA was run 
on a high percentage gel to ensure a good separation between the two DNA 
bands. All colonies had a DNA band a 774 bp, see Figure 36. Another 48 
minipreps were carried out but no bands of the correct size were obtained. 
Either the plasmid was re-ligating to itself (i.e. the CIPing didn’t work) or there 
was something wrong with the VP16 cassette. As a different calf alkaline 
phosphatase was used, the plasmid was dephosphorylated again with a fresh 
batch. 
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Figure 36: Gel showing the results from a mini prep of clone DNA that was then restriction 
digested to see if the correct insert was in the clone. All clones either had no insert or they 
were in the wrong orientation, all products were 774 bp. If they had the correct insert the 
product size would have been 896 bp.  
 
5.2.2.14 Ligation of VP16 into pGEM-Teasy 
As the method above was clearly not working the VP16 cassette was ligated into 
the pGEM-Teasy plasmid (protocol see 2.3.3.5) which allowed blue/white 
selection of colonies containing an insert. As a modification to the protocol, after 
the PCR amplification of the VP16, it was not cut with SpeI or NheI to remove the 
clamp. This time a lot of colonies were produced, the vast proportion were blue 
(i.e. they do not have an insert) but there were also plenty of white colonies.  
 
5.2.2.15 Miniprep and restriction digestion 
A miniprep of 24 white colonies was completed and they were digested with Eco 
RV to distinguish if there was an insert. There was no band at the expected size 
of 130 bp. David Pearton suggested to carry out a PCR to see if the VP16 insert 
was in the plasmid, all PCR reactions were positive for the VP16 cassette. This 
suggested that there was not enough DNA from the minipreps to see the small 
130 bp DNA fragment on a gel.  
 
5.2.2.16 Midi prep of colonies 1 and 2  
To get a higher concentration of plasmid DNA a midi prep was performed and 
the DNA was digested with Nae I and Sac I. If the insert was present a DNA 
fragment at 547 bp would be produced, if not a fragment at 417 bp would be 
present. Both plasmids had a DNA fragment at approximately 550 bp suggesting 
the VP16 insert was present, refer to Figure 37.  
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Figure 37: 1= 100 bp ladder, 2 and 3 = digested midi prep DNA showing correct sized DNA bands 
at 550 bp, 4 = ultra ranger DNA ladder. This means these clones had the correct insert.  
 
Since the VP16 cassette was finally in a plasmid, it was cut out of the p-Gem 
Teasy plasmid 20 µg of the midi prep DNA was digested in a 50 µl reaction with 
Spe I and Nhe I to remove to insert.. The VP16 cassette was gel purified and 
ligated into Elf5 mo ER pyCAGiZeo. The ligation product was transformed into 
DH5α max competent cells and after the transformation about 100 colonies 
were obtained.  
 
A miniprep was performed on 24 colonies and then the DNA was digested with 
Nhe I and Cla I. Only one clone with the correct insert was obtained. A maxi prep 
of this one clone was prepared and it was digested again to make sure the insert 
was still there, see Figure 38. A product of the expected size was obtained.  
 
 
Figure 38: Gel showing maxi prep DNA with the correct size insert at 896 bp 
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5.2.2.17 Sequencing of Elf5 mo VP16 ER pyCAGiZeo 
A few microlitres of the maxi prep DNA was sequenced at the University of 
Waikato sequencing facility. The primers that were used to sequence verify the 
insert were mElf5-f TCAAGACTGTCACAGCCGAACAA and VP16-Nhea (reverse 
primer, sequence given above). When the sequencing results came back it was 
discovered that there was an insert of 14 bp directly in front of the VP16 
sequence. 
 
 
Figure 39: Alignment of Elf5 mo VP16 ER PyCagiZeo (top) against the forward and reverse 
sequencing reactions. The sequence highlighted in yellow indicates the insert in the maxiprep 
DNA. 
 
Figure 39 shows the top sequence is the plasmid as it should be (i.e. the correct 
sequence of the plasmid in vector Nti), the second sequence down is the 
sequence from the mElf5-f forward primer and the bottom sequence is from the 
VP16-Nhea reverse primer. Because this insert is visible in both forward and 
reverse sequence fragments it is real. The chromatograms were also clean so 
was not a mistake or bad sequencing, especially since both orientations 
matched. 
 
5.2.2.17.1 The SpeI restriction digest did not work correctly  
After searching for this insert in the vector NTi files, this 14 bp insert was found 
in the pGem TEasy plasmid. Looking back at the p-Gem T Easy plasmid MCS, 
there was an SpeI site that matches the insert sequence (see Figure 40). So the 
VP16 insert went into this plasmid in the reverse orientation, was cut out from 
the plasmid by the SpeI site in p-Gem rather than the SpeI site on the end of the 
VP16 sequence. The VP16 was then inserted back into Elf5 mo ER pyCAGiZeo in 
the correct orientation, but accumulating an extra 14 bp to the start of the 
fragment. This clone could not be used as an insert that is not a multiple of three 
2495 25442500 2510 2520 2530
» Elf5-mo-VP16-E...(2495)
» 0352_Elf_VP16... (221)
« 0352_Elf_VP16... (824)
Consensus(2495)
            + + + + + + + + + + + + + +                         
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(3 bp codes for 1 amino acid) will cause a frame shift mutation and the DNA will 
no longer code for the correct protein. 
 
 
Figure 40: shows how the Spe I digestion went wrong, the restriction digest was not efficient 
and cut only at the Spe I site on the plasmid and not the one that was also in the fragment, see 
arrow. This resulted in a 14 bp insert in front of the sequence of interest. 
 
5.2.2.17.2 Repeat of miniprep 
As the above clone could not be used, 48 more minipreps were prepared of the 
colonies obtained from the previous transformation. The DNA was digested with 
ClaI and NheI to check for the insert. 12 clones looked like they may have the 
insert. The DNA was then digested with SpeI. If the clone had the correct insert it 
should only cut once with SpeI, if it had the 14 bp insert it would cut twice. The 
clone that had the 14 bp insert was run alongside the digestion to show what it 
looked like if it was cut at the wrong SpeI site. The uncut plasmid was also added 
as another control, see Figure 41 below.  
 
Figure 41: 1 is the clone with the 14 bp insert, 2 = uncut plasmid, 3-15 are different clones, 8 is 
an ultra ranger ladder. Clones that cut twice also had the 14 bp insert.  Clones that cut once 
were correct.  
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Clones 4-6, 11-12 and 14 had been cut twice which meant that they too had the 
14 bp insert at the start of the VP16 sequence. The initial digestion must have 
been inefficient for a lot of the clones to have this insert. Clones 10, 13 and 15 
had the correct fragment size and were sent for sequencing. Clones 3 and 9 did 
not have the correct sized fragments when digested with NheI and ClaI they 
were just added for comparison.  
 
5.2.2.18 Maxiprep and Sequencing 
A maxiprep of clones 10, 13 and 15 was prepared and the resulting DNA was 
sequenced at the University of Waikato sequencing facility. Clone 13 had a 
perfect sequence in comparison to the Elf5 mo VP16 ER pyCAGiZeo clone chart in 
an alignment, see Figure 42 below. 
 
 
Figure 42: Sequence of the beginning of the VP16 gene aligned with the Elf5 mo VP16 ER 
pyCAGiZeo file in vector NTi. This prep has the correct sequence and can therefore be used to 
transfect the cells.  
5.2.2.19 Preparation of Glycerol Stock 
A glycerol stock was made of clone 13 for later use. A glycerol stock was made 
with 15 % glycerol and 85 % bacterial suspension, this was flash frozen in liquid 
nitrogen and then stored at -80 °C. 
5.2.3 Stable Transfection of Elf5 mo Vp16 ER pyCAGiZeo 
5.2.3.1 Linearization of DNA for transfection 
The correct plasmid for transfection of mouse trophoblast stem cells for the over 
expression of Elf5 was finally produced. Before the TS cells could be transfected 
with the plasmid DNA, the DNA had to first be linearised for optimal integration 
into the trophoblast stem cell genome. The plasmid was cut in the Ampicillin 
resistance gene since that gene was not required once the DNA was in the TS 
cells. 30 µg of the plasmid DNA was cut with ScaI and then purified through a 
wizard column (see protocol 2.1.4.1). The DNA concentration was estimated on 
2596 26452610 2620 2630
» Elf5-mo-VP16-E...(2596)
» 0384_Elf_TxClo... (378)
Consensus(2596)
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the nanodrop so the optimal concentration of DNA could be used to transfect 
the cells. Surprisingly 10 µg of DNA was lost during the digestion and purification 
procedure.  
 
5.2.3.2 Transfection of mTS cells number one 
The TS cells were transfected with 4 µg of the Elf5 mo Vp16 ER pyCAGiZeo 
plasmid according to the protocol outlined in sections 2.1.4.2-2.1.4.4. Five 
transfections were carried out with one untransfected control line. The control 
line was important to ensure all of the un-transfected cells and therefore 
susceptible to zeocin die off before resistant colonies can be picked. Zeocin 
selection began 24 hr after the TS cells had been transfected, refer to section 
2.1.4.5.  
 
5.2.3.2.1 Trouble shooting  
A few days after the beginning to the zeocin selection the TS cells became 
completely confluent and some differentiation was beginning to appear. The 
control cell line was not beginning to die off as it should as these cells do not 
have any resistance to zeocin. According to the protocol outlined in Himeno et 
al., (2008) it should take seven to fourteen days for stable transfected colonies to 
appear when treated with 200 µg/ml zeocin. Upon reading the Zeocin user 
manual it was discovered that zeocin can take up to 6 weeks to generate 
resistant cell colonies. Zeocin does not cause cells to round up and detach from 
the plate like traditional selection antibiotics. This makes it difficult to determine 
which cells are in fact dead. According to the Zeocin manual the following 
morphological changes can be observed upon Zeocin treatment; increase in size, 
abnormal cell shape and the appearance of long appendages, presence of large 
empty vesicles in the cytoplasm and the breakdown of the plasma and nuclear 
membrane. Ultimately the cells completely break down and only cellular debris 
will remain. As the cells were extremely confluent the zeocin concentration was 
increased to 500 µg/ml one week after the beginning of the transfection. Once 
there was a large amount of cell death the zeocin concentration was decreased 
back to 200 µg/ml. After three weeks of selection resistant colonies were 
beginning to appear in the plates. 
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5.2.3.3 Kill Curve 
As the zeocin concentration used did not seem optimal a kill curve was prepared 
to determine what concentration of zeocin killed off untransfected cells after 1-2 
weeks under antibiotic selection. For a 10 cm2 dish a seeding density of 5 x105 
cells/ml was required. The kill curve was carried out in 6-well dishes to save 
media as the media needs to be changes every second day. The area of a 6-well 
dish is 3.7 cm2 so a seeding density of 1.85 x105 cells/ml was required to down 
scale the experiment accordingly. As 200 µg/ml was the recommended 
concentration of zeocin to use (Himeno et al., 2008), both lower and higher 
concentrations of this were tested. The TS cells were plated out the day before at 
the recommended concentration of 1.85 x105 cells/ml in 5 wells of a 6 well dish. 
24 hr later the media was replaced with 70 % conditioned media containing 100 
µg/ml to 600 µg/ml zeocin. The media was changed every second day and the 
cell death was monitored. 
 
Table 14: Optimisation of Zeocin concentration for trophoblast stem cells. Zeocin was a very 
slow acting antibiotic.  
Zeocin 
Concentration 
(ug/ml) 
Day 2 (% 
dead 
compared 
to 
untreated) 
Day 6 (% 
dead 
compared 
to 
untreated) 
Day 10 (% 
dead 
compared 
to 
untreated) 
Day 14 (% 
dead 
compared 
to 
untreated) 
Day 18 (% 
dead 
compared 
to 
untreated) 
0 Confluent 0 0 0 0 
100 Confluent 0 0 0 10 
200 Confluent 0 0 5 50 
400 Confluent 0 5 20 80 
600 Confluent 0 15 60 100 
 
After two days of antibiotic selection all the cells became confluent and the 
antibiotic selection didn’t seem to have much of an effect on the TS cells. No cell 
death was observed in any of the wells until 10 days of antibiotic selection. A 
small amount of cell death was becoming visible in the TS cells treated with 400 
and 600 µg/ml of zeocin. After 18 days of selection the majority of the cells were 
dead in both the 400 µg/ml and 600 µg/ml zeocin wells. No effect was seen with 
100 µg/ml zeocin and a minimal effect with 200 µg/ml of zeocin (refer to Table 
14). The major problem here seems to be the initial seeding density of the TS 
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cells is too high which leads to the cells becoming confluent only a few days after 
the beginning of the antibiotic selection. As zeocin is a slow acting antibiotic the 
cells become too confluent before it has time to take effect. Next time either the 
cells density will be decreased or a different antibiotic will be used.  
 
5.2.3.4 Picking of stably transfected cell lines 
One month after beginning the stable transfection resistant colonies were 
beginning to appear in the cell culture dishes. The colonies were of various sizes 
and some were growing faster than others. To establish clonal cell lines the 
zeocin resistant colonies were picked according to the protocol outlined in 
section 2.1.4.6. The following day the media was changed and 0.5 ml of 70 % 
conditioned media was aliquoted into each well of the 24 well plate. In total 58 
colonies were picked. Of the 58 colonies that were picked, only four wells had TS 
cell colonies that had survived the picking procedure. Apparently this is not 
uncommon. One and a half weeks after picking, one of the wells had very nice 
colonies growing fast enough to be able to passage into a well of a 6-well dish. 
Two of the colonies that were picked differentiated after passaging once into a 
12 well plate. This left only two cell lines that were well established.  
 
5.2.3.5 Transfection of mTS cells number two 
As the original transfection of the mTS cells with the Elf5 mo VP16ERpyCAGiZeo 
plasmid was very unsuccessful with only two cell lines being established, the 
transfection was repeated. This time the cells were co-transfected with a 
linearised plasmid containing the pac gene for puromycin resistance on it. The 
plasmid was provided by Craig Smith and was digested with EcoRI to linearise. 
Puromycin is an antibiotic produced by Streptomyces alboniger that inhibits the 
growth of prokaryotic and eukaryotic cells by interfering with protein synthesis 
by inhibiting peptidyl transfer on ribosomes. Resistance to puromycin is provided 
by the expression of the pac (puromycin N-acetyl transferase) gene (Sigma-
Aldrich, 2009). If the cells are transfected with equal amounts of Elf5 mo VP16 ER 
pyCAGiZeo and the puromycin plasmid it is likely that cells will be puromycin 
resistant but not contain the plasmid of interest. Due to this 1/10 of the 
puromycin plasmid was used in relation to the Elf5 mo VP16 ER pyCAGiZeo 
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plasmid so if cells were resistant to puromycin they would be likely also carry the 
transgene of interest. The Elf5 mo VP16 ER pyCAGiZeo plasmid was 8135 bp and 
the puro plasmid was 4706 bp. Which was already a 1:1.7 ratio to get equivalent 
molar ratios. This could then be divided by 10 to give an optimal DNA ratio of 
1/17. So to get the correct 1:10 ratio of Elf5 mo VP16 ER pyCAGiZeo to 
puromycin resistance, 5x105 cell/ml of TS cells should be transfected with 4 µg of 
Elf5 mo VP16 ER pyCAGiZeo DNA and 0.24 µg of the puromycin plasmid. 24 hr 
after the trasfection the cells were selected with 1 µg/ml puromycin (optimal 
concentration was determined by Deane (2007)). Refer to section 2.1.4.5.1 of 
methods. 
 
5.2.3.5.1 Trouble Shooting 
After one week of selection the control cells were only dying off slowly. This was 
contrary to what was expected. The control cells should have all be dead within 
one week of starting antibiotic selection. Dying cells should detach from the 
plate allowing easy identification of resistant colonies. It was concluded that the 
initial seeding density of the cells was too high which rendered the antibiotic 
ineffective as it works best on actively dividing cells. This experiment was 
abandoned. 
 
5.2.3.6 Transfection of mTS cells number three 
This time the initial seeding density was reduced by 2.5 x to 2x105 cells/ml as the 
seeding density of 5x105 cells/ml was far too high even when using puromycin as 
the selection antibiotic. The transfection was carried out as outlined in 5.2.3.5 
and selection with 1 µg/ml puromycin began 24 hr after the beginning of the 
transfection. As expected the control cells died off within four to seven days.  
 
5.2.3.7 Integration of the plasmid into the genome 
The genomic DNA of the stable cell lines must be analysed for integration of the 
plasmid DNA into the genome. The genomic DNA could be isolated from a small 
fraction of cells obtained during passaging (about 1/10 was plenty), see methods 
2.1.4.7. The integration of the plasmid DNA into the genome could be verified by 
PCR. Primers were designed to the zeocin resistance segment of the plasmid DNA 
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as Elf5 is also expressed endogenously so was not a good candidate for 
examination by PCR. Two sets of zeocin primers were used, ZeoF 
GACGACGTGACCCTGTTCATCA     ZeoR GTCCTGCTCCTCGGCCACGAA (product size 
243 bp) and Zeo F2 CAGGACCAGGTGGTGCCGGACAA and ZeoR2 
CTGCTCGCCGATCTCGGTCATG (product size 141 bp). Figure 43 below shows lines 
one and two from the first transfection were positive for integration into the 
genome, the second zeocin primer set was used for this PCR.  
 
 
Figure 43: gel of genomic DNA amplified with Zeocin primers. 1= MQ, 2, 3= untransfected TS 
cells, 4, 5= line 1, 6, 7= line 2, 8= 1:10,000 dilution of the purified Elf5 mo VP16 ER pyCAGizeo 
plasmid. Both line 1 and 2 contained the plasmid inserted into their genome.  
5.2.4 Immunocytochemistry 
Immunocytochemistry was carried out on fixed mouse trophoblast stem cells in 
chamber slides to ensure the cells were expressing the Elf5-VP16-ER protein and 
that it translocated into the nucleus upon the addition of 4-hydroxytamoxifen. 
See section 2.1.4.9 for the method of immunocytochemistry. The primary 
antibody was to the ER-alpha ligand binding domain (c-terminus) of the plasmid 
(ABBIOTEC, Australia). An Elf5 antibody could not be used as Elf5 is also 
expressed endogenously.  
 
5.2.4.1 Trial one: 
Control mouse trophoblast stem cells and line 2 cells were passaged in 8 well 
chamber slides and then induced by the addition of 1 µg/ml of 4-
hydroxytamoxifen 24 hr after passaging, one well was not induced as a control. 
24 hr later the cells were fixed with 4 % PFA at RT for 5 min and stored in the 
fridge until ready to use. The protocol outlined in 2.1.4.9 was followed. Two 
    1        2       3        4        5        6         7        8  
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concentrations of the primary antibody were tested- 1:200 and 1:400 as a 
concentration of 1:200-1:500 was recommended for immunocytochemistry by 
the suppliers. The secondary antibody was a donkey anti-rabbit antibody 
conjugated to Alexa 488, the concentration used was 1:1000 as this 
concentration had been successfully used in flow cytometry (refer to chapter 
six). Unfortunately no fluorescence was observed upon excitation at 495 nm. The 
H33342 gave very strong staining when excited with a UV light.  
 
5.2.4.2 Trial two: 
As the above experiment did not work this was repeated. One well was used as a 
no primary antibody control to show the level of non specific binding. As a 
positive control an antibody to H3 serine 10 phosphorylation was used in 
another well to ensure the protocol and the secondary antibody was working. A 
1:200 dilution of the primary antibody was used as this was shown to be optimal 
for flow cytometry (see section 6.2.3.1). The ER-alpha primary antibody was used 
at a concentration of 1:100 and the secondary was used at 1:500. The cells were 
also fixed in methanol this time. The layout of the experiment is shown in Table 
15 below. 
 
Table 15: the layout of the chamber slide used for immunocytochemistry. 
 
Un-induced Induced Induced Induced 
Control 
1:100 1°, 
1:500 2° 
1:100 1°, 
1:500 2° 1:500 2° 
1:200 H3s10 1°, 
1:500 2° 
Line 2 
1:100 1°, 
1:500 2° 
1:100 1°, 
1:500 2° 1:500 2° 
1:200 H3s10 1°, 
1:500 2° 
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Figure 44: photograph of the H3ser10 antibody on control mouse trophoblast stem cells. Strong 
green fluorescence was seen in the mitotic cells. The blue fluorescence is the H33342, a nuclear 
dye. This photograph was taken at 10x magnification.  
 
Strong fluorescence was observed with the histone 3 serine 10 antibody, see 
Figure 44 above. Only cells in the late G2/M phase of the cell cycle were labelled 
intensely with this antibody.  
 
Figure 45: Mouse trophoblast stem cell line 2 un-induced i.e. no tamoxifen has been added. Er 
alpha antibody binding in the cytoplasm is the green fluorescence. The blue staining is the 
H33342 in the nucleus. This photograph was taken at a 10x magnification.  
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Figure 46:  Mouse trophoblast stem cell line 2 with 1 µg/ml tamoxifen. Er alpha antibody 
binding in the cytoplasm is the green fluorescence. The blue staining is the H33342 in the 
nucleus. This photograph was taken at a 10x magnification. A lot of the protein generated from 
the exogenous plasmid still seems to be in the cytoplasm.  
 
The fluorescence observed with the Estrogen receptor antibody was not very 
strong. The protein was expressed in the cytoplasm as expected in line 2 (see 
Figure 45), but upon the addition of 4-hydroxytamoxifen there did not seem to 
be a big shift into the nucleus (see Figure 46). There was some expression in the 
nucleus but not all of it moves to the nucleus as first expected. Possibly only a 
fraction of the protein moved to the nucleus upon the addition of OHT. The level 
of protein expression also was not as high as expected.  
 
5.2.4.3 4-hydroxytamoxifen assay optimisation 
Two lines were obtained from the first transfection and they were tested for 
their induction of Elf5 over-expression in the presence of 4-hydroxytamoxifen 
(OHT). As it is the protein that is over expressed and not the gene we could not 
use real time PCR to analyse any changes in Elf5 upon the addition of OHT. 
Instead changes in the Elf5 targets had to be analysed. Two different 
concentrations of OHT were used, 0.5 µg/ml and 1 µg/ml (Niwa et al., 2005) for 
24 hr, as well as an untreated control. The OHT was left for 24 hr and then Trizol 
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was added to each well for RNA isolation (see methods 2.1.4.8). Untransfected 
cells were also treated with OHT to ensure it was not affecting normal gene 
expression as OHT can interfere with Errβ expression which is a gene involved in 
TS cell maintenance (Rielland et al., 2008). The expression of some of the target 
genes as well as the house keepers were analysed. The expression of the TS stem 
cell genes Eomes and Cdx2 were not changed upon the addition of OHT and their 
expression levels were similar for each cell line relative to the control cell line. 
The expression of Elf5 was unchanged in line one and 2-3 times higher in line two 
compared to the control (see Figure 47). There was no change in Elf5 expression 
upon the addition of OHT. The Elf5 primers will pick up both the introduced Elf5 
cDNA and the endogenous cDNA. This indicates that line two has higher 
expression levels due to expression from the introduced plasmid. Refer to the 
raw data in the appendices.  
 
 
Figure 47: The expression of Elf5 in the control and transfected mouse trophoblast stem cell 
lines. Line two shows a successful over expression of Elf5 at the RNA level compared to the 
control and line 1. Expression is shown relative to the geometric mean of Gapdh, β-actin and β-
tubulin. 
 
The expression of Cyr61, Calca, Sox2, Keratin7, Secretin, Wdr40B, Zic3, 
1700112c13, Spi8 and Gm784 (some of the predicted Elf5 targets) were analysed 
next. Of the genes analysed, 6/10 were regulated as predicted (Cyr61, Calca, 
Kertain7, Spi8, Secretin and Gm784).  Cyr61 was down regulated upon the loss of 
Elf5 and it was up regulated when Elf5 is over expressed indicating it is a direct 
target of Elf5. 4/10 of the genes analysed (Sox2, Wdr40B, Zic3 and 1700112c13) 
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did not behave as predicted indicating some other protein may be involved in its 
regulation. 
 
Sox2 relative expression levels were similar to the untransfected control (around 
0.2) and to those of Elf5. Figure 48 below shows Sox2 expression relative to the 
untreated/ no OHT sample. We would expect Sox2 to be up regulated upon the 
addition of 4-hydroxytamoxifen. Interestingly it was down regulated in both cell 
lines. This indicates there is a complex network of interactions between genes in 
the Elf5 transcriptional network.  
 
 
Figure 48: changes in the expression of Sox2 upon the addition of 4-hydroxytamoxifen (OHT) 
and therefore the over expression of Elf5. Results were normalised to the geometric mean and 
then to the 0 OHT control. Sox2 was down regulated when Elf5 was over expressed (addition of 
OHT) compared to the no OHT treatment. There was no change in Sox2 expression in the 
control.  
 
Calca was expressed at quite low levels in mouse TS cells. Compared to the 
control, Line 1 has similar expression levels. For an unknown reason Calca was 
expressed at even lower levels in line 2. See Figure 49. 
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Figure 49: relative levels of Calca expression in the different trophoblast stem cell lines 
compared to the geometric mean of three house keepers. Calca was expressed at low levels in 
mouse trophoblast stem cells.  
 
 
Figure 50: Calca expression shown relative to the no 4-hydroxytamoxifen (OHT) control for 
each trophoblast stem cell line. Upon the over expression of Elf5 (addition of OHT) Calca was 
up-regulated as expected. 
 
When the control/ 0 OHT was normalised to 1.0 there was a large up-regulation 
of Calca upon the addition of 4-hydroxytamoxifen in line 2, see Figure 50. There 
was only slight up-regulation in line 1. So even though Calca was expressed at 
quite low levels in TS cells it is still of interest as an Elf5 target gene.  
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Figure 51: secretion expression with Elf5 over expression in mouse trophoblast stem cells. 
Secretin was down regulated as expected with Elf5 over expression (the addition of 4-
hydroxytamoxifen). Expression was shown relative to the Geometric mean of three 
housekeeping genes.  
 
Basal Secretin expression levels in line 2 also differed compared to the basal 
control levels (almost 5 times greater), see figure 51. Secretin was 
downregulated when Elf5 was over expressed compared to the 0 OHT control. 
 
 
Figure 52: Wdr40B expression in mouse trophoblast stem cells with Elf5 over-expression. 
Wdr40B was down regulated upon the addition of 4-hydroxytamoxifen instead of up-regulated 
as expected. Expression is shown as levels relative to the Geometric mean of three 
housekeeping genes.  
 
Wdr40B is a gene that does not behave as expected. Theoretically it should have 
been up-regulated upon the over-expression of Elf5. The levels of expression in 
line 2 also differ to the control, see Figure 52.  
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
R
e
la
ti
ve
 e
xp
re
ss
io
n
 le
ve
l
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0.04
0.045
0.05
R
e
la
ti
ve
 e
xp
re
ss
io
n
 le
ve
l
 129 
 
The addition of 4-hydroxytamoxifen did seem to induce the over expression of 
Elf5. But there was also more going on, some of the genes did not behave as 
expected and the levels of the genes varied compared to the control. As this was 
only a preliminary experiment and done in singlicites, this experiment will need 
to be repeated in triplicate whilst using only 1 µg/ml of OHT in future studies. 
 
5.2.4.4 Analysis of genomic DNA of other clones 
Other lines were obtained from the third transfection using puromycin resistance 
as a selection marker. These lines would not necessarily have the Elf5 mo Vp16 
ER pyCAGiZeo plasmid inserted into their genome as it was a co-transfection with 
the puromycin cassette on another plasmid. Therefore it was necessary to do a 
PCR on the genomic DNA of these cells lines to ensure they have the plasmid of 
interest inserted into their genome. Once again a region was amplified by using 
the primers designed to the zeocin region of the plasmid. See Figure 53 below.  
 
 
Figure 53: screening of other lines for insertion of Elf5 mo VP16 ER pyCAGiZeo plasmid into the 
genome. 1= MQ, 2= untransfected TS cells, 3-11 = lines 3-11, 12= positive control plasmid 
diluted 1:10,000. Lines 4 and 7 did not contain the plasmid inserted into their genome. The 
other cell lines analysed did contain the Elf5 mo VP16 ER pyCAGiZeo plasmid into their 
genome. 
Lines four and seven did not have the plasmid inserted into the genome, they 
only had the puromycin resistance cassette. Lines 3, 5-6, 8-11 did have the 
plasmid inserted into their genome. These lines were grown up in 6-well plates 
and then frozen down according to the protocol outlined in 2.1.1.4 for future use 
and analysis.  
5.2.5 Summary 
The over expression of Elf5 was considered important as it provided more vital 
information regarding Elf5 as a transcriptional regulator. The initial Elf5-ERT2 
plasmid did not seem optimal so the transcriptional activation domain of the 
herpes simplex VP16 virus was inserted. The VP16 domain had been used 
  1        2        3       4         5       6        7        8       9      10       11     12 
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successfully by Niwa et al,. (2005) and others to help over express their gene of 
interest. The addition of the VP16 domain did have its issues. Firstly the size of 
the insert was relatively small so it made it very difficult to obtain after repeated 
digestion and gel purification steps. And then it would not ligate into the Elf5-
ErT2 plasmid. Once the decision had been made to insert the VP16 fragment into 
the p-GEM-T-EASY plasmid things began to work. All the subcloning procedures 
were very inefficient with only a few positive results at each step. Finally a clone 
was obtained with the correct insert and it was sequence verified.  
 
Two stable cell lines were generated from the first transfection. This was 
extremely inefficient but I have been told that it can occur. The initial problem 
generating the lines began with the zeocin selection. As zeocin was a slow acting 
antibiotic the cells became far too confluent before the antibiotic had time to act 
on the untransfected cells. The concentration had to be increased from 200 
µg/ml to 500 µg/ml. Eventually this caused a large amount of cell death and 
probably killed some colonies that should have been resistant to the antibiotic 
too. Once the antibiotic concentration was decreased back to 200 µg/ml some 
colonies started to appear. 58 colonies were picked but only two became 
established. This was probably due to inexperience with the picking technique.  
 
Of the two lines that were obtained, they were shown to express the plasmid 
and produce the protein by immunocytochemistry. The cells express the protein 
but not all of it went into the nucleus upon the addition of 4-hydroxytamoxifen. 
Increasing the concentration of OHT would not help as it would affect the 
controls as OHT also binds to Errβ a gene involved in TS cell maintenance.  
 
Although only a small amount of protein went into the nucleus, it did have an 
effect.  Firstly the levels of Elf5 were examined compared to the control. The Elf5 
levels were the same as the control in line one but 2-3 times higher in line 2. The 
TS cell marker genes Eomes and Cdx2 were expressed in line one and two at the 
same levels as the control line and they were not up or down regulated upon the 
addition of 4-hydroxytamoxifen. This was satisfying as we have previously shown 
that Eomes and Cdx2 were not affected by changes in Elf5 expression.  
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The preliminary results obtained were not as expected. Some of the trends 
differed to the knockdown data and to complicate matters more the expression 
levels of the genes in the lines varied compared to the controls. Some of the 
genes behaved as expected, Cyr61, Calca, Secretin, Keratin 7, GM784 and Spi8. 
They show trends that correlate to the knockdown data. For example secretin 
was up regulated when Elf5 was knocked down and it was down regulated when 
Elf5 was converted to an activator. But the levels of secretin expression differed 
to the control levels. This may have been due to leaky expression from the 
plasmid or some other contributing factor. Sox2 was one of the best targets that 
we had identified and it was not up regulated as expected when Elf5 was over 
expressed. Instead it was down regulated. This could indicate that Sox2 is not a 
direct target of Elf5, but that Elf5 regulates another protein involved in Sox2 
regulation. Sox2 was expressed at the same levels to the control. This preliminary 
data indicates that there is a very complex network of interactions taking place. 
 
Elf5 is a transcription factor and thus may normally work as a direct activator of 
some genes and a repressor of others, depending on other cofactors that bind to 
the target genes. In cases where Elf5 normally works as a repressor, the over 
expression of our Elf5-VP16 may well mimic knockdown. The removal of the 
repressor via knockdown is the same as the addition of an activator overcoming 
repression. For genes where Elf5 normally acts as a direct activator over 
expression of Elf5 may have no effect if endogenous levels in TS cells are high 
enough. This is why VP16 was added, to boost any effect. The likely reason that 
the expression of Sox2 goes down is because the effect of Elf5 on Sox2 is not 
direct. If Elf5 was an activator of Sox2, expression should have gone up, this was 
not the case. The most likely explanation is that Elf5 normally represses a 
repressor of Sox2.  
 
More experiments need to be carried out but they fall outside the scope of this 
thesis. Additional cell lines that contain the Elf5-mo VP16 ERpyCAGiZeo plasmid 
integrated into their genome have been obtained but they have not yet been 
analysed.  
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6 Chapter Six: Cellular changes to mouse Trophoblast stem 
cells upon Elf5 knock down 
6.1 Overview 
Chapter three to five described the genetic effect of the loss of Elf5, here we now 
investigate the cellular effect of the loss of Elf5. To assess the cellular changes 
that the trophoblast stem cells undergo when Elf5 is knocked down the 
morphology, differentiation, proliferation and apoptosis of these cells were 
studied. When Elf5 is knocked out in vivo the extra embryonic ectoderm (ExE) is 
missing, assumed to be due to the trophoblast being unable to maintain the 
trophoblast stem (TS) cells in an undifferentiated state (Donnison et al., 2005). 
The TS cells that reside in the ExE, and its precursor the polar trophectoderm  are 
thought to have precociously differentiated into ectoplacental cone (EPC) cells; 
which leads to an absence of the ExE by E6.5. It would be interesting to see what 
happens to the TS cells in vitro when Elf5 is knocked down since this study 
cannot be done in vivo.  
 
The major technique used currently to examine proliferation, changes in DNA 
content and apoptosis has been flow cytometry. Flow cytometry is a useful 
technique that can provide information about a cell’s size, granularity, internal 
complexity and other properties when the cells are labelled with fluorescent 
markers. Flow cytometry measures properties of single cells in a fluid suspension 
as they pass one at a time through the sample injection port (SIP). Large numbers 
of cells can be measured as the flow rate can be up to 2,000-5,000 cells per 
second. Flow cytometers measure light signals produced by the cells as they pass 
the 488 nm argon ion laser. Detectors are focused in line where the cell passes 
the light beam and measures forward scatter (FCS), side scatter (SSC) and there 
are also three fluorescent detectors for different wavelengths (green, yellow and 
red). Forward scatter is proportional to the cells size and side scatter provides 
information about the cells granularity and internal complexity. Cells labelled 
with Fluorescent markers and antibodies can provide information about the cell 
cycle, proliferation, viability and much more.  
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Before each assay the machine must be optimised with control cells. This is 
achieved by adjusting the voltage settings for FSC, SSC and the fluorescent 
channels until the unlabelled or negative control cell population is in the 100-101 
area of the histogram. A positive control must also be used to ensure there is a 
shift from the 100-101 area to above 101 and that the assay is in fact working 
successfully.  
6.2 Results 
6.2.1 Effect of Elf5 Knockdown on Cell Morphology 
The first change to be examined upon Elf5 knockdown was morphology. No 
morphological changes had been observed after 48 hr of Elf5 knockdown. Due to 
this, changes in morphology were investigated 5-6 days after Elf5 knockdown. 
Although Elf5 siRNA would have been diluted out after this period we were 
hoping to see some downstream effects from the knockdown of Elf5. Another 
reason for examining morphology after 5-6 days is that upon the removal of 
growth factors, differentiated giant cells do not begin to appear for 4 days 
(Erlebacher et al., 2004). Morphology was analysed by staining the cells with 
Phalloidin and Hoechst 33342. Phalloidin-TRITC binds to F-actin subunits. Actin is 
abundant in the cell membrane and can therefore be used to visualise the cell 
membrane and boundaries when excited at 532 nm. Hoechst 33342 is a nuclear 
dye, and fluorescence is enhanced upon binding to the minor groove of double 
stranded DNA. The use of phalloidin and H33342 together allows the 
visualisation of the cell nucleus and the cell membrane which provides 
information about the cells morphology and size.  The protocol was followed as 
in 2.2.1. 
 
6.2.1.1 Optimisation of Phalloidin concentration 
To optimise for phalloidin concentration two different concentrations of 
phalloidin were tested. The recommended range was 1-20 µg/ml so 20 µg/ml 
and 5 µg/ml of phalloidin were tested. Both concentrations gave good staining. 
The first time this assay was carried out the cells were far too confluent by 5 
days. The cells were growing on top of each other and it was hard to distinguish 
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individual cells. I decided the cells needed passaging 2-3 days after the initial 
transfection. Two days after the knockdown of Elf5 all cells were lifted by 
trypsinisation and the remaining cells were scraped to prevent the loss of any 
giant cells that had formed as giant cells tend to be more resistant to 
trypsinisation.  
 
6.2.1.2 Problems with morphology 
The TS cells had been grown in activin preceding these morphological 
experiments. It was noted that when the cells were grown in continuous culture 
with activin they had changed morphology compared to growth in conditioned 
media. The cells did not grow in tight colonies and the cells seemed very pointed. 
Also upon the removal of growth factors the cells did not dramatically increase in 
size and form giant cells as expected. Figure 54 shows cells stained with 
phalloidin and H33342 when grown in activin and after growth factor removal. 
These cells had been grown in activin for longer than two months. 
 
 
Figure 54: Non treated TS cells grown in the presence of activin (A) and cells with growth 
factors removed for 5 days (B). Note the appearance of the spiked cells in the no treatment 
cells and the cells do not increase in size upon the removal of growth factors. 10x 
magnification. 
Although according to Erlebacher et al., (2004) activin can replace conditioned 
media for the culture of trophoblast stem cells, some morphological changes are 
apparent. Morphological changes were observed within a few weeks of culture in 
activin compared to those grown in conditioned media. The cells seemed to lose 
their tight epithelial boundaries and appeared to grow as single cells rather than 
in colonies. The cells were more pointed compared to the rounded cells 
observed when cultured in conditioned media. The cells did not differentiate into 
A B 
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giant cells or syncytiotrophoblast cells, had an altered appearance. Cells grown in 
activin for 1.5 months in contrast to those grown in conditioned media for 1.5 
months can be seen in figure 55 below. 
Figure 55: Cells grown in activin for 1.5 months compared to those grown in conditioned 
media. Cells grown in CM at 10x magnification (A), and at a 20x magnification (B). Colonies with 
tight boarders are clearly visible. TS cells grown in activin for 1.5 months at 10x magnification 
(C) and at 20x magnification (D). The spiked appearance of the cells can be seen.  
 
In the short term there is no change in gene expression of TS cell marker genes 
(see Figure 7). Expression was not analysed after long term culture in activin. And 
therefore the cells could still be grown in activin in the short term for gene 
expression studies but cannot be used as indicators of changes in morphology. 
 
6.2.1.3 Changes in morphology upon Elf5 Knockdown 
As I was concerned with the morphological appearance of the TS cells after 
preliminary experiments I decided to change back to using conditioned media 
instead of activin. Theoretically using activin instead of conditioned media was 
better as it was a more controlled media. The levels of growth factors can vary in 
each batch of conditioned media. But there was obviously something extra in the 
conditioned media that the TS cells required. Elf5 was knocked down as outlined 
A B 
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in 2.2.1.1 and the morphology was examined after 6 days of Elf5 knockdown by 
the procedure explained in 2.2.1.2-2.2.1.4.  
 
 
Figure 56: Morphological changes to TS cells upon Elf5 knockdown. No Treated cells (A) Si 
negative control (B) 337 Elf5 knockdown (C) 733 Elf5 knockdown (D) No Growth factors (E & F) 
All pictures are a 10x magnification. The blue nuclear dye is H33342 and the red dye is 
phalloidin which binds to actin filaments in the cell membrane. 
 
When the cells were grown in conditioned media the cells had tight borders and 
grew in TS cell colonies, see Figure 56-A. There was no change in morphology 
with the si negative control (B) compared to the no treatment control (A). 6 days 
after Elf5 knockdown with the 337 siRNA there was possibly an increase in the 
number of larger cells (C). 6 days after Elf5 knockdown with the 733 siRNA there 
was a more definitive increase in the number of larger cells (D). The cells were 
A B 
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not fully differentiated as upon the removal of growth factors (E,F), but they did 
look different to the no treatment and si negative control cells. Upon the 
removal of growth factors the cell size increased dramatically and the 
cytoplasmic volume also increased.  These results were qualitative as there is no 
quantitative value assigned to morphological appearance. But these results were 
confirmed by analysing DNA content (see 6.2.2).  
 
6.2.1.4 RNA isolation and Real time PCR to confirm Elf5 Knockdown 
To ensure Elf5 was in fact knocked down during this morphology as well as the 
proliferation experiment (they were carried out on the same knockdown run) 
one well of TS cells which had been transfected was kept for RNA isolation. The 
cells were harvested 48 hr after the knockdown of Elf5.  
 
 
Figure 57: Percentage knockdown of Elf5 (337 and 733) for both the proliferation and 
morphology experiments. Expression is relative to the no treatment control.  The mTS control 
was cells grown for 48 hr without growth factors.  
 
A 70 % knockdown of Elf5 was obtained during this experiment, this level of 
knockdown was sufficient to observe the downstream effects in terms of 
morphology.  
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6.2.2 DNA content 
To provide further evidence of the state of the cell when Elf5 is knocked down 
the DNA content of a cell can be measured by staining with propidium iodide 
(PI). Propidium iodide is a fluorescent compound that binds stochiometrically to 
nucleic acids so the amount of PI bound in the cell and therefore its fluorescence 
is proportional to the amount of DNA in the cell (Riccardi and Nicoletti, 2006). PI 
can therefore be used to distinguish between 2N, 4N and 8N or greater DNA 
contents. A 2N DNA content represents cells that are quiescent or in the G1 
phase of the cell cycle. A 4N DNA content represents cells that are in the G2/M 
phase of the cell cycle. The synthesis phase of the cell cycle is between 2N and 
4N. When the growth factors are removed TS cells endoreplicate to form giant 
cells. They can be distinguished from normal TS cells (2N and 4N) by the DNA 
content in the cell. Differentiated TS cells have a DNA content of 8N or greater 
(refer to section 1.3).  
 
The cell must be permeabilised before the addition of PI as normal healthy cells 
can exclude PI. PI has been used previously to study the differentiation of TS cells 
upon the removal of growth factors (Tanaka et al., 1998) (see histogram below in 
Figure 58) and the addition of differentiation inducing agents (Yan et al., 2001).   
 
Figure 58: PI staining for DNA content of TS cells by Tanaka et al., (1998). Front histogram are 
untreated cells, moving back are 2,4, and 6 days after growth factor removal. There are three 
main peaks, the first is the 2N DNA content, second is the 4N DNA content and third is the 8N 
or greater peak. Note the 8N peak increases as the cells differentiate into giant cells when the 
growth factors are removed.  
 
6.2.2.1 Optimisation of the FACS for DNA content 
Before analysing DNA content of the TS cells upon Elf5 knockdown the FACS had 
to be optimised. For optimisation 1x106 untreated TS cells, differentiated TS cells 
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and mouse embryonic fibroblasts (MEFs) were grown up and fixed in 70 % 
ethanol over night. MEFs were used as a control cell line as they do not 
endoreplicate. They would only have a DNA content of 2N and 4N for non 
dividing and dividing cells respectively. The cells were stained with PI by the 
protocol outlined in 2.2.2.2-2.2.2.3. DNA QC particles (BD) were used for 
verification of instrument performance and quality control of the FACS before 
DNA analysis. These particles ensured there was a good separation between the 
G1, S, and the G2/M phases of the cell cycle. DNA staining by PI was measured in 
channel 3 (FL3, bandpass > 600 nm) with linear amplification. The MEFs were 
analysed for 2N and 4N DNA content. The histogram is shown below in Figure 59. 
M1 was a 2N DNA content and M2 was a 4N DNA content, M3-M4 was a DNA 
content greater than 4N. The small amount of cells with a DNA content of 8N 
were due to the heterogeneity of the embryonic fibroblast cell populations as 
these MEFs were only passage 2-3 of primary cells. The majority of the cells in 
this sample were in the M1 region which represents the 2N/G1 stage of the cell 
cycle. 
 
 
Figure 59: Mouse embryonic fibroblast (MEFs) cells used as a control for 2N and 4N DNA 
content. These cells do not endoreplicate so can be used as a control. The M1 peak in a 2N DNA 
content and the M2 peak is a 4N DNA content. The small peak in the M3 region is due to 
contaminating cell lines as MEFs are a primary cell line at an early passage number.  
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6.2.2.2 The Effect of Elf5 Knockdown on DNA content 
Once the FACS was optimised Elf5 was knocked down as in 2.2.2.1 and the cells 
were cultured for 6 days upon Elf5 knockdown. The cells were labelled by 
following the same protocol as above. The treatments were untreated, si 
negative, removal of growth factors and both of the Elf5 targeted siRNAs. Refer 
to table Table 21 in the appendices for raw data. 
 
 
 
Figure 60: No treatment cells showing normal DNA content of 2N and 4N with little 
differentiation (8N peak) (A). TS cells differentiated for 6 days, notice the large ≥8N peak (B) 
733 Elf5 knockdown (C) and 337 Elf5 knockdown (D), increase in ≥8N peak seen for both.  
 
Figure 60 are some examples of the histograms obtained 6 days after the 
knockdown of Elf5. Figure A shows what the DNA state of TS cells grown under 
normal conditions. Note there was only a small peak of cells with a DNA content 
of greater than 4N. Also note the similarity to the first histogram in Figure 58. 
When the growth factors were removed the number of differentiated cells 
increased from 11 % in the no treatment to 35 % after 6 days differentiation. This 
value may have been larger as some differentiating cells within the 4N peak may 
be endoreplicating not dividing. There was an increase in the number of 
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differentiated cells when Elf5 was knocked down. For the 337 Elf5 knockdown 
the number of cells with a 8N or greater DNA content increased by 6 % and when 
Elf5 was knocked down by the 733 siRNA this increased by 8 %. See Figure 61 for 
a bar graph of the difference in DNA content for the different treatments. 
Another interesting change to note was that the 2N and 4N population of 337 
and 733 changed compared to the untreated control. The 2N DNA content 
increased and the 4N decreased. This could have potentially been a proliferative 
effect which was examined later by a different technique. This change was also 
seen in the si negative control.  
 
 
Figure 61: Changes in DNA content upon Elf5 knockdown in mouse trophoblast stem cells. N=4. 
Note when the cells were transfected there was a decrease in the number of cells with a DNA 
content of 4N and an associated increase in the 2N peak. This was seen in the si negative as 
well as the Elf5 transfections so this was not specific to the knockdown of Elf5. There was also 
an increase in the 8N or greater peak when Elf5 was knocked down. Significance compared to 
the no treatment control ** P<0.01 
 
6.2.2.3 RNA isolation and Real Time PCR 
Again to ensure Elf5 had in fact been knocked down during the DNA content 
experiment one well of each treatment was kept for Trizol isolation 48 hr after 
the knockdown of Elf5. A 70 to 80 % knockdown of Elf5 was achieved for this 
experiment relative to the no treatment control.  
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Figure 62: Knockdown of Elf5 for the DNA content experiments, achieved greater than 80 % 
knockdown compared to the no treatment control in mouse trophoblast stem cells.  
6.2.3 Proliferation 
Elf5 is potentially a factor involved in the maintenance of proliferation in the 
trophoblast as in its absence the extraembryonic ectoderm cannot be 
maintained (Donnison et al., 2005; Rielland et al., 2008). A marker for 
proliferation is the phosphorylation of histone 3 at serine 10 that is initiated in 
late G2. It is at a maximum during metaphase and begins to diminish during 
anaphase of mitosis, being associated with chromosome condensation (Gurley et 
al., 1977; Hendzel et al., 1997). Antibodies to this marker are sensitive (see 
Figure 44) and can be combined with flow cytometry to determine the amount of 
proliferative cells in a given sample or treatment. As for morphology and DNA 
content the proliferation of the cells were examined 5 days after the knockdown 
of Elf5. 
 
6.2.3.1 Optimisation on the FACS 
Before the proliferation experiment could performed, the concentration of the 
primary antibody (rabbit antibody against H3 Serine 10 phosphorylation) needed 
to be optimised. Three different primary antibody concentrations were tested, 
1:100, 1:200 and 1:500 along with a 1:1000 dilution of the secondary antibody 
which was an Alexa 488 donkey anti rabbit antibody. The optimal concentration 
was 1:200, a distinct second peak was observed with this concentration.  
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The instrument settings also had to be optimised with control samples. The 
negative control was the secondary antibody alone without the primary antibody 
to give the level of non specific binding. Mitomycin C was used as a negative 
control, it is a DNA cross linker so it prevents DNA replication. The positive 
control was cells treated with nocodazole. Nocodazole causes late G2 or mitotic 
arrest (Kwak et al., 2005), which is useful as a control as Histone 3 serine 10- 
phosphorylation occurs at the late G2/M phase of the cell cycle. The cells were 
treated with nocodazole and mitomycin C for 16 hr. The protocol for the analysis 
of proliferation is outlined in 2.2.3.  
 
6.2.3.2 The Effect of Elf5 Knockdown on Proliferation 
Elf5 was knocked down as in the other assays and the cells were analysed for this 
proliferative marker 5 days after transfection. The cells had to be passaged once 
during this treatment as they became too confluent. 
 
Under normal conditions the percentage of mitotic cells in a population of TS 
cells is 4.7 %, see Figure 63. This was the total number of cells going through the 
late G2/M phase at the give time point. The cells were not selected by shaking to 
detach the mitotic cells. This level of proliferation seemed relatively low but we 
were only capturing unsynchronised cells at a certain time point. Upon 50 ng/ml 
nocodazole treatment the percentage of mitotic cells was significantly increased 
to 14.2 %. This concentration was saturating as 100 ng/ml nocodazole did not 
increase the number of proliferative cells. Mitomycin C treatment only 
decreased the number of mitotic cells to 2.6 %. The removal of growth factors 
decreased cells proliferation to 1.1 %. This was what was expected as the 
majority of the cells would not be going through the G2/M phase of the cell 
cycle. Instead they will be going through repeated rounds of DNA synthesis. The 
knockdown of Elf5 did not have any significant effect on cell proliferation using 
this mitotic marker. Refer to table Table 19 in the appendices for raw data.  
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Figure 63: Levels of histone 3 serine 10 phosphorylation in different treatments which shows 
the number of mitotic cells in each treatment. N=5. Significance compared to the no treatment 
**p<0.01. There was no change in proliferation upon the knockdown of Elf5 (337 and 733). 
6.2.4 Apoptosis 
Apoptosis is programmed cell death that occurs in eukaryotic cells. Apoptosis is 
involved in many processes in a cell including disease, tumorgenesis and 
embryogenesis and can occur in response to stress, inflammation and infection. 
Apoptosis occurs in an orderly fashion which includes cell shrinkage, activation of 
caspases, loss of membrane integrity, DNA fragmentation and the formation of 
apoptotic bodies. These processes can be exploited and used as indicators of 
apoptosis (Vermes et al., 2000). Activation of DNases during apoptosis results in 
extensive DNA fragmentation in the cell. These DNA strand breaks can be used as 
an indicator of apoptosis by labelling the strand breaks with a fluorochrome. This 
is termed a TUNEL assay (Terminal deoxynucleotidyl transferase-mediated dUTP 
Nick end labelling). The 3’-OH termini of DNA double strand breaks can be 
labelled with BrdU when incorporated with BrdUTP by the terminal 
deoxynucleotidyl transferase (TdT) enzyme (see Figure 64 below). The strand 
breaks can then be detected by a BrdU secondary antibody conjugated to an 
Alexa 488 dye and measured by flow cytometry (Darzynkiewicz et al., 2008). 
Flurochromes other than BrdU are commonly used but BrdU increases the 
sensitivity of the assay by giving a four-fold higher signal (Vermes et al., 2000). A 
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drawback of this method is that DNA strand breaks can occur in other modes of 
death too. The incorporation of PI staining into this method allows the 
identification of cells that have a sub-diploid DNA content which is another 
marker of apoptosis. An APO-BrdUTM TUNEL Assay Kit was purchased from 
Molecular ProbesTM (invitrogen) and was used in this section in combination with 
flow cytometry.  
 
 
Figure 64: Schematic showing TdT incorporating BrdUTP into cleavage site of the DNA. An 
Fluorescently labelled secondary antibody to BrdU then binds to it (Darzynkiewicz et al., 2008). 
The number of fluorescing cells can then be determined by flow cytometry. Figure borrowed 
from Darzynkiewicz et al.,(2008) 
 
6.2.4.1 Initial trial of the tunnel assay 
Before knocking down Elf5, the assay must be optimised for the TS cells. In the 
first instance untreated cells were labelled by following the protocol outlined in 
2.2.4.2. Both positive and negative control cells were provided with the kit. The 
positive control cells were a human lymphoma cell line treated with the DNA 
topoisomerase inhibitor camptothecin. Camptothecin induces apoptosis 
selectively during S phase of the cell cycle (Darzynkiewicz et al., 2008). The 
negative control line was the same cells untreated. The protocol provided with 
the kit worked well on the positive and negative control cell lines. There was no 
detectable apoptosis in the untreated TS cells, see Figure 65. But a negative 
result did not necessarily mean that there was no apoptosis, as the assay may 
have not been working on the TS cell line.  
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Figure 65: Positive control cells (A), Negative control cells (B), TS cells untreated (C). FL1 is 
green fluorescence which was BrdU labelling, FL3 is PI staining. A shift to 10
2
-10
4
 in FL1 
indicates apoptotic cells. A shift into the 10
2
-10
4
 region on the Fl1 spectrum was seen in the 
positive control cell line and no shift was seen in the negative cell line. 
 
6.2.4.2 DNase treatment of the TS cells 
Due to the negative result, during the next assay the TS cells were treated with 
DNase for 10 min at RT. After the cells had been fixed and stored in ethanol 
overnight, the cells were washed twice with DNase I buffer and then 
resuspended in 100 µl DNase buffer. 5 units of DNase I was added and the cells 
were incubated at RT for 10 min. DNase induces DNA strand breaks and 
therefore can act as a positive control. The cells were then washed with wash 
buffer and the usual protocol was followed. No positive cells were obtained after 
DNase treatment. This indicated that either the DNase treatment wasn’t working 
or the assay was not optimised for the TS cells. See Figure 66 below.  
 
 
Figure 66: TS cells treated for 10 min at RT with DNase, there was no DNA strand breaks as 
there was no fluorescence observed at 10
2
-10
4
 in the FL1 channel.  
 
 
A    B       C 
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6.2.4.3 DNase treatment of the negative control cell line 
To make sure the DNase treatment was not the problem the negative control cell 
line provided with the kit was treated with 5 units of DNase for 10 min as above. 
The majority of the cells were positive for DNA strand breaks using this method 
(see Figure 67 below). This showed that the DNase treatment did work and that 
the assay conditions needed optimising for the TS cells themselves.  
 
 
Figure 67: Treatment of negative control cell lines with DNase. Note all cells are now positive 
for DNA strand breaks as they have moved to the 10
2
-10
4 
region on the histogram. 
 
6.2.4.4 Optimisation of assay conditions 
According to the protocol supplied with the Tunnel assay the incubation times 
with the TdT enzyme may need to be optimised. The incubation time with the 
TdT enzyme for the control cells was 1 hr. The incubation time with the TdT 
enzyme was increased to 4 hr. During this assay some cells that were floating in 
the media from another experiment were included as another control. These 
cells turned out positive in the tunnel assay and so did the DNase treated cells. 
The untreated TS cells did shift into the positive area of green fluorescence but 
this level of apoptosis was far too high to be correct so the incubation time was 
decreased to 2-3 hr for the next optimisation experiment. A TdT incubation time 
of 3 hr was concluded to be the optimal incubation time as the majority (93 %) of 
the DNase treated cells were positive for apoptosis as you would expect in an 
efficient digestion and the untreated cells did not shift to give false positives.  
The 2 hr TdT incubation was not long enough as only 61 % of the DNase treated 
cells were positive for DNA strand breaks.  
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6.2.4.5 Knockdown of Elf5 and analysis of apoptosis 
Elf5 was knocked down in the TS cells according to the protocol outlined in 2.2.4. 
As the time that the cells would be undergoing apoptosis due to the knockdown 
of Elf5 was not known, apoptosis was analysed both 48 hr and 5 days after the 
initial transfection. To ensure Elf5 was in fact knocked down RNA was isolated 
from an extra well 48 hr following transfection; Figure 68 shows the knockdown 
of Elf5 achieved for apoptosis.  
 
 
 
Figure 68: Elf5 knockdown for the apoptosis experiment in trophoblast stem cells. Greater than 
80 % knockdown of Elf5 was achieved in comparison to the untreated control for the apoptosis 
experiment. As expected when the growth factors were removed, Elf5 was down regulated.  
 
6.2.4.6 Apoptosis results 
The tunnel assay was carried out on two separate days as there were far too 
many samples to do at once. The samples were incubated with the TdT enzyme 
for 3 hr as this time period was determined to be optimal by analysis of DNase I 
treated cells (see section 6.2.4.4). 48 hr following the transfection there were 
very few cells undergoing apoptosis in any of the treatments. The highest was 
0.76 % in the si negative treatment. There was no difference between the 
samples in which Elf5 was knocked down in and the no treatment. There was no 
increase in apoptosis when the growth factors had been removed from the TS 
cells for 48 hr either. After 5 days in culture the number of cells undergoing 
apoptosis upon Elf5 knockdown increased significantly compared to the 5 day no 
treatment sample but this also occurred in the si negative control so it was not 
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specific to the knockdown of Elf5. There was no significant difference between 
the 5 day apoptosis levels between the si negative and the two samples with Elf5 
knocked down.  There was a large increase in the number of cells undergoing 
apoptosis when the growth factors had been removed for 5 days. See Figure 69 
below for a summary of the effect of Elf5 knockdown and removal of growth 
factors on apoptosis. Refer to Table 20 in the appendices for the raw data.  
 
 
Figure 69: Total number of cells undergoing apoptosis in different treatments in mouse 
trophoblast stem cells. Only 0.7 % of cells were undergoing apoptosis in normal healthy TS 
cells. Significance difference compared to the no treatment control *p<0.05, **p, <0.01. N=2. 
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6.2.5 Summary 
 In addition to the changes in gene expression upon the knockdown of Elf5, the 
cellular changes in the TS cells upon the knockdown of Elf5 were examined. 
Changes in morphology, DNA content, proliferation and apoptosis were studied 
as these are stem cell characteristics that could change due to the loss of 
expression of a critical gene.  
 
The removal of growth factors as expected, had the most dramatic effect on the 
TS cellular characteristics (Cross et al., 2003; Hemberger et al., 2004; Yan et al., 
2001). Changes in morphology were apparent 4-6 days after the removal of 
growth factors. There was an increase in cell size, especially the formation of a 
much larger nucleus and cytoplasm compared to TS cells. To coincide with the 
large nucleus there was an increase in the 8N or greater DNA content of the cell 
due to DNA endoreplication. There was also a decrease in proliferation due to 
endoreplication as the cells continue to synthesise their DNA without going 
through cell division. There was no change in apoptosis 48 hr after the removal 
of growth factors but there was a large increase after 5 days of differentiation. 
 
The knockdown of Elf5 caused a definitive increase in the number of larger cells 
compared to the untreated control by morphological observation.  There was no 
change in morphology in the si negative control cells. The analysis of DNA 
content confirmed the increase in the number of larger cells. This change was 
not as large as the removal of growth factors, only some of the cells were 
differentiating. There was no increase in 8N DNA content in the si negative 
control. A decrease in the number of cells with a 4N DNA content was observed 
along with an increase in the 2N DNA content. This latter effect could have been 
a proliferative effect. The same change was seen in the si negative control. 
Although there was a change in the number of cells with a 4N DNA content upon 
the knockdown of Elf5, there was no change in proliferation. A change in 
proliferation could have possibly been seen at an earlier time point (for example 
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2-3 days after knockdown). The levels of apoptotic cells when Elf5 was knocked 
down did not change in relation to the si negative control.  
These results indicate Elf5 is likely to be involved in the prevention of 
differentiation of the TS cells into EPC/giant cells. Elf5 is not involved in apoptosis 
of the TS cells. Elf5 is not involved in cell proliferation at the time point studied 
but it could well be involved at an earlier time point.  
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7 Chapter 7: Discussion 
7.1 Overview 
The placenta is an essential organ for mammalian development as it mediates 
the interaction between the foetus and the maternal blood stream. At the early 
blastocyst stage of embryo development, two cell lineages can be distinguished, 
the inner cell mass (ICM) and the trophectoderm (TE). The ICM gives rise to the 
embryo proper and the extra embryonic endoderm, the TE the foetal part of the 
placenta. The polar trophectoderm which lies above the ICM receives signals 
from the ICM to form the extra embryonic ectoderm (ExE) and the ectoplacental 
cone (EPC) which can form all cells of the placenta (Simmons and Cross, 2005). 
Pluripotent trophoblast stem (TS) cells can be derived from the ExE and can be 
cultured in vitro in the presence of embryonic conditioned media, FGF4 and 
heparin (Tanaka et al., 1998). A DNA transcription factor Elf5, has been identified 
that is expressed in the ExE lineage and has been hypothesised to be required for 
TS cell maintenance (Donnison et al., 2005). Deane (2007) identified Elf5 target 
genes by RNA interference in TS cell lines by knocking down Elf5, followed by 
global gene expression analysis using an microarray (affymetrix) array. This gave 
a group of genes that were up or down regulated upon loss of Elf5. This work 
was continued here by investigating the effects of Elf5 knockdown (via siRNA 
technology) on target genes after a period of 24 or 48 hr. In situ hybridisation 
was used to determine if the genes were expressed at the right time and in the 
correct place to be Elf5 targets. The initial ground work to get the over 
expression of Elf5 via the tamoxifen inducible system up and running has been 
done, with further work required in the future. The TS cell characteristics when 
Elf5 was knocked down were also investigated with some interesting results.  
7.1.1 Generation of Elf5 knockdown 
The aim of this section was to validate the Elf5 targets by repeating the 
knockdown of Elf5 in mouse trophoblast stem cells. Two siRNAs had been 
identified by Deane (2007) as giving greater than 80 % knockdown of Elf5 after 
24 hr of transfection. In this study two different time points were investigated, 
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24 and 48 hr after the initial transfection. The changes in target gene expression 
were analysed by real time PCR.  
The generation of a reasonable knockdown of Elf5 was problematic and it was 
clear the system needed optimising. Optimisation was carried out using an 
Alexafluor fluorescent oligo. Different seeding densities, oligo and lipofectamine 
concentrations and forward and reverse transfections were tested. Flow 
cytometry was the best technique to determine transfection efficiency. Upon 
optimisation of the FACS it was established that greater than 90 % of the cells 
had been transfected with the fluorescent oligo when the cells were seeded in a 
6-well plate. This was due to the fact that the cells did not clump in the middle of 
the well, as they did in 12 well plates making the cells more accessible to the 
siRNA/fluorescent oligo. When RNA was isolated after a transfection under the 
same conditions an 80-90 % knockdown of Elf5 was achieved.  
  
7.1.1.1 Replacement of Conditioned media with Activin 
TGF-β and activin are key components of embryonic fibroblast conditioned 
media Erlebacher et al,. (2004). Studies (Erlebacher et al., 2004; Guzman-Ayala et 
al., 2004; Natale et al., 2009) have shown that the use of activin or TGF-β in place 
of conditioned media was possible and had no effect on the TS cells themselves. 
Due to these reports our group decided to change from using conditioned media 
to activin plus FgF4 and heparin to culture the TS cells. This was desirable as the 
levels of growth factors would not fluctuate. To ensure that there was no change 
in gene expression the expression of TS cell marker genes were analysed in four 
samples grown in activin versus four grown in conditioned media. The expression 
of Elf5, Eomes, Bmp4, Cdx2 and Fgfr2 was investigated.  There was variability in 
expression between individual samples but when the levels were averaged they 
were similar. There was no significant change in expression of any of the marker 
genes. There was a 2x increase in Cdx2 when the cells were grown in activin but 
this was not statistically significant due to the variation of the individual 
treatments.  
 
After culture in activin for over 1 month changes in the cell morphology were 
noticed. The cells did not grow as colonies, instead they almost grew as 
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individual cells. They also adopted a spiked appearance, they no longer looked 
like cobble stones. It was concluded that culture in activin was satisfactory for 
short term culture but was not optimal for the long term due to changes in 
morphology. Clearly there was something else in the conditioned media that the 
TS cells required, even if it was required at relatively low levels.  
 
These findings are contrary to those of Erlebacher et al., (2004) who find that 
activin or TGF-β are a suitable replacement of embryonic fibroblast conditioned 
media for the long term culture of TS cells. Neither Erlebacher (2004) nor Natale 
(2009) mention any changes to the TS cell morphology when cultured in activin.  
 
7.1.1.2 Real time data and whole mount in situ hybridisation results 
The analysis of the spatial and temporal expression of the Elf5 target genes 
provided further evidence that these genes are in fact targets of Elf5. Elf5 is 
expressed in the extra embryonic ectoderm from E5.5 and later in the chorion, 
the derivate of the ExE at E8.5 (refer to Figure 14). Genes that were expressed in 
this region during this time and were affected by the knockdown of Elf5 were 
likely to be targets of Elf5.  
 
7.1.1.3 Genes of Interest 
Cyr61 codes for a cystine-rich angiogenic inducer 61, a secreted heparin-binding 
protein. It is encoded by a growth factor inducible immediate early gene which is 
rapidly activated when cells are stimulated with FgF, platelet derived growth 
factor and tumor transforming growth factor β (Mo et al., 2002). Results in this 
study indicated that Cyr61 is expressed in the ExE at day 6.5 and later the chorion 
and allantois at day 7.5. It was also expressed in the EPC at this stage. Later on it 
is expressed in the giant cells surrounding the placenta and the 
spongiotrophoblast (E11.5) (O'Brien and Lau, 1992). Cyr61 is also expressed in 
the developing embryo, in the smooth muscle and cartilage. The knockout of 
Cyr61 in mice is embryonic lethal. One third die due to failure in chorioallantoic 
fusion and the rest due to placental vascular insufficiency and compromised 
vessel integrity (Mo et al., 2002). Cyr61 is thus essential for vascular 
development in the placenta (Mo et al., 2002) and for growth, differentiation 
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and morphogenesis of the cartilage of the developing embryo (O'Brien and Lau, 
1992). Expression data indicates Cyr61 is a good target of Elf5, it was expressed 
at the right time and place to be an Elf5 target and it was differentially expressed 
upon Elf5 knockdown. Cyr61 was significantly down regulated at 24 and 48 hr 
after Elf5 knockdown and it was also down regulated with differentiation. Down 
regulation with differentiation agrees with the fact that Cyr61 is stimulated by 
FgF and TGF-β. All this data suggests Cyr61 is an important target of Elf5 that is 
involved in the development of the placenta.  
 
Sox2 is required in both the epiblast and trophectoderm lineages of the early 
embryo. It is also expressed in embryonic stem and trophoblast stem cells at high 
levels. The loss of Sox2 causes the loss of pluripotency (Avilion et al., 2003). So 
the finding that Sox2 was down regulated upon Elf5 knockdown and growth 
factor removal, was important. Sox2 is expressed in the ICM of the blastocyst 
and later the anterior neuroectoderm of the embryo. In the extraembryonic 
tissues expression is initiated in the ExE and is maintained in the ExE part of the 
chorion (Avilion et al., 2003). Our in situ data confirmed this with mRNA 
expression in the ExE at D6.5. Sox2 homozygous mutants die a short time after 
implantation, this is due to failure to maintain epiblast which also leads to 
problems in the extraembryonic tissues (Avilion et al., 2003). A rescue 
experiment with wild type ES cells (ES cells only contribute to the epiblast of the 
embryo) and Sox2 homozygous mutant blastocysts allowed survival beyond 
implantation, but embryos died around E7.5-8.5 due to failure to develop the 
chorion (Avilion et al., 2003). This proved that Sox2 is vital for the 
extraembryonic tissues as death was not due to failure of the epiblast. 
Accordingly TS cells could not be isolated from Sox2 mutant embryos as the 
tissue that they originate from was missing. This data indicates Sox2 is essential 
for the developing embryo, placenta and TS cell maintenance and proliferation. 
 
Wdr40B is part of the WD repeat protein family and has an unknown function. 
This family is thought to be involved in a variety of processes including the cell 
cycle, signal transduction, apoptosis and gene regulation (Lawson and Zhang, 
2009). Wdr40B was expressed in the ExE and was down regulated when Elf5 was 
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knocked down or differentiation was induced. Although it has an unknown 
function it could have an important role in any of the above processes. 
 
Mme encodes the enzyme neprilysin, a membrane metallo-endopeptidase that is 
involved in tachykinin metabolism in the mammalian uterus (Patak et al., 2005). 
Tachykinins cause contraction in the uterine smooth muscle of rats, mice and 
humans (Patak et al., 2005). Mme was expressed in the ExE and EPC at D6.5, 
although it was expressed in the same place as Elf5, it does not appear to be a 
direct Elf5 target. Expression is only changed 48 hr after Elf5 knockdown and not 
at a great level.  
 
According to the whole mount in situ hybridisation data gained here, Calca 
appears to be expressed in the node. The node is the organiser of the embryo. 
The node specifies the fates of the different cell populations and then organises 
the different tissues in a body plan along the neural tube (Davidson and Tam, 
2000). This was not expected as Calca was rapidly down regulated upon Elf5 
knockdown and more so upon growth factor removal. Expression was expected 
to be in the ExE. Calca levels in mouse trophoblast stem cells were quite low, 
between 0.01-0.02 (relative to the geomean) whereas genes like Elf5, Sox2 and 
Cyr61 were expressed at levels of 0.2-0.5 (relative to the geomean). If TS cells 
were the only site of Calca expression it would probably be picked up in the ExE. 
But because it was also expressed in the node at high levels, if the probe is left to 
develop any longer the dye would have just spread over the entire embryo 
leading to non specific staining.  
 
Ly6a, lymphocyte antigen 6 complex (Sca1) is a marker for hematopoietic stem 
cells (Ottersbach and Dzierzak, 2005). Ly6a is therefore expressed in all known 
hematopoietic tissues. Ly6a was expressed in the extra embryonic tissues during 
the development of the placenta. It was expressed in the extra embryonic 
ectoderm and at lower levels in the ectoplacental cone at E6 -7.5 of 
development. Later on in development it is also expressed in foetal vessels of the 
labyrinth, the umbilical artery and the major vessels of the yolk sac (Ottersbach 
and Dzierzak, 2005). After 24 hr of knockdown Ly6a was up-regulated, this 
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confirms the microarray results. Unfortunately there was also a strong si 
negative effect in the 24 hr samples. The change in expression was still significant 
compared to the si negative control. This gene was interesting as it was one of 
the few genes that did not follow the same trend upon Elf5 knockdown as 
growth factor removal (it is down regulated significantly upon growth factor 
removal).   
 
Secretin is a gene characteristic of the placenta and is expressed in TS cells 
(Tanaka et al., 2002). Secretin was expressed in the EPC and was up regulated 
upon growth factor removal and the knockdown of Elf5. This gene is possibly 
involved in TS cell differentiation into other cell types.  
 
Deletion of the Drosophila homolog of Elavl2 (embryonic lethal abnormal vision 
like 2), as its name suggests, is embryonic lethal due to the abnormal 
development of neurons (Robinow et al., 1988). Elavl2 has been found to be 
expressed in the developing mouse oocyte and the surrounding granulosa cells 
at all stages of folliculogenesis (Malcuit et al., 2009). Elavl2 expression declines 
after the first cleavage stage (Malcuit et al., 2009). In this study Elavl2 expression 
was found at very low levels in the ExE at E6.5 and 7.5 in mouse embryos. This 
corresponded to very low expression in TS cells. Elavl2 was down regulated when 
TS cells differentiated. However, Elavl2 did not appear to be an Elf5 target as it 
underwent the same changes in expression as the si negative control.  
 
Spi8 (serine protease inhibitor 8), belongs to the Serpin super family of protease 
inhibitors that bind irreversibly to target proteases. Its physiological role is 
unknown but in vitro experiments suggest that it may inhibit Furin by means of 
analysis of binding sites and interactions (Gillard et al., 2006). In the mouse Spi8 
is highly expressed in the kidney with lower levels in the brain, liver, lymph nodes 
and the skin (Gillard et al., 2006). Furin is expressed in the ExE during early 
development and is required to activate Nodal in the epiblast which is required 
for anterio-posterior patterning. Furin is also involved in the activation of Bmp4 
(Beck et al., 2002). Therefore Spi8 may play a role in regulating Furin during this 
stage of development as it too is expressed in the ExE at the same time as Furin. 
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When Elf5 was knocked down or the TS cells differentiated Spi8 was down 
regulated. Elf5 could thus play an indirect role in embryonic patterning.  
 
Hmga2 is a member of the high mobility group A family that encodes a small 
chromatin associated protein that can alter transcription by changing chromatin 
structure. Hmga2 is expressed throughout foetal development and is associated 
with proliferative undifferentiated cells and tissue. As development continues 
expression becomes more restricted (Hirning-Folz et al., 1998). Hmga2 encodes a 
stem cell factor that controls the maintenance and self renewal of neural stem 
cells in young mice. In Hmga2 knockout mice it was shown that it is not required 
for the generation of neural stem cells but it is required for proliferation and self 
renewal (Nishino et al., 2008). The knockout of Hmga2 also results in a pygmy 
phenotype with a very low body weight (Zhou et al., 1995). There is no published 
data relating to Hmga2 in the placenta, but it could play a similar role in TS cells. 
Hmga2 is down regulated upon the knockdown of Elf5 and growth factor 
removal.  
 
Zic3 is a zinc finger transcription factor, Zic family members are expressed in 
multiple tissues during development. Zic3 is required for left-right asymmetry as 
mutations in Zic3 cause X-linked heterotaxy in humans which results in abnormal 
positioning of internal organs with respect to each other in the L-R axis 
(Purandare et al., 2002). In mice a knockout of Zic3 causes embryonic lethality in 
50 % of mice, and another 30 % die postnataly.  These mice have defects in 
turning, cardiac development, neural tube closure, and vertebral and rib defects 
(Purandare et al., 2002). Zic3 is expressed in the ExE at day 5.0 and in some 
epiblast cells. As gastrulation begins, expression in the ExE declines and Zic3 
begins to be expressed in the tissue that is lined by mesoderm that emerges 
from the primitive streak to encircle the embryonic portion of the egg cylinder. It 
then goes on to be expressed in the anterior definitive endoderm. Zic3 is 
expressed in the ectoderm adjacent to the node but not in the node (Elms et al., 
2004), our in situ data has confirmed these findings. Zic3 induces the formation 
of the neural crest (Kitaguchi et al., 2000). Zic3 has been shown to act upstream 
of Nodal (Purandare et al., 2002) and Pitx2 (Kitaguchi et al., 2000) in L-R 
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asymmetry as their expression is random in Zic3 mutants. Zic3 is thus essential 
for L-R specification and also anterior-posterior axis patterning (Elms et al., 2004; 
Kitaguchi et al., 2000; Klootwijk et al., 2000; Purandare et al., 2002). Although 
Zic3 was not expressed in the ExE at the time points studied, it is expressed in 
the ExE at day 5.0 (Elms et al., 2004). Zic3 is likely to be an indirect target of Elf5 
as it was slow to change expression upon Elf5 knockdown and it is not expressed 
in the ExE. 
 
Keratin7 is a cytosketetal protein. Keratin 7 is expressed in all subtypes types of 
trophoblast in a full term placenta (Pötgens et al., 2001). It was expressed at high 
levels in the EPC at E6.5-7.5, it was not expressed in the ExE. Keratin 7 was up 
regulated upon Elf5 knockdown and differentiation. Elf5 could act to prevent the 
expression of this gene in undifferentiated TS cells.  
 
In the embryo, Bex1 (Brain-expressed X linked gene) is initially transcribed at the 
2-cell stage of development and reaches a peak at the 4 to 8 cell stage of 
development. Expression then declines at the morula stage and rapidly increases 
at the expanded blastocyst stage (Williams et al., 2002). The expression of Bex1 
in isolated inner cell mass is 30 fold lower than that in the whole blastocyst 
indicating trophectoderm specific expression (Williams et al., 2002). Bex1 is also 
expressed in ES cells (Hosler et al., 1989). In this study it was expressed in the ExE 
and EPC but it did not appear to be a target of Elf5 as there was no change in 
gene expression upon knockdown. There may not have been a change in gene 
expression upon Elf5 knockdown as Bex1 expression levels are very high in TS 
cells, as high as the ubiquitous housekeeping genes.  
 
Hopx was only expressed in the giant cells surrounding the embryo. Its 
expression data did not correlate with the microarray as it was up-regulated 
when initially studied. 1700112c13 RIKEN cDNA, is a peptidase (ingenuity). There 
is no published expression data on this gene, it was possibly expressed in the 
chorion in later embryos but the probe did not work well. It was dramatically 
down regulated upon Elf5 knockdown and growth factor removal so it is a gene 
of interest but its role is unknown. GM784 is a fibronectin type 3 repeat, there is 
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no published knock out or expression data on this gene. It had mosaic expression 
in the ExE and seemed to be a good target.  
 
The majority of these results correlated with the microarray with the 48 hr 
results being more exaggerated. These results are beginning to shed light on the 
role of Elf5 in the mouse trophoblast. Elf5 seems to play a role in both the 
maintenance of TS cells and indirectly in embryonic patterning.  
7.1.2 The over expression of Elf5 
Progress has been made in the generation of an Elf5 inducible TS cell line. A 4-
hydroxytamoxifen (OHT) inducible system was used where the Elf5-ER protein 
would not translocate into the nucleus and fulfil its transcriptional functions until 
OHT had been added to the culture. The VP16 transcriptional activation domain 
was inserted successfully to turn Elf5 into a potent activator and stable lines 
were generated. First by selection with Zeocin which was encoded on the 
plasmid, and secondly by selection with puromycin as time was limited. These 
lines had the plasmid integrated into their genome and expressed the protein. 
Immunocytochemical analysis showed that only a small amount of protein was 
going into the nucleus upon OHT addition. This was a problem as the 
concentration of OHT cannot be increased without affecting the expression of TS 
genes. This was due to the interaction of OHT with orphan estrogen related 
receptors expressed in TS cells.  
 
The TS cell marker, the orphan estrogen related receptor Errβ, is structurally 
related to ERα and ERβ. Orphan nuclear receptors lack identified synthetic or 
natural ligands (Tremblay et al., 2001). Estrogen related receptors do not interact 
with natural estrogens, but OHT has been illustrated to disrupt Errβ binding with 
its co regulator protein and inhibit its transcriptional activity (Tremblay et al., 
2001). This was a problem as Errβ is a stem cell marker required for trophoblast 
maintenance. The expression of stem cell markers will need to be monitored 
closely in future control experiments. The addition of 1 µg/ml of OHT did not 
affect the expression of the stem cell genes.  
 162 
 
 
The gene expression of a few genes were analysed in preliminary experiments. 
Line 2 showed an increase in Elf5 expression in comparison to the control. The 
changes in gene expression upon addition of 4-hydroxytamoxifen were not as 
straight forward as expected. Sox2 for example looked like a very good target 
from the knockdown and expression data. But when Elf5 was turned into an 
activator it was down regulated instead of up regulated as expected. Another 
interesting fact was that the basal levels of genes were changed in the 
transfected cell lines compared to the control. This could have possibly been due 
to leaky expression from the plasmid. The up-regulation of Elf5 would have been 
interesting but clearly it is a complicated story. There have been further lines 
generated that are awaiting analysis but they unfortunately fall outside the 
scope of this thesis.  
7.1.3 Changes to the TS cellular characteristics 
The changes in morphology, DNA content, proliferation and apoptosis were 
investigated upon Elf5 knockdown. These characteristics were investigated 5-6 
days upon Elf5 knockdown as no changes in morphology were seen 48 hr after 
the initial knockdown and because giant cells do not begin to appear until 4 days 
after the removal of growth factors (Erlebacher et al., 2004).  
 
The knockdown of Elf5 did have an effect on the morphology of the TS cells. The 
cells were larger compared to the untreated and si negative control. They did not 
look like the growth factor removal treatment but there was a definitive increase 
in the size of the nucleus and cytoplasm which is characteristic of giant cells. 
These morphological results were confirmed by DNA content analysis. There was 
an increase in the number of cells with a DNA content of 8N or greater which 
corresponds to endoreplicating cells. This increase in DNA content was not as 
great as the increase observed when growth factors were removed. There was a 
decrease in proliferation observed when the growth factors were removed, from 
5 % to 1 % of cells in the late G2/M phase. There was no change in proliferation 
observed upon the knockdown of Elf5. There was also an increase in apoptosis 
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observed 5 days after the removal of growth factors, but that was not observed 
when Elf5 was knocked down. The knockdown of Elf5 did have an impact on the 
stem cellular characteristics of the TS cells. It was not as severe as the removal of 
growth factors as proliferation and apoptosis were not affected. Only a 
proportion of the cells displayed characteristics of giant cells. This could have 
been to differing levels of Elf5 knockdown in each cell. The cells that did not 
receive the siRNA would have diluted out the effect of the siRNA.   
 
Elf5 is part of the ETS family of transcription factors which are involved in the 
control of cell proliferation and tumorigenesis (Zhou et al., 1998). In the mouse 
mammary gland Elf5 is required for proliferation and differentiation of the 
alveolar epithelial cells during pregnancy and lactation (Zhou et al., 2005). A 
study by Oakes et al., (2008) found that Elf5 is required for the differentiation of 
CD61+ luminal progenitor cells into the secretory alveolar lineage during 
pregnancy. Elf5 thus promotes differentiation in the mouse mammary gland. Elf5 
seems to play a slightly different role in the mouse trophoblast, it acts to 
maintain the TS cells in an undifferentiated stem cell fate. By doing so it could act 
to preserve the ExE and prevent the precocious differentiation into the EPC/giant 
cells. It could also maintain cellular proliferation at an earlier time point, before 
the cells differentiate upon the loss of Elf5. These findings could explain why the 
ExE was missing in Elf5 homozygous mutants. TS cells which reside in the ExE 
could not be maintained. Elf5 is a marker of undifferentiated TS cells and when 
Elf5 was knocked out or down regulated, the TS cells differentiated into EPC 
precursors and finally giant cells (Donnison et al., 2005). This was further 
supported by the fact that Elf5 was down regulated upon differentiation.  
Furthermore most of the genes that were identified as Elf5 targets were affected 
the same way by Elf5 knockdown and growth factor removal. This lends further 
support to the idea that Elf5 maintains the TS cells in an undifferentiated state.  
7.1.4 Future work 
The over expression of Elf5 will be a valuable tool to gain an understanding of the 
transcriptional networks Elf5 is involved in.  Preliminary results have 
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demonstrated that the story is more complicated than once thought. There are 
other lines that need analysing for Elf5 over-expression by real time PCR, as they 
have been shown to have to plasmid inserted into their genome by PCR. These 
lines have been stored in liquid nitrogen for future use. It would also be 
interesting to over express Elf5 in ES cells as Ng and colleagues (2008) have done. 
They find that the over expression of Elf5 in ES cells causes differentiation into 
trophoblast cells. It would be interesting to see what genes are up-regulated 
when this occurs.  
 
We investigated proliferation 6 days after the knockdown of Elf5. I think it would 
be valuable to examine proliferation at an earlier time point. Possibly 2-3 days 
after Elf5 knockdown while Elf5 levels are still low. I think there would be a 
decrease in cell proliferation upon knockdown. This is due to the fact that a few 
of the genes that Elf5 regulates are involved with proliferation and self-renewal.  
 
The role of some of the target genes in vivo or in vitro could be elucidated by 
creating a knockout mouse or knockdown in TS cells. This way the Elf5 
transcriptional networks involved in placental development may be revealed.   
7.1.5 Conclusions 
Elf5 is an essential transcription factor that is directly involved in the 
maintenance of the extraembryonic ectoderm and trophoblast stem cells. It may 
also be indirectly involved in embryonic patterning by the regulation of Spi8 and 
Zic3. We have shown that Elf5 acts to maintain the trophoblast stem cells in an 
undifferentiated state. Elf5 may also play a role in TS cell proliferation but this 
has not been confirmed. The over-expression of Elf5 in the future will further 
verify its role in the placenta.  
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9 Appendices 
9.1 Materials 
Mammalian cell culture reagents 
Cell culture media 
All reagents were kept at 4 °C. The protocols for cell culture media were 
obtained from Placenta and Trophoblast methods and protocols (Quinn et al., 
2006). 
 
2 x RPMI media 
1 packet of RPMI Medium 1640 powder (Gibco, Invitrogen life technologies, 
Auckland, NZ) 
500 ml MQ water 
2.0 g Sodium Bicarbonate (Life Sciences, Sigma-Aldrich, USA) 
HCl 10 M to adjust pH 
Filter sterilised through a 0.22 µm filter 
 
2 x DMEM F12 
1 packet of DMEM F12 medium powder (Gibco, Invitrogen life technologies) 
500 ml MQ water 
2.438 g Sodium Bicarbonate (Life Sciences, Sigma-Aldrich, USA) 
HCl 10 M to adjust pH 
Filter steralised through a 0.22 µm filter  
 
Mouse trophoblast stem cell media (mTS) 
To make 200 ml: 
100 ml of 2 x RPMI 
40 ml Foetal calf serum (20 % FCS) (ICP Biologicals, Auckland, NZ) 
2 ml of Sodium Pyruvate (1 mM) (100x Gibco, Invitrogen life technologies) 
2 ml of Glutamax (2mM) (100x Gibco, Invitrogen life technologies) 
364 µl β mercaptoethanol (0.1 mM) (Sigma-Aldrich, USA) 
MQ water to 200 ml 
 
Mouse embryonic fibroblast media (MEF media) 
To make 200 ml: 
100 ml of 2x DMEM F12 
20 ml FCS (10%) (ICP biologicals, Auckland, NZ) 
2 ml Sodium Pyruvate (1 mM) (100x Gibco, Invitrogen life technologies) 
1 x Antibiotic/ Antimycotic (100x, 10,000 units of penicillin, 10,000 µg of 
streptomycin, 25 µg amphotercin B per ml) (Invitrogen life technologies) 
MQ water to 200 ml 
 
70 % Conditioned Media 
70 % embryonic fibroblast conditioned media (see methods) 
30 % mTS media 
25 ng/ml Fgf4 (Sigma-Aldrich, USA) 
1 µg/ml Heparin (Sigma-Aldrich, USA) 
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2x mTS freezing media 
50 % FCS 
30 % mTS media 
20 % Dimethyl Sulphoxide (DMSO) (Sigma-Aldrich, UK) 
Cool to 4 °C 
Add 500 µl to 500 µl of cells in mTS media 
NalgeneTM Cryo 1°C Freezing Container 
 
PBS (DulbeccoA, OXOID limited, Basingstoke, Hampshire, England) 
10 tablets were dissolved in 1L of MQ and then autoclaved 
 
Growth Factors and Antibiotics 
Fibroblast growth factor 4 human recombinant, 25 µg (Sigma-Aldrich, USA) 
Resuspend in 1 ml PBS  (Oxoid, UK) containing 0.1 % BSA (Invitrogen life 
technologies) to give a concentration of 25 µg/ml. Aliquot out into 50 µl aliquots 
and store at -80 °C. Dilute 1:1000 when adding to cells to give 25 ng/ml. 
 
Heparin 10,000 units (Sigma-Aldrich, USA) 
Dilute in PBS to give a 1 mg/ml stock, aliquot and store at -80°C. When needed 
thaw and keep at 4 °C. Add to media to a final concentration of 1 µg/ml. 
 
Mitomycin C 2mg from Streptomyces caespitosus (Sigma-Aldrich, USA) 
Resuspend in 2ml of PBS, aliquot and store at -80 °C. 
 
Zeocin (invitrogen) 
Puromycin (Sigma-Aldrich, USA) 
 
Cell culture consumables 
6 well plates (Nunc, Kamstrupvej, Denmark) 
12 well plates (Nunc, Kamstrupvej, Denmark) 
100 mm tissue culture dish (Nunc, Kamstrupvej, Denmark) 
35 mm petri dishes (Falcon, BD, USA) 
TrypLETM Express (Gibco, Invitrogen life technologies Auckland, NZ) 
Cryovials (Nunc, Kamstrupvej, Denmark) 
Chamber slides- 2, 4 and 8 well (LAB-TEK, Nalgene Nunc International, USA) 
Pipette Serological – 5 and 10 ml (LabServ, BioLab) 
Pipette Serological -25 ml (Corning Incorporated, USA) 
T75 tissue culture vented easy flask (Nunc, Kamstrupvej, Denmark) 
T175 cm2 Tissue culture vented cap (Nunc, Kamstrupvej, Denmark) 
 
Transfection Reagents 
OptiMEM reduced serum media (Gibco, Invitrogen life technologies) 
LipofectamineTM 2000 stored at 4 °C (Invitrogen life technologies, Auckland, NZ) 
Reduced serum mTS media 
Made up the same as mTS media but with only 5 % FCS instead 
 
RNAi and DNA constructs 
RNAi molecules are resuspended in DEPC water and stored at -80°C 
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Stealth Elf5 siRNA (Invitrogen life technologies) diluted to a working 
concentration of 50nM 
Stealth siRNA negative control (Invitrogen life technologies) also diluted to a 
working concentration of 50nM 
Elf5 mo ER pyCAGiZeo stored at -20°C (donated by Craig Smith, AgResearch, 
Ruakura), once modified also kept at -20°C.  
P-Tet on Advanced plasmid (Clontech Lab Inc, USA) 
Puromycin resistance plasmid (provided by Marion Woodcock, Transgenics 
group, AgResearch, Ruakura) 
 
Molecular Biology Reagents 
RNA Isolation and cDNA Synthesis 
TRIZOL Reagent (Invitrogen life technologies) 
pENSpike – provided by Craig Smith 
MS2 RNA (Roche, Germany) 
Linear Acrylamide (Ambion) 
DNase buffer (Invitrogen life technologies) 
DNase (Invitrogen life technologies) 
25 mM EDTA (Invitrogen life technologies) 
3M sodium acetate (BDH, England) 
DEPC water and adjusted to pH 5.0 with 3M acetic acid 
10 mM dNTP mix (Roche, Germany) 
Oligo dT14VN (Invitrogen life technologies) 
5 x First strand buffer (Invitrogen life technologies) 
RNAseOUTTM Rnase Inhibitor (Invitrogen life technologies) 
SuperscriptTM III Reverse Transcriptase (Invitrogen life technologies) 
RNAse HTM (Invitrogen life technologies) 
 
Real time PCR Reagents 
2 x SYBR green master mix (Takara), kept at 4°C once thawed 
MQ water 
Primers (Sigma or Invitrogen) 
Resuspend to 1 nmol/µl (1mM) in TE and make working stocks at 10pmol/µl or 
(10µM) in DEPC or MQ water. 
Corbett Research gene discs 
DEPC treated water 
% diethyl pyrocarbonate (DEPC, Sigma-Aldrich, USA) 
MQ water 
Left mixing over night at room temperature 
Autoclaved 
 
Traditional PCR reagents 
10 x PCR buffer with MgCl2 (Invitrogen life technologies) 
10mM dNTP Mix (Roche, Germany) 
Fast start Taq Polymerase (Invitrogen life technologies) 
 
Agarose (Invitrogen life technologies or Raylab, New Zealand)  
Ethidium Bromide 10 mg/ml (Sigma-Aldrich) 
Sybr® safe DNA gel stain- 10,000 x conc in DMSO (invitrogen, Molecular Probes) 
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Ampicillin stock 100 mg/ml (Sigma-Aldrich) 
 
LB Broth 
25g Luria Broth powder (Invitrogen life technologies) 
Dissolve in 1L of MQ water 
Autoclave and when cool add ampicillin to a final concentration of 100 µg/ml. 
Store at 4 °C 
 
LB/ampicillin plates 
25g Luria Broth powder (Invitrogen life technologies) 
1.5 g agar Difco™ Agar, Granulated, (BD, USA) 
Dissolve in 1L of MQ water 
Autoclave and when cool (about 50 °C) add ampicillin to a final concentration of 
100 µg/ml. Pour into petri dishes and when set store at 4 °C with the agar up.  
 
Ladders 
100 bp DNA ladder (ABgene, Surrey, UK) 
1 KB DNA ladder (ABgene, Surrey, UK) 
Ultra ranger DNA ladder (ABgene, Surrey, UK) 
Lambda DNA ladder , (Provided by Peter Pfeffer) 
Gel loading buffer –6x loading buffer blue and red 
 
DNA purification kits 
GENECLEAN® II Kit (QBiogene) 
Wizard gel clean up (Promega, Madison, USA) 
Mermaid® Spin Kit (BIO 101, CA) 
DNA purification maxi kit (QIAGEN Incorporated, Biolab scientific Limited, NZ) 
Ligation mighty mix (Takara) 
 
Invitrogen DH5α Max efficiency cells (>109/µg) 
Thaw on ice and re-freeze and aliquots in a slurry of dry ice and isopropanol 
 
Reagents for blue/white selection 
40 µl of 20 mg/ml IPTG plus 20 µl of 20 mg/ml X-Gal spread onto an LB-Amp 
plate 
 
Restriction enzymes 
All from Roche, stored at -20°C EcoR1, Cla1, Pst1, Sac1, Sca1, Asp718, Nco1, 
Sph1, Sal1, Hpa1, BamH1, Spe1, Nhe1, Not1, Apa1, SacII/Ksp1, Xhol, HindIII, 
EcoRV, Ssp1 and Nae1. 
Restriction buffers H, M, A, L, B (Roche, Indianapolis, USA) 
Calf Intestinal phosphatase (Roche, Indianapolis, USA) 
Buffers 
 
Tris EDTA buffer 
10mM Tris- HCl pH 8.0 (BDH, England) 
1 mM EDTA 
DEPC water 
Autoclaved 
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T0.1 E Buffer 
10mM Tris- HCl pH 8.0 
0.1 mM EDTA 
DEPC water 
Autoclaved 
 
50 x TAE buffer 
2M Tris pH 8.0 
0.57 % acetic acid (J.T Baker, USA) 
500 mM EDTA 
MQ water 
Autoclaved 
 
TBS buffer 
25 mM Tris dissolved in MQ and adjusted to pH 7.5 with conc HCl 
150 mM NaCl 
 
TBS-tween 
TBS buffer above with 0.1 % tween 
 
Miniprep buffers 
Alkaline Lysis Solution one 
50 mM glucose 
25 mM Trsi-Cl pH 8.0 
10 mM EDTA pH 8.0 
Autoclaved 
 
Alkaline lysis Solution two 
0.2 M NaOH 
1 % SDS 
 
Alkaline lysis Solution three 
3 M potassium acetate 
5 M glacial acetic acid 
MQ water 
 
Incubation Buffer (Proliferation) 
0.5g Bovine Serum Albumin (Sigma) dissolved in 100 ml 1 x PBS and stored at 4 
°C 
 
Lysis buffer for genomic DNA isolation (store at RT) 
100 mM NaCl 
10 mM Tris pH 8.0 
25 nM EDTA 
0.5 % SDS 
Proteinase K 1 mg/ml (Roche, Germany), added fresh before use. 
 
Solvents 
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Phenol/chloroform (invitrogen life technologies, NZ) 
Chloroform (AnalaR) 
Isopropanol (LabServ, BioLab, Australia) 
Ethanol (LabServ, BioLab, Australia) 
Methanol (LabServ, BioLab, Australia) 
Whole mount in situ Hybridisation Reagents 
Paraformaldehyde 4 % in PBS (Sigma-Aldrich) 
Proteinase K 25 mg (Sigma-Aldrich) 
Glutaraldehyde 25 % (Sigma-Aldrich) 
Yeast RNA 20 mg/ml (Sigma-Aldrich) 
Heparin 50 mg/ml (Sigma-Aldrich) 
Tween-20 (Polyoxyethylenesorbitan Monolaurate) 10 % and 0.1 % (Sigma-
Aldrich) 
RNase A (Sigma-Aldrich) 
RNase Away (Molecular BioProducts Inc, San Diego, CA) 
Maleic acid (Sigma-Aldrich) 
Formamide (Fluka) 
Quick spin columns for RNA (Boehringer Ingelheim, Germany) 
Boehringer Blocking reagent (Boehringer Ingelheim, Germany) 
BCIP (Boehringer Ingelheim, Germany) 
NBT (Boehringer Ingelheim, Germany) 
Anti-Dig Alkaline phosphatase (Boehringer Ingelheim, Germany) 
Dig RNA labeling kit (Boehringer Ingelheim, Germany) 
T7 RNA polymerase (Roche, Germany) 
SP6 RNA polymerase (Roche, Germany) 
Lamb serum (Gibco, invitrogen life sciences) 
PBT- PBS plus 1 % Tween-20 added fresh 
Glycerol 100 % 
Lithium Chloride 4M 
 
1x MAB 
100 mM Maleic acid, dissolve and pH to 7.5 
150 mM NaCl 
 
1x MABT 
100 mM Maleic acid, dissolve and pH to 7.5 
150 mM NaCl 
% Tween-20 
MQ water 
 
1x MABT500 
100 mM Maleic acid 
500 mM NaCl 
% Tween-20 
 
NTMT 
mM Tris (pH 9.5) 
100 mM NaCl 
50 mM MgCl2 
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1 % Tween-20 
 
Hybridisation Mix 
Formamide 50 %  
SSC, pH 5.0 with citric acid 1.3x  
EDTA pH 8.0, 5 mM 
Yeast RNA, 50 µg/ml 
Tween-20 0.2 % 
CHAPS 0.5 % 
Heparin 100 µg/ml 
MQ to 50 ml 
Flow Cytometry reagents 
Sheath Fluid (PBS) 
Dulbecco’s Phosphate Buffered Saline (Gibco) 
IsoFlow (Beckman Coulter Inc, Fullerton, CA) 
 
DNA extraction buffer 
NaHPO4 200 mM 
Citric Acid 100 mM 
Mix 96 ml of solution A with 4 ml of solution B. Check pH = 7.8, if necessary 
titrate to pH 7.8 with solution B. 
 
PI staining solution 
To 9 ml of sterile PBS add 500 µl PI (50 µg/ml) of 1 mg/ml stock, and add 500 µl 
RNase A (50 µg/ml) of 1 mg/ml stock. Make fresh each time and keep in dark. 
 
DNA beads for calibration- CaliBRITE™3 beads (BD Biosciences) 
DNA QC particles (Becton Dickinson) 
Propidium Iodide (invitrogen) 
RNase A (invitrogen) 
APO-BrdUTM TUNEL Assay Kit (Molecular Probes, invitrogen) 
Nocodazole (Sigma-Aldrich) 
Make 1 mg/ml stocks in MQ and dilute to a working concentration before use.  
Hoechst 33342 nuclear dye (invitrogen) 
Phalliodin (Sigma-Aldrich) 
 
Antibodies 
Histone H3 serine 10 phospho primary antibody (Upstate) 
Estrogen receptor ligand binding domain primary antibody (Abcam) 
IgG-rabbit Alexa 488 secondary antibody (invitrogen) 
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9.2 Raw Data 
 
Table 16: Raw real time data for the 24 hrsamples when Elf5 was knocked down in mouse trophoblast stem cells.  
 
 
 
Replicate mean of three measurements divided by the house keeping genes 
        
24 hr Elf5 Cyr61 Sox2 Wdr40B Calca Mme Bex1  1700112c13 Elavl2 Keratin 7 Ly6a Zic3 Hopx Gm784 Spi8 Hmga2 Secretin 
337 Elf5 KD 0.0945 0.0664 0.0806 0.0365 0.0056 0.0040 1.3635 0.0346 0.0037 0.3245 0.0760 0.0209 0.0256 0.0291 0.0227 0.2165 0.4550 
337 Elf5 KD 0.0955 0.0626 0.0977 0.0332 0.0046 0.0060 1.5329 0.0351 0.0039 0.3289 0.0760 0.0188 0.0309 0.0275 0.0167 0.2565 0.3479 
337 Elf5 KD 0.0781 0.0695 0.0910 0.0321 0.0055 0.0047 1.5355 0.0459 0.0038 0.2716 0.0721 0.0202 0.0254 0.0301 0.0238 0.2129 0.2808 
733 Elf5 KD 0.0701 0.0920 0.0774 0.0272 0.0047 0.0083 1.7313 0.0386 0.0034 0.3590 0.0677 0.0136 0.0335 0.0291 0.0272 0.1438 0.2816 
733 Elf5 KD 0.0830 0.0829 0.0846 0.0229 0.0038 0.0063 1.6808 0.0350 0.0025 0.4621 0.0732 0.0112 0.0390 0.0209 0.0274 0.1177 0.3131 
733 Elf5 KD 0.0599 0.0751 0.0742 0.0224 0.0041 0.0066 1.5972 0.0326 0.0032 0.3890 0.0671 0.0119 0.0365 0.0204 0.0243 0.1251 0.2543 
Si Negative 0.4744 0.1562 0.1283 0.0439 0.0074 0.0092 1.6103 0.0477 0.0034 0.2755 0.0548 0.0207 0.0294 0.0332 0.0294 0.2959 0.2169 
Si Negative 0.3597 0.1521 0.1120 0.0472 0.0074 0.0076 1.7119 0.0444 0.0034 0.2138 0.0551 0.0149 0.0330 0.0344 0.0291 0.2452 0.1935 
No Treatment 0.4213 0.1895 0.1211 0.0438 0.0104 0.0107 1.5050 0.0449 0.0049 0.2297 0.0393 0.0186 0.0318 0.0345 0.0324 0.2270 0.2142 
No Treatment 0.4366 0.1890 0.1255 0.0421 0.0102 0.0097 1.5610 0.0472 0.0038 0.2451 0.0398 0.0145 0.0276 0.0297 0.0336 0.2063 0.2095 
No Growth 
Factors 0.1770 0.1273 0.0101 0.0092 0.0004 0.0101 1.7264 0.0009 0.0011 0.4368 0.0085 0.0008 0.0246 0.0086 0.0180 0.0787 0.2693 
No Growth 
Factors 0.1481 0.1212 0.0065 0.0090 0.0004 0.0095 1.5024 0.0005 0.0010 0.4240 0.0080 0.0005 0.0189 0.0070 0.0139 0.0709 0.3138 
 
 
 
 
  
1
8
2
 
 
Table 17: Raw real time data for the 48 hrsamples when Elf5 was knocked down in mouse trophoblast stem cells. 
 
Replicate mean of three real time measurements divided by the mean of three house keeping genes 
      
48 hr Elf5 Cyr61 Sox2 Wdr40B Calca Mme Bex1  1700112c13 Elavl2 Keratin 7 Ly6a Zic3 Hopx Gm784 Spi8 Hmga2 Secretin 
337 Elf5 KD 0.0841 0.0156 0.0823 0.0171 0.0070 0.0056 0.4889 0.0333 0.0009 0.2033 0.0630 0.0070 0.0219 0.0029 0.0197 0.0505 0.1323 
337 Elf5 KD 0.0822 0.0355 0.1470 0.0256 0.0095 0.0132 0.8835 0.0514 0.0023 0.2018 0.0839 0.0097 0.0360 0.0092 0.0311 0.0950 0.1062 
337 Elf5 KD 0.0951 0.0333 0.1792 0.0273 0.0102 0.0126 1.0730 0.0561 0.0020 0.2284 0.0933 0.0081 0.0401 0.0099 0.0321 0.0926 0.1305 
733 Elf5 KD 0.0488 0.0229 0.0669 0.0094 0.0036 0.0053 1.0749 0.0126 0.0009 0.2754 0.0290 0.0033 0.0142 0.0027 0.0094 0.0658 0.0885 
733 Elf5 KD 0.0501 0.0490 0.1003 0.0174 0.0057 0.0109 1.6129 0.0138 0.0013 0.2233 0.0442 0.0052 0.0229 0.0065 0.0165 0.1049 0.0928 
733 Elf5 KD 0.0561 0.0458 0.0664 0.0111 0.0033 0.0111 1.1619 0.0104 0.0013 0.1849 0.0319 0.0036 0.0190 0.0045 0.0117 0.0923 0.0696 
Si Negative 0.5106 0.1010 0.2961 0.0565 0.0371 0.0200 1.3774 0.1624 0.0016 0.1766 0.0699 0.0092 0.0314 0.0201 0.0690 0.1173 0.0751 
Si Negative 0.4645 0.1010 0.3204 0.0525 0.0274 0.0185 1.2500 0.1556 0.0017 0.1444 0.0710 0.0118 0.0280 0.0201 0.0676 0.1129 0.0688 
No Treatment 0.4477 0.1469 0.3142 0.0469 0.0267 0.0188 1.0124 0.1416 0.0042 0.1157 0.0631 0.0114 0.0282 0.0198 0.0598 0.1568 0.0484 
No Treatment 0.5087 0.1310 0.3201 0.0410 0.0251 0.0143 1.1181 0.1667 0.0034 0.1377 0.0665 0.0112 0.0290 0.0142 0.0589 0.1187 0.0568 
No Growth 
Factors 0.1155 0.0348 0.0074 0.0142 0.0002 0.0026 1.2665 0.0004 0.0002 0.4136 0.0013 0.0053 0.0063 0.0015 0.0096 0.0630 0.3157 
No Growth 
Factors 0.0714 0.0125 0.0044 0.0142 0.0004 0.0014 0.6563 0.0011 0.0005 0.4499 0.0012 0.0014 0.0026 0.0006 0.0126 0.0632 0.2751 
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Table 18: Raw  real time data for the geometric mean of three house keeping genes for the 
knockdown of Elf5.  
 
copies per microlitre 
 SAMPLE 24 hr GAPDH Bactin Btubulin Geomean  
337 Elf5 KD 628808.1 89961.3 19764.66 103789.7 
337 Elf5 KD 628808.1 68644.76 19764.66 94842.92 
337 Elf5 KD 732118.1 71739.98 25196.06 109788.9 
337 Elf5 KD 595691.5 85224.81 22120.04 103942 
337 Elf5 KD 700666.8 131366.1 24756.12 131590.9 
337 Elf5 KD 772819.1 144919.6 25196.06 141312 
337 Elf5 KD 407891.4 52379.22 10057.95 59896.89 
337 Elf5 KD 407891.4 52379.22 8986.958 57690.65 
337 Elf5 KD 403754.6 57783.33 12120.05 65635.91 
733 Elf5 KD 869958.1 124449.7 34703.45 155461 
733 Elf5 KD 869958.1 146373.6 29310.8 155118.3 
733 Elf5 KD 1012888 161475.4 35320.16 179430.7 
733 Elf5 KD 506443.9 89961.3 23400.99 102158.3 
733 Elf5 KD 534598.9 76486.84 22120.04 96709 
733 Elf5 KD 558595.8 94017.7 25196.06 109785.9 
733 Elf5 KD 869958.1 163095.6 32803.81 166963.5 
733 Elf5 KD 700666.8 124449.7 34703.45 144641.4 
733 Elf5 KD 861135 211619 37365.51 189539.2 
Si Negative 869958.1 138667 34703.45 161168.9 
Si Negative 918322.1 154508.5 36713.09 173349.6 
Si Negative 909008.5 152973.7 44240.09 183231.5 
Si Negative 628808.1 105809.5 24756.12 118097.8 
Si Negative 628808.1 131366.1 22120.04 122253.8 
Si Negative 772819.1 161475.4 25196.06 146500.5 
No Treatment 1341133 251396.7 51464.87 258889.3 
No Treatment 1341133 280116.6 48647.73 263405.3 
No Treatment 1739916 262732.3 52379.45 288226.7 
No Treatment 1494395 202488.7 45984.79 240525 
No Treatment 1415691 172159.8 48647.73 228027.7 
No Treatment 1561475 248899.4 52379.45 273048.6 
MTS Control 1415691 295684.5 64462.06 299939.6 
MTS Control 1494395 312117.6 64462.06 310953.8 
MTS Control 1739916 363455.7 58621.59 333436 
MTS Control 1665170 295684.5 60933.47 310728.5 
MTS Control 1577473 312117.6 60933.47 310726.8 
MTS Control 1836644 383655.3 73426.18 372625.3 
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copies per microlitre 
 SAMPLE 48 hr GAPDH Bactin btubulin Geomean  
337 Elf5 KD 814700.1 149658.2 34482.89 161398.9 
337 Elf5 KD 1006532 185720.3 38615.31 193263 
337 Elf5 KD 1012538 184150.5 43854.09 201464.3 
337 Elf5 KD 3978506 608882.8 76154.35 569267.2 
337 Elf5 KD 3978506 517862.5 80588.42 549628.2 
337 Elf5 KD 4944625 637216.2 86485.91 648318.6 
337 Elf5 KD 3978506 440448.6 76154.35 511018.5 
337 Elf5 KD 4422164 490653.3 80588.42 559191.7 
337 Elf5 KD 5213036 572014.9 91521.53 648645.1 
733 Elf5 KD 1243532 243253 34482.89 218494 
733 Elf5 KD 1243532 230472.1 36490.65 218685 
733 Elf5 KD 1545505 315915 41441.19 272494.4 
733 Elf5 KD 2001123 270980.2 45760.77 291676.6 
733 Elf5 KD 2224275 301868 45760.77 313208.1 
733 Elf5 KD 2359009 315915 51968.95 338335.8 
733 Elf5 KD 3054450 546580.6 71964.25 493440.3 
733 Elf5 KD 3054450 576891.2 76154.35 511965.3 
733 Elf5 KD 3415321 637216.2 81727.35 562378.3 
Si Negative 2345017 301868 34482.89 290083 
Si Negative 2472312 301868 36490.65 300862 
Si Negative 3072675 315915 39161.04 336238.2 
Si Negative 2224275 286007.5 30792.7 269569.8 
Si Negative 2109751 286007.5 30792.7 264861.4 
Si Negative 3072675 371440.7 37006.36 348252.4 
No Treatment 3395063 395381 57385.88 425490.2 
No Treatment 3579358 395381 60727.16 441300.7 
No Treatment 4219501 436725.6 58196.89 475105.3 
No Treatment 2109751 218362.8 29098.45 237552.6 
No Treatment 2224275 230472.1 29098.45 246164.6 
No Treatment 2622071 268689.7 34970.22 290981 
MTS Control 3220256 490653.3 60727.16 457807.3 
MTS Control 3395063 517862.5 64262.99 483438.3 
MTS Control 4448551 603736 72981.29 580888 
MTS Control 533750.8 127286.2 11118.47 91072.71 
MTS Control 533750.8 108258.5 11118.47 86287.62 
MTS Control 663363.9 140596.4 11932.12 103629 
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Table 19: Proliferation results for the knockdown of Elf5 in mouse trophoblast stem cells. The 
average and the standard error of the mean was calculated. 
No 
treatment 
Si 
negative 337 733 No Gf 
Nocodazole 
15 ng 
Noc 
30ng 
Noc 50 
ng 
Mito 
1ug 
5.14 3.92 4.42 4.82 1.27 6.52 8.87 14.37 2.5 
5.47 4.41 5.25 5.29 1.02 6.18 8.06 14.1 2.67 
5.3 3.9 4.62 4.98 
  
8.51 14.85 2.67 
5.12 4.31 5.13 5.83 
   
14.13 
 4.92 
 
5.02 6.2 
   
13.82 
 3.88 
      
13.66 
 4.2 
        3.83 
        4.16 
         
 
 
Table 20: Apoptosis results for the knockdown of Elf5 in mouse trophoblast stem cells. 
Duplicates were done for each time point.  
 
48 hr 48 hr 5 days 5 days 
337 0.36 0.39 0.98 0.98 
733 0.24 0.3 0.84 0.91 
si negative 0.76 0.75 0.83 0.84 
No treatment 0.4 0.48 0.4 0.39 
No Growth 
factors 0.38 0.51 7.4 8.2 
 
 
 
Table 21: DNA content results for the knockdown of Elf5 in mouse trophoblast stem cells 
 
No Treatment 
  
Ave sem 
2N 45.0 42.0 43.0 46.9 44.2 1.1 
4N 43.0 46.0 44.0 43.7 44.2 0.6 
>8N 
(M3) 8.8 9.0 9.0 6.2 8.3 0.7 
>8N 
(M4) 2.2 2.5 2.8 2.7 2.6 0.1 
Total 
(M3 + 
M4) 11.0 11.5 11.8 8.9 10.8   
       
 
Si Negative 
  
Ave sem 
2N 50.0 52.0 54.0 55.0 52.8 1.1 
4N 40.0 40.0 39.0 38.5 39.4 0.4 
>8N 
(M3) 8.5 8.0 7.1 6.3 7.5 0.5 
>8N 
(M4) 1.7 1.7 1.3 1.1 1.5 0.1 
Total 10.2 9.7 8.4 7.4 8.9   
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337 Elf5 knockdown 
 
Ave sem 
2N 48.0 51.0 49.0 50.0 49.5 0.6 
4N 32.0 32.0 32.0 32.0 32.0 0.0 
>8N 
(M3) 13.0 12.0 13.0 12.0 12.5 0.3 
>8N 
(M4) 4.4 4.0 5.2 4.7 4.6 0.3 
Total 17.4 16.0 18.2 16.7 17.1   
       
 
733 Elf5 knockdown 
 
Ave sem 
2N 47.3 47.6 48.2 48.6 47.9 0.3 
4N 31.9 32.6 32.3 32.5 32.3 0.2 
>8N 
(M3) 14.1 14.1 13.4 13.8 13.8 0.2 
>8N 
(M4) 6.0 5.0 5.0 4.7 5.2 0.3 
Total 20.1 19.0 18.3 18.5 19.0   
       
 
No Growth factors 
 
Ave sem 
2N 25.5 26.5 25.5 25.7 25.8 0.3 
4N 37.2 35.3 35.2 35.9  35.9 0.7 
>8N 
(M3) 22.8 23.5 24.0  23.3 23.4 0.4 
>8N 
(M4) 11.4 11.0 11.9  11.3 11.4 0.3 
Total 34.2 34.5 35.9 34.6 34.9   
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Table 22: Raw real time data for the geometric mean of the three housekeeping genes for Elf5 
overexpression.  
SAMPLE GAPDH Bactin Btubulin Geomean  
Control 0 Tx 1.90E+06 3.89E+05 1.50E+05 480336.6 
Control 0 Tx 2.00E+06 5.34E+05 1.50E+05 543389.6 
Control 0 Tx 2.12E+06 5.66E+05 1.77E+05 596987.5 
Control 0.5 ug/ml 2.00E+06 2.98E+05 1.09E+05 402738.6 
Control 0.5 ug/ml 1.90E+06 3.15E+05 1.15E+05 409897.8 
Control 0.5 ug/ml 1.72E+06 3.71E+05 1.29E+05 434735.4 
Control 1ug/ml 1.38E+06 2.29E+05 8.39E+04 298493.8 
Control 1ug/ml 1.62E+06 2.29E+05 8.85E+04 320290.6 
Control 1ug/ml 1.63E+06 2.56E+05 9.90E+04 345737.1 
Line 1 0 Tx 1.01E+06 6.11E+04 6.44E+04 158290.5 
Line 1 0 Tx 9.06E+05 7.96E+04 6.79E+04 169849.3 
Line 1 0 Tx 1.07E+06 8.01E+04 8.01E+04 189919.6 
Line 1 0.5 ug/ml 1.90E+06 2.69E+05 1.28E+05 402738.6 
Line 1 0.5 ug/ml 1.80E+06 2.55E+05 1.28E+05 388793.3 
Line 1 0.5 ug/ml 2.12E+06 2.70E+05 1.59E+05 450328.5 
Line 1 1ug/ml 1.46E+06 1.76E+05 1.04E+05 298493.8 
Line 1 1ug/ml 1.38E+06 1.85E+05 1.04E+05 298493.8 
Line 1 1ug/ml 1.63E+06 2.07E+05 1.22E+05 345737.1 
Line 2 0 Tx 1.18E+06 1.67E+05 1.15E+05 283125.2 
Line 2 0 Tx 1.31E+06 1.76E+05 1.15E+05 298493.8 
Line 2 0 Tx 1.25E+06 1.97E+05 1.43E+05 327936.1 
Line 2 0.5 ug/ml 1.06E+06 2.42E+05 1.28E+05 320290.6 
Line 2 0.5 ug/ml 9.55E+05 2.55E+05 1.28E+05 314696.6 
Line 2 0.5 ug/ml 1.32E+06 3.17E+05 1.51E+05 398074 
Line 2 1ug/ml 1.18E+06 2.83E+05 1.28E+05 349788.4 
Line 2 1ug/ml 1.24E+06 2.69E+05 1.35E+05 356006.3 
Line 2 1ug/ml 1.47E+06 3.34E+05 1.68E+05 434735.4 
 
 
Table 23: Raw values for the over expression of Elf5. These values are shown as expression 
relative to the geometic mean of Gapdh, βactin and βtubulin. 
  Elf5 Sox2 Calca Secretin Wdr40B 
Control 0 Tx 0.3563 0.1526 0.0083 0.1425 0.0470 
Control 0.5 ug/ml 0.2968 0.1431 0.0089 0.1177 0.0432 
Control 1ug/ml 0.2570 0.1540 0.0098 0.1584 0.0427 
Line 1 0 Tx 0.2654 0.2479 0.0089 0.1064 0.0382 
Line 1 0.5 ug/ml 0.1596 0.1659 0.0124 0.0351 0.0228 
Line 1 1ug/ml 0.1657 0.1465 0.0134 0.0367 0.0195 
Line 2 0 Tx 0.5881 0.2106 0.0007 0.4545 0.0195 
Line 2 0.5 ug/ml 0.6724 0.0529 0.0032 0.1142 0.0090 
Line 2 1ug/ml 0.7584 0.0525 0.0024 0.1318 0.0088 
 
